Top

Rajyalakshmi Luthra, Ph.D.

Department of Hematopathology, Division of Pathology-Lab Medicine Div

Present Title & Affiliation

Primary Appointment

Professor (Joint appointment), Department of Translational Molecular Pathology, Division of Pathology-Lab Medicine Div, The University of Texas MD Anderson Cancer Center, Houston, TX

Adjunct Professor, Department of Master of Science in Diagnostic Genetics, School of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX

Executive Advisor, Master of Science in Diagnostic Genetics, School of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX

Executive Advisor, Molecular Genetic Technology Program, Allied Health Science Program, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Adjunct Professor, Department of School of Allied Health Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor (Joint appointment), Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Adjunct Professor, Department of Master of Science in Diagnostic Genetics, School of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX

Adjunct Professor, Department of Master Program for Molecular Pathology, School of Allied Health Sciences, Texas Tech University Health Science Center, Lubbock, TX

Professor, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Adjunct Professor, Department of School of Allied Health Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1977	University of Arizona, Tucson, Arizona, US, Major in Biochemistry, Minor in Molecular Biology, Ph.D
1970	Osmania University, Hyderabad, IN, Human Genetics, Microbiology, M.S
1968	Osmania University, Hyderabad, IN, Biological Sciences, BS

Postgraduate Training

1977-1979

Post-doctoral Fellowship, University of Arizona, Tucson, Arizona

Licenses & Certifications

2015	New York State Department of Health Certificate of Qualification for Clinical Laboratory, Director Molecular Oncology)

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2006

Associate Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2003

Assistant Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1996 - 2000

Instructor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1992 - 1995

Administrative Appointments/Responsibilities

Director, Department of Molecular Diagnostics Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, 2025 - Present

Section Chief, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present

Director, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2015 - Present

Director, Department of Molecular Genetic Pathology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2020

Executive Advisor, Department of Molecular Genetic Technology Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - Present

Executive Advisor, Department of School of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - Present

Associate Director, Department of Molecular Genetic Pathology Fellowship Program, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2004 - 2008

CLIA Director, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2023

Director, Department of Core Molecular Diagnostic Laboratory, Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1993 - 1998

Scientific Director, The University of Texas MD Anderson Cancer Center, Houston, TX, 1989 - 1998

Other Professional Positions

Chair/Presenter, Next Generation Summit, Washington, DC, 2018

Chair, External Advisory Board, Princess Margaret's Cancer Genomics Program, Toronto, Canada, 2015 - 2015

Advisory Board, Roche Molecular Diagnostics, Pleasanton, CA, 2015 - 2015

Chair, External Advisory Board, Applied Cancer Genomics Department, Toronto, 2015 - 2016

International Advisory Committee Member, 34th Annual Conference of the Indian Association for Cancer Research (IACR), Jaipur, 2014 - 2015

Key Opinion Leader, NGS Advisory Board, Agilent Technologies, Inc, Santa Clara CA, 2013 - 2014

Executive Advisor, Master of Science in Diagnostic Genetics, School of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

Faculty, 29th Conference of the Indian Cooperative Oncology Network, Jaipur, 2013

Hematopathology Subdivision Program Committee Representative, Association for Molecular Pathology, N/A, 2012 - 2013

Judge, Trainee Research Day, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010

Faculty, Transplant Immunology Director Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2018

Subcommittee on Nucleic Acid Amplification Assays for Molecular Hematopathology, Clinical and Laboratory Standard Institute (CLSI), Houston, TX, 2009 - Present

Faculty, Molecular Genetic Pathology Fellowship Program, Baylor College of Medicine, Houston, TX, 2008 - Present

Executive Advisor, Molecular Genetic Technology Program, Allied Health Science Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present

Consultant for development of diagnostic molecular assays, Asuragen, Inc, Austin, TX, 2006 - 2009

Faculty, Molecular Pathology Resident Program, The University of Texas Health Science Center, Houston, TX, 2005 - Present

Consultant for development of novel microRNA detection, Parlem Biobiz, Arcadia, CA, 2005 - Present

Scientific Committee, 2nd International Gastrointestinal Oncology Conference, Arlington, VA, 2005

Molecular Task Force Working Group Member, Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL, 2005 - 2006

Expert Advisor, RST Regional Cancer Center, Nagpur, 2005 - 2007

Faculty Advisor, Molecular Pathology Program, Texas Tech University Health Science Center, Lubbock, TX, 2004 - Present

Faculty Advisor, Molecular Genetic Technology Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - Present

CAP Inspection Team Member, Inspection of Scott and White Hospital, Temple, TX, 2003 - 2004

Consultant for development of multiplex PCR assays for clinical use, Ambion Diagnostics, Ambion Inc, Austin, TX, 2003 - 2006

Member, 12th International Congress on Anti-Cancer Treatment, Paris, 2001

Research Associate, The University of Texas MD Anderson Cancer Center, Houston, TX, 1989 - 1991

Research Associate, The University of Texas MD Anderson Cancer Center, Houston, TX, 1987 - 1989

Research Scientist, Baylor College of Medicine, Houston, TX, 1984 - 1986

Sr. Research Associate, The University of Texas Health Science Center, Houston, TX, 1980 - 1983

Extramural Institutional Committee Activities

Voting Member, Genomic Testing Executive Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

Chair Search Committee Member, Department of Laboratory Medicine Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

Search Committee Co-Chair, Department of Hematopoietic Biology and Malignancy Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022

Dean Search Committee Member, School of Health Professions Dean Search Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022

Member, Conflict of Interest Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2020

Research Faculty Appointment, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2017

Member, Clinical Research Operations Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2018

Member, Molecular Test Evaluation Committee/Clinical Biomarker Oversight Task Force, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, Appointment and Promotion Committee, School of Health Professions, The University of Texas MD Anderson Cancer Center, 2009 - Present

Member, Graduate Medical Education Institutional Review Committee, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Kleeberg Molecular Marker Working Group, The University of Texas MD Anderson Cancer Center, 2005 - 2007

Member, Pathology and Laboratory Medicine Outreach Proposal, The University of Texas MD Anderson Cancer Center, 2005 - 2007

Member, Multi-Year Appointment Award Review committee, The University of Texas MD Anderson Cancer Center, 2003 - 2006

Member, Goodwin Molecular Monitoring Committee, The University of Texas MD Anderson Cancer Center, 2000 - 2005

Member, Steering Committee, Division of Pathology & Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1999 - Present

Member, Section Head Search Committee, The University of Texas MD Anderson Cancer Center, 1998 - 1999

Editorial Activities

Co-Editor, Cancer Genetics, 2016

Honors & Awards

2024 - Present	2024 Top Scholar, ScholarGPS
2020 - 2024	Education & Mentorship Advancement, MD Anderson Cancer Center
2016	Certificate of Visiting Professor, Zhejiang Cancer Hospital
2014	Certificate of Appreciation, The Saudi Arabian Cultural Mission Department of Medical and Health Science Programs
2014	Waun Ki Hong Award for Excellence in Team Science, MD Anderson Cancer Center
2012	Faculty Educator of the Month, February, The University of Texas MD Anderson Cancer Center
2006	Outstanding Clinical Instructor, School of Allied Health Sciences, Texas Tech Health Sciences Center
2004	Outstanding Clinical Instructor, School of Allied Health Sciences, Texas Tech Health Sciences Center
1973	Junior Research Fellowship Award, Osmania University
1972	Osmania University Grant Commission, Osmania University
1970	First Class with First Merit Award

Professional Memberships

Personal Genome Diagnostics (PGDx) Scientific Advisory Board

2018

American Association of Clinical Chemistry

2016 - 2017

American Association of Cancer Research

2005 - Present

Association for Molecular Pathology

2002 - Present

Selected Presentations & Talks

National Presentations

2019. Association for Molecular Pathology 2019. Invited. AMP. Baltimore, MD, US.
2018. Circulating Cell Free Tumor DNA (ctDNA) Genotyping in Cancer Patient Management. Invited. Next Generation Dx Summit. Washington, DC, US.
2018. Clinical and Translational Biomarker track. Invited. CHI: Biomarker & Immuno-Oncology. Boston, MA, US.
2014. The Challenges of Bringing Circulating Cancer Biomarkers Into A Clinical Laboratory. Invited. Hansonwade. Boston, MA, US.
2014. Realizing the Dream of Precision Medicine. Invited. Association of Molecular Pathology (AMP). Washington, DC, US.
2014. Recent Advances in Molecular Diagnostics. Invited. Hackensack University Medical Center. Hasbrouck, NJ, US.
2014. Clinical Next Generation Sequencing in Oncology. Invited. Next Generation Dx Summit. Washington, DC, US.
2013. N/A. Invited. NCI-Match Kickoff Meeting. Baltimore, MD, US.
2013. Clinical-Next-Generation Sequencing Based Mutation Profiling of Cancers: Interpretation and Reporting Strategies. Invited. Association of Molecular Pathology (AMP). Phoenix, AZ, US.
2012. Genomic Testing in CLIA Environment,. Invited. 11th Oncology Update: Advances and Controversies, US.
2012. Next Generation Sequencing in CLIA environment. Invited. RTOG symposium, US.
2011. Identification of Rare Mutations in Cancers While Screening for High Frequency Mutations Using Sequenom® MassARRAY System. Conference. Poster Presentation at the Annual Meeting of the Association for Molecular Pathology. Grapevine, UT, US.
2011. High Resolution Melting Analysis as an Upfront Cost Effective Screening Method for Detection of KIT Exon 17 Mutations in Acute Myeloid Leukemia in the Clinical Laboratory. Conference. Poster Presentation at the Annual Meeting of the Association for Molecular Pathology. Grapevine, TX, US.
2011. Distinct Molecular Characteristics of FLT3 Mutations Involving Multiple Internal Tandem Duplications. Conference. Poster Presentation at the Annual Meeting of the Association for Molecular Pathology. Grapevine, TX, US.
2011. NPM1 Mutation Occurs in a Subset of Ph+ AML Suggesting that this Entity Is Distinct from CML in Myeloid Blast Phase. Conference. Poster Presentation at the Annual Meeting of the Association for Molecular Pathology. Grapevine, TX, US.
2011. KIT Mutation Is Rare in Acute Myeloid Leukemias, Almost Always Involves Exon 17, and Occurs Predominantly in AML with t(8;21)(q22;q22). Conference. Poster Presentation at the Annual Meeting of the Association for Molecular Pathology. Grapevine, TX, US.
2011. Validation of High Resolution Melting Curve Analysis (HRMA) Using Light Cycler 480 for Screening of TP53 Mutations in Human Malignancies. Conference. Poster Presentation at the Annual Meeting of the Association for Molecular Pathology. Grapevine, TX, US.
2011. Comparison of SNaPshot® Fluorescent Capillary Electrophoresis and Sequenom® MassARRAY Based Platforms for Multiplex Solid Tumor Mutation Screening. Conference. Poster Presentation at the Annual Meeting of the Association for Molecular Pathology. Grapevine, TX, US.
2011. Somatic Deletions of the PolyA Tract in the 3 UTR of EGFR are Common in Microsatellite Instability-High Endometrial and Colorectal Carcinomas. Conference. Poster Presentation at the Annual Meeting of the Association for Molecular Pathology. Grapevine, TX, US.
2011. High Resolution Melt Analysis (HRMA), a Sensitive Screening Method to Detect Exonic Mutations in Phosphatase and Tensin Homologue (PTEN) Gene in Cancers. Conference. Poster Presentation at the Annual Meeting of the Association for Molecular Pathology. Grapevine, TX, US.
2011. A Novel Nanofluidics-Based Approach for Simultaneous and Quantitative Detection of Multiple Recurrent Translocations in Hematologic Malignancies. Conference. Poster Presentation at the Annual Meeting of the Association for Molecular Pathology. Grapevine, TX, US.
2011. Double Mutations of NRAS and KRAS in Acute Myeloid Leukemia and Myelodysplastic Syndrome Are Associated with Monocytic Differentiation, Multilineage Dysplasia, Increased Myeloblasts and Prior Chemotherapy. Conference. 100th Annual Meeting United States and Canadian Academy of Pathology. San Antonio, TX, US.
2011. Discordance between Molecular and Immunohistochemical Analyses for Lynch Syndrome Assessment. Conference. 100th Annual Meeting United States and Canadian Academy of Pathology. San Antonio, TX, US.
2011. Increased Expression of MicroRNA-210 in Microsatellite Instability High Endometrial Carcinoma and Its Potential Role in DNA Damage Repair. Conference. 100th Annual Meeting United States and Canadian Academy of Pathology. San Antonio, TX, US.
2011. Quality Control in Microsatellite Instability Testing. Conference. 100th Annual Meeting United States and Canadian Academy of Pathology. San Antonio, TX, US.
2011. RAS Mutational Analysis in 9334 Solid and Hematopoietic Malignancies. Conference. 100th Annual Meeting United States and Canadian Academy of Pathology. San Antonio, TX, US.
2011. microRNA Profiling in Blastoid Mantle Cell Lymphoma. Conference. 100th Annual Meeting United States and Canadian Academy of Pathology. San Antonio, TX, US.
2011. Molecular and Clinicopathologic Characterization of De Novo AML with Isolated Trisomy 4. Conference. 100th Annual Meeting United States and Canadian Academy of Pathology. San Antonio, TX, US.
2011. Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia: An Analgorithmic Approach Using High Resolution Melting Curve Analysis. Conference. 100th Annual Meeting United States and Canadian Academy of Pathology. San Antonio, TX, US.
2011. A nanofluidic-based qPCR strategy for rapid detection and identification of multiple recurrent translocation in hematological malignancies. Invited. Association for Molecular Pathology, US.
2010. Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction. Conference. 52nd Annual Meeting of the American Society of Hematology. Orlando, FL, US.
2010. Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia. Conference. 52nd Annual Meeting of the American Society of Hematology (ASH). Orlando, FL, US.
2010. Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant. Conference. 52nd Annual Meeting of the American Society of Hematology (ASH). Orlando, FL, US.
2010. Impact of RAS Mutations In Myelodysplastic Syndrome (MDS). Conference. 52nd Annual Meeting of the American Society of Hematology (ASH). Orlando, FL, US.
2010. NPM1 Mutation Detection: A Comparative Study of Quantitative Real-Time PCR and Capillary Electrophoresis in 157 Clinical Samples. Conference. Presentation at the 99th Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2010. Histologic Subtypes of Microsatellite Instability-High (MSI-H) Colorectal Adenocarcinomas (CRCs) and Their Association with Clinicopathologic Features and Prognosis. Conference. Presentation at the 99th Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2010. Molecular Diagnostics in Personalized Medicine and Cancer Therapy. Invited. Healthcare Business Women's Association. San Antonio, TX, US.
2010. Multiplex Mutation Detection Panels for Personalized Cancer Management. Invited. Healthcare Business Women's Association. San Antonio, TX, US.
2010. False Positive vs True-Positive Results of EGFR Mutation Analysis Using Formalin Fixed Paraffin Embedded Tissue. Conference. Presentation at the Annual Meeting of the Association for Molecular Pathology 2010. San Jose, CA, US.
2010. Incorporation of Laser Capture Microdissection into Clinical Molecular Testing Workflow. Conference. Presentation at the Annual Meeting of the Association for Molecular Pathology 2010. San Jose, CA, US.
2010. PicoPure DNA Extraction A Simple and Efficient Method of DNA Extraction from Formalin Fixed Paraffin Embedded Tissue for Clinical Diagnostic Applications. Conference. Presentation at the Annual Meeting of the Association for Molecular Pathology 2010. San Jose, CA, US.
2010. Design and Evaluation of a Solid Tumor Mutation Panel by Sequenom MassARRAY System. Conference. Presentation at the Annual Meeting of the Association for Molecular Pathology 2010. San Jose, CA, US.
2010. Assessment of High Resolution Melting Analysis and Immunohistochemical Staining for the Detection of PTEN Mutations. Conference. Presentation at the Annual Meeting of the Association for Molecular Pathology 2010. San Jose, CA, US.
2010. Validation of a Leukemia Tumor Mutation Panel by Sequenom MassArray System. Conference. Presentation at the Annual Meeting of the Association for Molecular Pathology 2010. San Jose, CA, US.
2010. MicroRNA Expression and Response to Sorafenib, Cytarabine, and Idarubicin in Patients with Acute Myeloid Leukemia. Conference. Presentation at the 99th Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2010. MicroRNA Expression during the Colorectal Adenoma-Adenocarcinoma Sequence. Conference. Presentation at the 99th Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2010. Molecular Profiles of EGFR and KRAS Mutations in Non-Small-Cell Lung Carcinoma: A Survey of 344 Cases. Conference. Presentation at the 99th Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2010. MicroRNA Profiling of Anaplastic Large Cell Lymphoma. Conference. Presentation at the 99th Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2010. The Study of Novel IDH1(R132) Mutations in Acute Myeloid Leukemias. Conference. Presentation at the 99th Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2010. Different Roles of NPM1 and FLT3 Mutations in Myelodysplastic Syndromes. Conference. Presentation at the 99th Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2009. Genetic Instability and RAS Mutations Characterize Leukemic Progression in t(9;11)-Bearing Acute Myeloid Leukemia. Conference. Presentation at the 98th Annual Meeting of the United States and Canadian Academy of Pathology. Boston, MA, US.
2009. Application of COLD-PCR for Improved Detection of KRAS Mutations in Clinical Samples. Conference. Presentation at the 98th Annual Meeting of the United States and Canadian Academy of Pathology. Boston, MA, US.
2009. Clinicopathologic Analysis of 18 Cases with Refractory Anemia with Ringed Sideroblasts and Thrombocytosis. Conference. Presentation at the 98th Annual Meeting of the United States and Canadian Academy of Pathology. Boston, MA, US.
2009. Expression of Annexin A1 and Constitutive Activation of the Akt/mTOR Pathway in High-Grade Diffuse Gliomas: A Potential Connection with S Phase Kinase-Associated Protein (Skp2) in Glioma Progression. Conference. Presentation at the 98th Annual Meeting of the United States and Canadian Academy of Pathology. Boston, MA, US.
2009. Extra Copies of GLI1 Gene at 12q13.12 Are Detected in a Subset of Cases of Trisomy 12 Negative Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomas. Conference. Presentation at the 98th Annual Meeting of the United States and Canadian Academy of Pathology. Boston, MA, US.
2009. microRNA-196A: A Potential Marker of Progression in Barrett's Esophagus-Dysplasia-Adenocarcinoma Sequence. Conference. Presentation at the 98th Annual Meeting of the United States and Canadian Academy of Pathology. Boston, MA, US.
2009. Sonic Hedgehog Signaling Pathway as a Therapeutic Target in Diffuse Large B-Cell Lymphoma. Conference. Presentation at the 98th Annual Meeting of the United States and Canadian Academy of Pathology. Boston, MA, US.
2009. Structural Alterations of the 14q32/IGH Locus in CLL Revealed by Fluorescence In Situ Hybridization and Array-Based Comparative Genomic Hybridization. Conference. Presentation at the 98th Annual Meeting of the United States and Canadian Academy of Pathology. Boston, MA, US.
2009. Detection of Cytogenetic Abnormalities Associated with Outcome Differences in Acute Myeloid Leukemia Using Array-Based Comparative Genomic Hybridization (aCGR) Analysis. Conference. Presentation at the 51st Annual Meeting of the American Society of Hematology. New Orleans, LA, US.
2008. Frequent loss of heterozygosity (LOH) of chromosome 1q in esophageal adenocarcinoma. Conference. Presentation at the 97th Annual Meeting of the United States and Canadian Academy of Pathology. Denver, CO, US.
2008. Genomic profiling using array-based comparative genomic hybridization (aCGH) in chronic lymphocytic leukemia (CLL). Conference. Presentation at the 97th Annual Meeting of the United States and Canadian Academy of Pathology. Denver, CO, US.
2008. Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years. Conference. Presentation at the 50th Annual Meeting of the American Society of Hematology. San Francisco, CA, US.
2008. miRNA Expression in Colorectal Carcinoma by RT-qPCR: Consideration of Multiple Normalization Strategies and Correlation with Microsatellite Instability. Conference. Presentation at the 14th Annual Meeting of the Association for Molecular Pathology. Grapevine, TX, US.
2008. miRNA expression in colorectal carcinoma: Correlation with microsatellite instability. Conference. Presentation at the 97th Annual Meeting of the United States and Canadian Academy of Pathology. Denver, CO, US.
2008. Carcinoma of the Lower Uterine Segment: A Newly Described Association With Lynch Syndrome. Conference. Presentation at the 97th Annual Meeting of the United States and Canadian Academy of Pathology. Denver, CO, US.
2008. Sonic hedgehog signaling is activated by NPM/ALK in ALK-positive anaplastic large cell lymphomas. Conference. Presentation at the 97th Annual Meeting of the United States and Canadian Academy of Pathology. Denver, CO, US.
2008. Utility of the world health organization (WHO) criteria for diagnosis of systemic mastocytosis (SM) in bone marrow (BM). Conference. Presentation at the 97th Annual Meeting of the United States and Canadian Academy of Pathology. Denver, CO, US.
2007. Array-based comparative genomic hybridization (aCGH) of splenic and nodal marginal zone lymphomas (MZLs). Conference. Presentation at the 96th Annual Meeting of the United States and Canadian Academy of Pathology. San Diego, CA, US.
2007. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Conference. Presentation at the 96th Annual Meeting of the United States and Canadian Academy of Pathology. San Diego, CA, US.
2007. Comparison of INFORM HPV in situ hybridization with PCR assay for detection of human papillomavirus (HPV) in cervical carcinoma and cervical intraepithelial neoplasia. Conference. Presentation at the 96th Annual Meeting of the United States and Canadian Academy of Pathology. San Diego, CA, US.
2007. Somatic hypermutation status in CLL correlates with patterns of genotypic aberrations: Results of a large single institution data set. Conference. Presentation at the 96th Annual Meeting of the United States and Canadian Academy of Pathology. San Diego, CA, US.
2006. Quantitative detection of the Kit D816V mutation using pyrosequencing helps to differentiate mastocytosis from mixed mast cell myeloproliferative disorders. Conference. Presentation at the Annual Meeting of the Association for Molecular Pathology. Orlando, FL, US.
2006. Kinase domain point mutations in Ph plus acute lymphoblastic leukemia (ALL) and lymphoid blast crisis of chronic myeloid leukemia (CML) and their emergence following therapy with Bcr-Abl kinase inhibitors. Conference. Presentation at the 48th Annual Meeting of the American Society of Hematology. Orlando, FL, US.
2006. High-dose (HD) imatinib provides better responses in patients with untreated early chronic phase (CP) CML. Conference. Presentation at the 48th Annual Meeting of the American Society of Hematology. Orlando, FL, US.
2006. Activates STAT3 but not MAP kinase p38 is expressed in acute promyelocytic leukemia (APL). Conference. Presentation at the 95th Annual Meeting of the United States and Canadian Academy of Pathology. Atlanta, GA, US.
2006. GST11 genotype predicts for failure to achieve molecular remission in adult Philadelphia chromosome positive acute lymphoblastic leukemia. Conference. Presentation at the 12th Annual Meeting of the Association for Molecular Pathology. Orlando, FL, US.
2006. Clinical implications of quantitative and qualitative post-treatment detection of AML1-ETO in AML. Conference. Presentation at the 95th Annual Meeting of the United States and Canadian Academy of Pathology. Atlanta, GA, US.
2006. Chronic lymphocytic leukemia with intermediate rates of VH mutation encompass both pre-germinal and post-germinal subjects. Conference. Presentation at the 95th Annual Meeting of the United States and Canadian Academy of Pathology. Atlanta, GA, US.
2006. Sequence analysis proves clonal identity in five patients withtypical and blastoid mantle cell lymphoma. Conference. Presentation at the 95th Annual Meeting of the United States and Canadian Academy of Pathology. Atlanta, GA, US.
2005. Global Gene Expression and Ingenuity Pathway Analysis in Esophageal Cancers: Identification of Potential Functional Pathways Associated with Chemoradiation Resistance. Conference. Poster presentation at the 11th Annual Meeting of the Association for Molecular Pathology. Scottsdale, AZ, US.
2005. RAS mutations are associated with monocytic differentiation in myeloid leukemias and are an adverse prognostic factor in chronic myelonnonocytic leukemia (CMML). Conference. Presentation at the 94th Annual Meeting of the United States and Canadian Academy of Pathology. San Antonio, TX, US.
2005. Quantitative Detection of the V617F Mutation in JAK 2 and its Role in the Diagnosis of Chronic Myeloproliferative Disorders. Conference. Poster presentation at the 11th Annual Meeting of the Association for Molecular Pathology. Scottsdale, AZ, US.
2005. Pyrosequencing as an Alternative Method for Detection of ras Mutations in Clinical Tumor Samples. Conference. Poster presentation at the 94th Annual Meeting of the United States and Canadian Academy of Pathology. San Antonio, TX, US.
2005. Mutational Analysis of CEBPA in Acute Myeloid Leukemia: An Integrated Approach using Denaturing and Non-denaturing Capillary Electrophoresis and Direct Sequencing. Conference. Platform presentation at the 94th Annual Meeting of the United States and Canadian Academy of Pathology. San Antonio, TX, US.
2005. Morphologic, cytogenetic and molecular abnormalities in therapy-related acute promyelocytic leukemia. Conference. Presentation at the 94th Annual Meeting of the United States and Canadian Academy of Pathology. San Antonio, TX, US.
2005. Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: addition of a novel second monoclonal antibody improves correlation with IgVh mutation status. Conference. Presentation at the 47th Annual Meeting of the American Society of Hematology. Atlanta, GA, US.
2005. A pyrosequencing method for quantitation of mutated BCR-ABL transcripts in chronic myelogenous leukemia patients with imatinib resistance. Conference. Presentation at the 94th Annual Meeting of the United States and Canadian Academy of Pathology. San Antonio, TX, US.
2005. A Multiplex Bead Array-Based Assay for Rapid Identification of the Common Leukemia Associated Translocations. Conference. Poster presentation at the 11th Annual Meeting of the Association for Molecular Pathology. Scottsdale, AZ, US.
2005. Multiplex Method for Molecular Detection of Leukemia-associated Chromosomal Translocations. Invited. Association for Molecular Pathology 2005 Annual Meeting. Las Vegas, NV, US.
2004. Long-term incidence and outcome of BCR-ABL mutations in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate - P-loop mutations are not associated with worse outcome. Conference. Presentation at the 46th Annual Meeting of the American Society of Hematology. San Diego, CA, US.
2004. Imatinib resistance in chronic myelogenous leukemia is frequently associated with either ABL kinase mutations or with secondary rearrangements of the BCR-ABL. Conference. Presentation at the Annual Meeting of the Association for Molecular Pathology. Los Angeles, CA, US.
2004. Imatinib mesylate for patients (pts) with hypereosinophilic syndrome (HES) and systemic mastocytosis (SM): A phase II trial. Conference. Presentation at the 46th Annual Meeting of the American Society of Hematology. San Diego, CA, US.
2004. GeneScan Assessment of Clonal IgH Rearrangements Amplified by Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) Improves Specificity of Monitoring for Minimal Residual Disease in B-cell Leukemia/Lymphoma Patients. Conference. Poster presentation at the Annual Meeting of the Association for Molecular Pathology. Los Angeles, CA, US.
2004. Clinical significance of molecular monitoring in chronic myeloid leukemia (CML) in chronic phase (CP) with imatinib therapy. Conference. Presentation at the 46th Annual Meeting of the American Society of Hematology. San Diego, CA, US.
2004. Molecular Profiling of Esophageal Cancers. Invited. Annual Esophageal Cancer and Barrett’s Metaplasia Research Summit. Las Vegas, NV, US.
2004. Workshop, Hematopathology I. Invited. Association for Molecular Pathology, US.
2004. Applications of Pyrosequencing for Ras Mutation Analysis. Invited. Association for Molecular Pathology 2004 Annual Meeting. Los Angeles, CA, US.
2004. Routine somatic hypermutation analysis of the IgH variable region in clinical samples: Methodology and correlation with other candidate prognostic markers in CLL. Conference. Presentation at the Annual Meeting of the Association for Molecular Pathology. Los Angeles, CA, US.
2003. Workshop: Molecular Subclassification of Malignant Lymphoma: How Far Can We Go in 2003?. Invited. Association for Molecular Pathology, US.
2003. Clinical significance of molecular response in chronic myeloid leukemia (CML) after imatinib mesylate (Gleevec) therapy: Low levels of residual disease predict for response duration. Conference. Presentation at the 45th Annual Meeting of the American Society of Hematology. San Diego, CA, US.
2003. Comprehensive correlation of conventional cytogenetics (CC), FISH and quantitative real-time reverse transcriptase PCR (qRT-PCR) results for detecting t(9;22) in chronic myeloid leukemia (CML) patients. Conference. Poster presentation at the 92nd Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2003. Quantitative t(9;22) PCR in CML patients for BCR-ABL transcripts and normalizer by single tube multiplex Taqman PCR coupled with capillary electrophoresis and genescan analysis. Conference. Poster presentation at the 92nd Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2003. The use of molecular studies to aid in the diagnosis of lymphoproliferative disorders by fine needle aspiration. Conference. Poster presentation at the 92nd Annual Meeting of the United States and Canadian Academy of Pathology. Washington, DC, US.
2002. Microsatellite Instability in ovarian endometrioid carcinoma: Identification of frameshift mutations in DNA mismatch repair genes, hMSH3 and hMSH6. Conference. Poster presentation at the United States and Canadian Academy of Pathology Meeting. Chicago, IL, US.
2001. Workshop: Disease Burden Assessment by Quantitative PCR: How and Why?. Invited. Workshop: Disease Burden Assessment by Quantitative PCR: How and Why?, US.
2001. A molecular approach to monitoring disease progression in mycosis fungoides (MF). Conference. Platform presentation at the 90th Annual Meeting of the United States and Canadian Academy of Pathology. Atlanta, GA, US.
2001. Characterization of TCRγ-gene rearrangements patterns in T-cell lymphomas: a four color multiplex PCR and GeneScan (GS) Analysis. Conference. Poster presentation at the 90th Annual Meeting of the United States and Canadian Academy of Pathology. Atlanta, GA, US.
2001. Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas. Conference. Presentation at the 90th Annual Meeting of the United States and Canadian Academy of Pathology. Atlanta, GA, US.
1999. Workshop: Long range PCR for the detection of t(2;5) translocation associated with anaplastic large cell lymphoma. Invited. Association for Molecular Pathology, US.

International Presentations

2025. Liquid Biopsy Testing in precision Oncology. Invited. International Conference on Pathology & Genomics for Precision Medicine; PAGE-2025, Puducherry, India. Puducherry, IN.
2020. Molecular Pathology-The way forward for All Medical Specialites. Invited. 8th Annual onference of Molecular Pathology Association of India. Sitapura, IN.
2019. Assay validation, quality controls and quality assurance of NGS. Invited. APOLLO CANCER CONCLAVE 2019. ITC Grand Chole, IN.
2018. Assay validation, quality conrol and quality assurance of next generation sequence. Invited. Encore. Shanghai, CN.
2018. Molecular Diagnostics: Technology and Clinical Applications. Invited. Encore. Shanghai, CN.
2016. Circulating Tumor DNA Genotyping in Cancer Patient Management. Invited. Hangzhou International Symposium of Oncology. Hangzhou, CN.
2015. Clincal NGS for Solid Tumor Testing. Invited. Biomarkers and Diagnostics World Congress. Philadelphia, US.
2014. Next Generation Sequencing Assay in Clinic. Conference. Biomarkers and Diagnostics World Congress. Philadelphia, US.
2013. Next Generation Sequencing in Clinical Oncology. Invited. 29th Conference of the Indian Cooperative Oncology Network, IN.
2013. Semi-Conductor Based Next Generation Sequencing for Cancer Patient Management. Invited. International Conference on Molecular Pathology and 2nd Annual Conference of MPAI, IN.
2012. Molecular Diagnostics in Personalized Cancer Therapy: Lessons Learned from Solid Tumor Testing. Invited. International Symposium on Molecular Pathology. New Delhi, IN.
2011. Miminal Residual Disease Monitoring in Patients with Philadelphia-Chromosome Positive (PH1) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of HyperCVAD and a Tyrosine Kinase Inhibitor. Conference. 11th International Conference on Malignant Lymphoma. Lugano, CH.
2010. Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors. Conference. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Berlin, DE.
2009. A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph plus ALL). Conference. Presentation at the 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, US.
2006. Molecular Diagnostics in Clinical Management of Cancer Patients. Invited. International Symposium on Frontiers of Genetics and Biotechnology. Hyderabad, IN.
2006. Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. Conference. Presentation at the 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, US.
2006. High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up. Conference. Presentation at the 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, US.
2006. Molecular mechanisms in Barrett's metaplasia and its progression. Presentation at the European Gastrointestinal Conference on Research Driven Clinical Approaches to Gastrointestinal Oncology. Conference. Presentation at the European Gastrointestinal Conference on Research Driven Clinical Approaches to Gastrointestinal Oncology. Paris, FR.
2006. Transcription factor NF kappa B a potential molecular marker for predicting and improving treatment efficacy in esophageal cancer. Conference. Presentation at the 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, US.
2005. Association of activated transcription factor NF-kappaB with chemoradiotherapy resistance and poor outcome in esophageal adenocarcinoma. Conference. Presentation at the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, US.
2005. Advances in the Biology of Esophageal Cancer. Invited. International Society of Gastrointestinal Oncology. Arlington, US.
2005. Defining criteria for Lynch Syndrome/HNPCC in women under 50 with endometrial cancer: Final results of a prospective, multi-center study. Conference. Presentation at the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, US.
2005. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Conference. Presentation at the 2nd Annual International Society of Gastrointestinal Oncology Conference. Arlington, US.
2005. Association of activated transcription factor nuclear factor kappa B with chemoradiation resistance and poor outcome in esophageal carcinoma. Conference. Presentation at the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, US.
2004. Molecular predictors of patients with localized upper gastrointestinal cancers after chemoradiation. Conference. Presentation at the 40th Annual Meeting of the American Society of Clinical Oncology. New Orleans, US.
2003. Prevalence of MLH1 or MSH2 germline mutations in young women with endometrial cancer. Conference. Presentation at the 2nd Annual AACR International Conference on Frontiers in Cancer Prevention Research. Phoenix, US.
2002. Predictive Molecular Markers of Esophageal Carcinoma. Invited. 2001 International GI Conference. Paris, FR.
1999. Novel real-time PCR assay for the detection of t(14;18)(q32;21) in patients with follicular lymphoma. Conference. European Society of Hematology. Amsterdam, NL.
1996. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Conference. Presentation at the 6th International Conference on Malignant Lymphoma. Lugano, CH.

Formal Peers

2015. Clinical NGS for Solid Tumor Testing. Invited. Philadelphia, PA, US.
2014. Implementation of Next Generation in a Clinical Molecular Laboratory for Solid Tumor Testing. Recent Advances in Molecular Diagnostics Symposium. Invited. Hasbrouck, NJ, US.
2014. Validation and Implementation of Next Generation Sequencing Assays in a Clinical Molecular Oncology Laboratory, Pathology Grand Rounds. Invited. Temple, TX, US.
2011. Molecular Diagnostics in Personalized Cancer Therapy. Invited. Houston, TX, US.
2010. Molecular profiling of tumor to personalize cancer therapy. Invited. Wisconsin, US.
2006. Minimal Residual Disease Monitoring in Leukemia Patients. Invited, IN.
2004. Applications of Pyrosequencing for Ras mutation analysis: Sponsored by Biotage. Invited, US.
2004. Molecular Diagnostics in Pathology,Grand Rounds. Invited, US.
1999. Sequence analysis for identifying mutations. Invited, US.
1997. Mismatch repair genes in HNPCC. Invited. Birmingham, AL, US.

Less

Grant & Contract Support

Date:	2022 - 2023
Title:	S20-089F2 ComboMATCH
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	FP00018431

Date:	2022 - 2023
Title:	NCI Adult MATCH
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	75N91019D00024

Date:	2022 - 2024
Title:	NCI Adult MATCH
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	75N91019D00024

Date:	2022 - 2023
Title:	Therapeutic approaches for TGF-beta-enriched minimal residual disease in patients with colorectal cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP220416 / PID 13678

Date:	2022 - 2023
Title:	S20-089F1 MDNet - Site Management
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	60653

Date:	2020 - 2028
Title:	Minimal Residual Disease Assessment in Colorectal Cancer
Funding Source:	GUARDANT HEALTH INC
Role:	Collaborator
ID:	PA18-1171

Date:	2020 - 2024
Title:	Circulating Tumor DNA Defined Minimal Residual Disease in Colorectal Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP200356

Date:	2019 - 2024
Title:	Intrathecal Anti-PD-1 Immunotherapy for Metastatic Melanoma Patients with Leptomeningeal Disease (LMD)
Funding Source:	UT MD Anderson Cancer Center Spore Project 2
Role:	Co-I
ID:	1P50CA221703-01A1

Date:	2019 - 2024
Title:	The University of Texas MD Anderson Cancer Center SPORE in Melanoma
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5P50CA221703-04

Date:	2019 - 2024
Title:	The University of Texas MD Anderson Cancer Center SPORE in Melanoma
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5P50CA221703-04

Date:	2019 - 2024
Title:	Targeting the PI3K pathway to overcome resistance to immunotherapy in melanomas with loss of PTEN
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 P50 CA221703-01A1

Date:	2019 - 2021
Title:	Liquid Biopsy Pipeline to Inform Immuno_Oncology Trials
Funding Source:	FNIH
Role:	Co-PI
ID:	2018-PACT001

Date:	2019 - Present
Title:	MDACC Tissue Qualification Laboratory and Molecular Diagnostic Laboratory for tissue processing for NCI CTEP Trials 10076
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	CA186688

Date:	2019 - 2020
Title:	Tissue Qualification Laboratory (TQL) and Molecular Diagnostics Laboratory
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	5UM1CA186688-05

Date:	2019 - 2020
Title:	Precision Oncology through Multiplex Testing for Antibody Drug Conjugate
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	3UM1CA186688-05S2

Date:	2019 - 2022
Title:	MOLECULAR ANALYSIS FOR THERAPY CHOICE (MATCH) RESEARCH COLLABORATION AGREEMENT for Correlative Study CS-MATCH-0014ctR
Funding Source:	NIH/NCI
Role:	Co-PI

Date:	2018 - 2024
Title:	Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML). - PrE0905
Funding Source:	PrECOG,LLC
Role:	Collaborator
ID:	56500

Date:	2018 - 2023
Title:	Colorectal Cancer Molecular Subtype Assay Development and Validation
Funding Source:	NIH/NCI
Role:	PI
ID:	UH2CA207101

Date:	2018 - 2019
Title:	Circulating Tumor DNA Defined Minimal Residual Disease in the Treatment of Colorectal Cancer
Funding Source:	CRC Moon Shot
Role:	Co-PI

Date:	2018 - 2023
Title:	Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1R01CA218230-01A1

Date:	2018 - 2022
Title:	National Clinical Laboratory Network (NLCN) for Precision Oncology – Clinical Next Generation (NGS) Assays
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	14X082Q6

Date:	2018 - 2020
Title:	ECOG-ACRINOperations Center – EA1131 BIQSFP Supplement-MDA5
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	U10CA180820-02S1

Date:	2017 - 2020
Title:	Leidos Biomedical Research, Inc
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	14X082Q4

Date:	2016 - 2019
Title:	Leidos Biomedical Research, Inc
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	14X082Q3

Date:	2016 - 2019
Title:	NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trials
Funding Source:	NIH/NCI
Role:	Co-PI

Date:	2013 - 2018
Title:	Leukemia Spore Grant
Funding Source:	NIH/NCI
Role:	Collaborator

Date:	2013 - 2018
Title:	Leukemia Moonshot Program
Funding Source:	MDACC
Role:	Collaborator

Date:	2013 - 2018
Title:	Brain Spore Grant
Funding Source:	NIH/NCI
Role:	Collaborator

Date:	2010 - 2014
Title:	Molecular Monitoring for CGX-635-CML-202 and 203 Clinical Trials
Funding Source:	ChemGenex Pharmaceuticals
Role:	PI

Date:	2010 - 2012
Title:	Molecular Monitoring for a Phase I Phosphoinositide 3-Kinase Inhibitor trial in Patients with Solid Tumors or Lymphoma
Funding Source:	GlaxoSmithKline, LLC (GSK)
Role:	PI

Date:	2009 - 2009
Title:	Phase II Calibration of BCR-ABL Assay Study
Funding Source:	SAIC-Frederick Inc. (NIH/NCI)
Role:	PI

Date:	2008
Title:	Phase I Calibration of BCR-ABL Assay Study
Funding Source:	SAIC-Frederick Inc (NIH/NCI)
Role:	PI

Date:	2008 - 2009
Title:	A Bead Array Based Assay for Leukemia Risk Stratification
Funding Source:	NIH/SBIR Grant
Role:	PI

Date:	2006 - 2007
Title:	Identification of Molecular Predictors of Therapy Response in Esophageal Cancer
Funding Source:	Anonymous Donor Fund
Role:	PI

Date:	2006 - 2015
Title:	Development of a Circulating Tumor Cell Detection Assay Using Multiplex, Selective PCR Strategies
Funding Source:	Astra Zeneca Strategic Alliance Project
Role:	Co-PI

Date:	2006 - 2008
Title:	Minimal Residual Detection in Mantle Cell Lymphoma by High-sensitivity Molecular Cloning
Funding Source:	MDACC IRG
Role:	Collaborator

Date:	2006 - 2009
Title:	Molecular Monitoring for INNO-406 Kinase Inhibitor Trial
Funding Source:	Innovive Pharmaceuticals
Role:	Co-PI

Date:	2006 - 2008
Title:	Development of Array CGH Based Clinical Genomic Assays for Leukemias and Solid Tumors
Funding Source:	Agilent Technologies
Role:	PI

Date:	2005 - 2006
Title:	ABL mutation detection strategies in CML kinase inhibitors trial
Funding Source:	Novartis Pharmaceuticals
Role:	Co-PI

Date:	2005 - 2007
Title:	Prediction of Response of Esophageal Cancers to Therapy by Gene Expression Profiling
Funding Source:	Donor Fund
Role:	PI

Date:	2005 - 2006
Title:	Validation of a Multiplex Method for Molecular Detection of Leukemia-associated Chromosomal Translocations
Funding Source:	Ambion Diagnostics
Role:	PI

Date:	2005 - 2006
Title:	Utilizing Rapid Therapy-Related Shifts in Tumor Subclones to Identify Targetable Pathways Associated with Transformation in Myeloid Leukemia
Funding Source:	Leukemia Spore Development Award
Role:	Co-I

Date:	2004 - 2005
Title:	Esophageal Carcinoma: Molecular Mechanisms of Progression and Response to Therapy
Funding Source:	(project 5) Multidisciplinary Research Program Award
Role:	PI

Date:	2004 - 2005
Title:	Multidisciplinary Research Program Award, Therapeutic approaches to lymphoma by targeted induced apoptosis
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2004 - 2005
Title:	Oncology Assay Development using Pyrosequencing Platform
Funding Source:	Biotage
Role:	PI

Date:	2003 - 2007
Title:	Endometrial Spore
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2003 - 2007
Title:	Leukemia Spore
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2000 - 2004
Title:	8-CL-Adenosine mediated cytotoxicity in multiple myeloma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	RO1-CA85195

Date:	2000 - 2003
Title:	Modulation of putative surrogate endpoint biomarkers in endometrial biopsies from women with HNPCC
Funding Source:	NIH/NCI
Role:	Co-I
ID:	N01-CN-05022-57

Date:	1998 - 1999
Title:	Detection of occult micrometastases by immunohistochemistry and novel exonuclease-based automated PCR assays in invasive breast cancer
Funding Source:	Breast Cancer Research Program Award
Role:	Co-I

Date:	1998 - 1999
Title:	Breast cancer patients with germline mutations in mismatch repair genes
Funding Source:	Breast Cancer Research Program Award
Role:	Co-I

Date:	1997 - 1999
Title:	Mutation analysis DNA mismatch repair genes hMSH2, hMLH1, hPMS1 in hereditary nonpolyposis colorectal cancer (HNPCC) patients
Funding Source:	Department of Clinical Cancer Prevention
Role:	PI

Date:	1996 - 1998
Title:	Molecular analysis of clonal B-Cell lymphoproliferation in B-cell lymphomas of mucosa-associated lymphoid tissue: Comparative DNA sequence analysis of clone-specific CDR3 and VH genes
Funding Source:	Physicians’ Referral Service
Role:	Co-PI

Date:	1995 - 2000
Title:	Paradigm of multistep human urinary bladder carcinogenesis
Funding Source:
Role:	Co-I
ID:	R29CA66723

Title:	Identifying Novel Pathways Mediating Imatinib Resistance in CML
Funding Source:	Department of Defense
Role:	Co-I

Selected Publications

Peer-Reviewed Articles

Court, K, Teka, B, Cisneros-Napravnik, T, Karpinets, T, El Alam, MB, Firdawoke, E, Chanyalew, Z, Mihret, A, Addissie, A, Gizaw, M, Lan, J, Haymaker, CL, Duose, D, Luthra, R, Colbert, LE, Jhingran, A, Kantelhardt, EJ, Kaufmann, AM, Abebe, T, Klopp, AH. Linking Microbiome Diversity and Immune Profiles in Ethiopian Patients With Cervical Cancer. JCO Global Oncology 11:e2500060, 2025. e-Pub 2025. PMID: 41435214.
Saul, EE, Urrutia, S, Yang, H, Montalban Bravo, G, Tang, G, Toruner, GA, Patel, KP, Luthra, R, Bueso-Ramos, CE, Wang, S, Chien, KS, Sasaki, K, Atluri, H, Goulart, H, Thakral, B, Garcia-Manero, G, Kanagal Shamanna, R. A Case of Cryptic CBFB::MYH11 Acute Myeloid Leukemia With Noncanonical Breakpoints Detected by Optical Genome Mapping. JNCCN Journal of the National Comprehensive Cancer Network 23(6), 2025. e-Pub 2025. PMID: 40345240.
Maher MH, Treekitkarnmongkol W, Ghatak S, Dai J, Liu S, Nguyen T, Duose DY, Kim MP, Hu TY, Hurd MW, Paris PL, Kirkwood KS, Maitra A, Luthra R, Sen S, Roy-Chowdhuri S. An integrated multi-omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid. Cancer Cytopathol 133(4), 2025. e-Pub 2025. PMID: 40106268.
Wang P, Yang RK, Jelloul FZ, Luthra R, Routbort MJ, Chen H, Loghavi S, Ok CY, Kanagal-Shamanna R, Roy-Chowdhuri S, Medeiros L, Patel KP. Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time. JCO Precis Oncol 9, 2025. e-Pub 2025. PMID: 40138600.
Bhamidipati D, Johnson JR, Lin K, Pelicano H, Eng C, Huey R, Wolff RA, Halperin DM, Frumovitz MF, Wistuba II, Duose DY, Mallampati S, Luthra R, Morris VK. The Clinical Utility of a Next-Generation Sequencing-Based Approach to Detecting Circulating HPV DNA in Patients with Advanced Anal Cancer. Cancers (Basel) 17(2), 2025. e-Pub 2025. PMID: 39858090.
Yang, RK, Alvarez, HA, Lucas, AS, Roy Chowdhuri, S, Rashid, A, Chen, H, Ballester, L, Sweeney, K, Routbort, MJ, Patel, KP, Luthra, R, Medeiros, LJ, Toruner, GA. Microsatellite instability and high tumor mutational burden detected by next generation sequencing are concordant with loss of mismatch repair proteins by immunohistochemistry. Cancer Genetics 290-291:44-50, 2025. e-Pub 2025. PMID: 39700818.
Maher, MH, Duose, D, Wistuba, II, Luthra, R, Arjuna, S, Roy Chowdhuri, S. A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens. Cancer Cytopathology 133(1), 2025. e-Pub 2025. PMID: 39704279.
Marczyk VR, Fazeli S, Dadu R, Busaidy NL, Iyer P, Hu MI, Sherman SI, Hamidi S, Hosseini SM, Williams MD, Ahmed S, Routbort MJ, Luthra R, Roy-Chowdhuri S, San Lucas FA, Patel KP, Hong DS, Zafereo M, Wang JR, Maniakas A, Waguespack SG, Cabanillas ME. NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy. JCO Precis Oncol 9, 2025. e-Pub 2025. PMID: 39983078.
Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst R, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. Clin Cancer Res. e-Pub 2024. PMID: 38277235.
Diks J, Tang Z, Altan M, Anderson S, Chen H, Rashid A, Yang RK, Routbort MJ, Patel KP, Toruner GA, Medeiros LJ, Tang G, Luthra R, Roy-Chowdhuri S. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization. Cancer Cytopathol 132(1):41-49, 2024. e-Pub 2024. PMID: 37747438.
Arjuna S, Shah M, Dono A, Nunez-Rubiano L, Pichardo-Rojas PS, Zhu JJ, Riascos RF, Luthra R, Roy-Chowdhuri S, Duose D, Wang DH, Lang FF, Esquenazi Y, Ballester LY. Rapid detection of mutations in CSF-cfTNA with the Genexus Integrated Sequencer. J Neurooncol. e-Pub 2023. PMID: 38160230.
Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers (Basel) 16(1), 2023. e-Pub 2023. PMID: 38201434.
Goltsov AA, Maru DM, Katkhuda R, Duose DY, Luthra R, Correa AM, Wang F, Futreal PA, Hofstetter WL. ANPEP/CD13 Expression as a Marker of Lymphovascular Invasion and Survival in Esophageal Adenocarcinoma. Ann Thorac Surg. e-Pub 2023. PMID: 37806335.
Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. e-Pub 2023. PMID: 37824798.
Sharma S, Makkar M, Luthra R, Arora S, Pathania P, Das G, Chaturvedi S. Fracture load assessment of digitally fabricated post and prefabricated fibre post in endodontically treated teeth. Technol Health Care 31(2):447-458, 2023. e-Pub 2023. PMID: 36336943.
Zuo Z, Medeiros LJ, Garces S, Routbort MJ, Ok CY, Loghavi S, Kanagal-Shamanna R, Jelloul FZ, Garcia-Manero G, Chien KS, Patel KP, Luthra R, Yin CC. Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology (Basel) 12(1), 2022. e-Pub 2022. PMID: 36671709.
Gouda MA, Duose DY, Lapin M, Zalles S, Huang HJ, Xi Y, Zheng X, Aldesoky AI, Alhanafy AM, Shehata MA, Wang J, Kopetz S, Meric-Bernstam F, Wistuba II, Luthra R, Janku F. Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. Oncologist. e-Pub 2022. PMID: 36200910.
Garcia A, Rivera Rolon MDM, Barkoh B, Chen W, Luthra R, Roy-Chowdhuri S. Assessment of BRAF V600E (VE1) immunochemistry for the detection of BRAF V600E mutation in non-small cell lung carcinoma cytology specimens. Cancer Cytopathol. e-Pub 2022. PMID: 36200799.
Yang RK, Chen H, Roy-Chowdhuri S, Rashid A, Alvarez H, Routbort M, Patel KP, Luthra R, Medeiros LJ, Toruner GA. Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods. Cancers (Basel) 14(19), 2022. e-Pub 2022. PMID: 36230473.
Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, Kadia T, Chien K, Rush D, Nguyen H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Kantarjian H, Medeiros LJ, Luthra R, Kanagal-Shamanna R. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia 36(9):2306-2316, 2022. e-Pub 2022. PMID: 35915143.
Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, R|| L, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. e-Pub 2022. PMID: 35690645.
Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, R|| L, Medeiros LJ, Patel KP. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res 116:106827, 2022. e-Pub 2022. PMID: 35430388.
Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CC. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. e-Pub 2022. PMID: 35467000.
Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol. e-Pub 2022. PMID: 34989420.
Michikawa C, Torres-Saavedra PA, Silver NL, Harari PM, Kies MS, Rosenthal DI, Le QT, Jordan RC, Duose DY, Mallampati S, Trivedi S, Luthra R, Wistuba II, Osman AA, Lichtarge O, Foote RL, Parvathaneni U, Hayes DN, Pickering CR, Myers JN. Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Adv Radiat Oncol 7(6):100989, 2022. e-Pub 2022. PMID: 36420184.
Kanagal-Shamanna R, Bao H, Kearney H, Smoley S, Tang Z, Luthra R, Yang H, Zhang S, Lin P, Wu D, Medeiros LJ, Lu X. Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia. Leuk Lymphoma:1-11. e-Pub 2021. PMID: 34898335.
Jabbour E, Patel K, Jain N, Duose D, Luthra R, Short NJ, Zugmaier G, San Lucas A, Velasco K, Tran Q, Zaman F, Konopleva M, Kantarjian H. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. Am J Hematol 96(10):E379-E383, 2021. e-Pub 2021. PMID: 34161631.
Quesada AE, Luthra R, Jabbour E, Patel KP, Khoury JD, Tang Z, Alvarez H, Mallampati S, Garcia-Manero G, Montalban-Bravo G, Medeiros LJ, Kanagal-Shamanna R. Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harb Mol Case Stud 7(3), 2021. e-Pub 2021. PMID: 34117074.
Faber E, Grosu H, Sabir S, San Lucas FA, Barkoh BA, Bassett RL, Luthra R, Stewart J, Roy-Chowdhuri S. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy. J Clin Pathol. e-Pub 2021. PMID: 33952592.
Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
Shah M, Takayasu T, Zorofchian Moghadamtousi S, Arevalo O, Chen M, Lan C, Duose D, Hu P, Zhu JJ, Roy-Chowdhuri S, Riascos RF, Chen H, Luthra R, Esquenazi Y, Ballester LY. Evaluation of the Oncomine Pan-Cancer Cell-Free Assay for Analyzing Circulating Tumor DNA in the Cerebrospinal Fluid in Patients with Central Nervous System Malignancies. J Mol Diagn 23(2):171-180, 2021. e-Pub 2021. PMID: 33531134.
Ramani NS, Patel KP, Routbort MJ, Alvarez H, Broaddus R, Chen H, Rashid A, Lazar A, San Lucas FA, Yao H, Manekia J, Dang H, Barkoh BA, Medeiros LJ, Luthra R, Roy-Chowdhuri S. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. e-Pub 2021. PMID: 33493304.
Ramani NS, Chen H, Broaddus RR, Lazar AJ, Luthra R, Medeiros LJ, Patel KP, Rashid A, Routbort MJ, Stewart J, Tang Z, Bassett R, Manekia J, Barkoh BA, Dang H, Roy-Chowdhuri S. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. e-Pub 2020. PMID: 33119213.
Morris JS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, Routbort MJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, Kopetz S, Maru DM. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res. e-Pub 2020. PMID: 33109741.
Gupta SK, Jain N, Tang G, Futreal A, Wang SA, Khoury JD, Yang RK, Fang H, Patel KP, Luthra R, Routbort M, Barkoh BA, Chen W, Mao X, Zhang J, Medeiros LJ, Bueso-Ramos CE, Loghavi S. A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw 18(10):1300-1304, 2020. e-Pub 2020. PMID: 33022638.
Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol 33(9):1678-1689, 2020. e-Pub 2020. PMID: 32238878.
Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer 126(7):1502-1511, 2020. e-Pub 2020. PMID: 31999839.
Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv 4(8):1670-1677, 2020. e-Pub 2020. PMID: 32324887.
Sakhdari A, Thakral B, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Medeiros LJ, Wang SA, Patel KP, Ok CY. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med 9(3):849-858, 2020. e-Pub 2020. PMID: 31804006.
Ruiz-Cordero R, Ma J, Khanna A, Lyons G, Rinsurongkawong W, Bassett R, Guo M, Routbort MJ, Zhang J, Skoulidis F, Heymach J, Roarty EB, Tang Z, Medeiros LJ, Patel KP, Luthra R, Roy-Chowdhuri S. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer 20(1):83, 2020. e-Pub 2020. PMID: 32005111.
Nizamaddin SK, Mehrotra M, Nadhim ASH, Luthra R, Roy-Chowdhuri S. Detection of EGFR T790M Mutation by Droplet Digital Polymerase Chain Reaction in Lung Carcinoma Cytology Samples. Arch Pathol Lab Med. e-Pub 2020. PMID: 31904278.
Mejbel HA, Arudra SKC, Pradhan D, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Duose DY, Luthra R, Prieto VG, Ballester LY, Aung PP. Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity. Cancers (Basel) 11(11), 2019. e-Pub 2019. PMID: 31684113.
Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
Mallampati S, Zalles S, Duose DY, Hu PC, Medeiros LJ, Wistuba II, Kopetz S, Luthra R. Development and Application of Duplex Sequencing Strategy for Cell-Free DNA (cfDNA)-Based Longitudinal Monitoring of Stage IV Colorectal Cancer. J Mol Diagn 21(6):994-1009, 2019. e-Pub 2019. PMID: 31401123.
Chen Z, Wang SA, Goswami M, Tang G, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leuk Res 86:106227, 2019. e-Pub 2019. PMID: 31557598.
Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer. Ann Oncol 30(9):1521-1530, 2019. e-Pub 2019. PMID: 31282941.
Shi X, Duose DY, Mehrotra M, Harmon MA, Hu P, Wistuba II, Kopetz S, Luthra R. Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA. Cancer Genet 237:82-89, 2019. e-Pub 2019. PMID: 31447070.
Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi S. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol 41:38-42, 2019. e-Pub 2019. PMID: 31132650.
Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul S, Luthra R, Meric-Bernstam F, Sahin AA. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Hum Pathol. e-Pub 2019. PMID: 31351155.
Hannigan B, Ye W, Mehrotra M, Lam V, Bolivar A, Zalles S, Barkoh BA, Duose D, Hu PC, Broaddus R, Stewart J, Heymach J, Medeiros LJ, Wistuba I, Luthra R, Roy-Chowdhuri S. Liquid Biopsy Assay for Lung Carcinoma Using Centrifuged Supernatants from Fine Needle Aspiration Specimens. Ann Oncol 30(6):963-969, 2019. e-Pub 2019. PMID: 30887015.
Mallampati S, Duose DY, Harmon MA, Mehrotra M, Kanagal-Shamanna R, Zalles S, Wistuba II, Sun X, Luthra R. Rational "Error Elimination" Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies. J Mol Diagn 21(3):471-482, 2019. e-Pub 2019. PMID: 30794984.
Donaldson K, Buchanich JM, Grigson PS, Deneke E, Donaldson K, Vrana KE, Sacks DB, Kuehn GJ, Cardamone D, Pesce A, Smiley S, Nickley J, Krock K, Thomas R, Wilkerson ML, Farag HA, Challa SR, Tice AM, Wolk DM, Prichard J, Grant ML, Regmi S, Kerbacher B, Quinton LE, Farag HA, Tice AM, Wolk DM, Olson J, Haynes A, Yu E, McCully KS, Assi J, Wong M, Zarrin-Khameh N, Nifong TP, Hawker CD, Carlton GT, Rivera JM, Foulis PR, Zuraw A, Morlote D, Peker D, Reddy V, Harada S, Crutchfield C, Zander D, Barbhuiya MA, Pederson EC, Straub ML, Scott SC, Neibauer TL, Salter WF, Creer MH, Zhu Y, Bornhorst JA, Theobald JP, Algeciras-Schimnich A, Cao L, Knox J, Hardy R, Texas HJ, McGuire MF, Hunter RL, Brown RE, Hicks J, Hicks J, Cai Z, Brown RE, Ali Y, Cheng KC, Katz SR, Ding Y, Vanselow DJ, Yakovlev MA, Lin AY, Clark DP, Vargas P, Xin X, Copper JE, Canfield VA, Ang KC, Wang Y, Xiao X, De Carlo F, van Rossum DB, La Rivière PJ, Newell J, Hossler C, Roche M, Warrick J, Phaeton R, Kesterson J, Donaldson K, Myers C, Barrios R, Mintz P, Robyak K, Hamilton C, McGhee P, Pederson C, Straub M, Scott S, Neibauer T, Salter W, Creer M, Zhu Y, Hamilton C, Robyak K, McGhee P, Pederson C, Straub M, Scott S, Neibauer T, Salter W, Creer M, Zhu Y, Singh N, Morlote D, Vnencak-Jones C, Yemelyanova A, Harada S, Shah M, Moghadamtousi SZ, Lan C, Duose D, Hu P, Esquenazi Y, Luthra R, Ballester LY, Koenig AN, Liu CG, Zhang J, Kalia A, Al-Habib A, Van Arsdall M, Dhingra S, Patel K, Tatevian N. Abstracts of Presentations at the Association of Clinical Scientists 139th Meeting Hershey, PA, May 15-18, 2019. Ann Clin Lab Sci 49(3):403-416, 2019. e-Pub 2019. PMID: 31308044.
Pisapia P, Malapelle U, Roma G, Saddar S, Zheng Q, Pepe F, Bruzzese D, Vigliar E, Bellevicine C, Luthra R, Nikiforov YE, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Bihl M, Savic S, Bubendorf L, de Biase D, Tallini G, Hwang DH, Sholl LM, Vander Borght S, Weynand B, Stieber D, Vielh P, Rappa A, Barberis M, Fassan M, Rugge M, De Andrea CE, Lozano MD, Lupi C, Fontanini G, Schmitt F, Dumur CI, Bisig B, Bongiovanni M, Merkelbach-Bruse S, Büttner R, Nikiforova MN, Roy-Chowdhuri S, Troncone G, Meeting Group MC. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathol 127(5):285-296, 2019. e-Pub 2019. PMID: 31021538.
Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. e-Pub 2019. PMID: 30963592.
Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. e-Pub 2019. PMID: 30924136.
Bolivar AM, Luthra R, Mehrotra M, Chen W, Barkoh BA, Hu P, Zhang W, Broaddus RR. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients. Mod Pathol 32(3):405-414, 2019. e-Pub 2019. PMID: 30315273.
Olar A, Tran D, Mehta VP, Reinhardt A, Manekia JH, Garnovskaya M, Ellezam B, Luthra R, Sulman EP, Mohila CA, Campbell GA, Powell SZ, Fuller GN, Aldape KD, Adesina AM. ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features. Clin Neuropathol 38(2):59-73, 2019. e-Pub 2019. PMID: 30499772.
Ye W, Hannigan B, Zalles S, Mehrotra M, Barkoh BA, Williams MD, Cabanillas ME, Edeiken-Monroe B, Hu P, Duose D, Wistuba II, Medeiros LJ, Stewart J, Luthra R, Roy-Chowdhuri S. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules. Cancer Cytopathol 127(3):146-160, 2019. e-Pub 2019. PMID: 30620446.
Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125(4):559-574, 2019. e-Pub 2019. PMID: 30508305.
Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KP. Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia. Haematologica 104(2):305-311, 2019. e-Pub 2019. PMID: 30171025.
Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, DiNardo CD, Luthra R, Medeiros LJ. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection. J Mol Diagn 21(1):89-98, 2019. e-Pub 2019. PMID: 30577887.
Badar T, Luthra R, Kantarjian H, Jabbour E, Borthakur G, Garcia-Manero G, Huang X, Singh R, Alvarez B, Austermiller B, Morrison TB, Patel KP, Cortes J. New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Appl Immunohistochem Mol Morphol 27(1):33-39, 2019. e-Pub 2019. PMID: 28682832.
Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol 10(1111):831-835, 2018. e-Pub 2018. PMID: 29265180.
Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype and TP53 disruption. Hum Pathol 82:215-231, 2018. e-Pub 2018. PMID: 30086334.
Ahmadi Moghaddam P, Singh R, Mahmoodi M, Mehrotra M, Benaim G, Luthra R, Paniz-Mondolfi A. Poorly differentiated osteoclast-like giant cell variant of cutaneous squamous cell carcinoma: Uncovering its mutational landscape through massive parallel sequencing. Pathol Res Pract 18(10):1898-1903, 2018. e-Pub 2018. PMID: 30146254.
Chen H, Luthra R, Patel KP, Routbort M, Rashid A, Roy-Chowdhuri S, Lazar A, Broaddus R, Manekia J, Singh RR, Yemelyanova A. Challenges in next generation sequencing analysis of somatic mutations in transplant patients. Cancer Genet 226-227:17-22, 2018. e-Pub 2018. PMID: 30005850.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
Montes-Moreno S, Routbort MJ, Lohman EJ, Kanagal-Shamanna R, BUeso-Ramos CE, Singh RR, Medieros LJ, Luthra R, Patel KP. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoSONE 13(9), 2018. e-Pub 2018. PMID: 30222780.
Jabbar KJ, Yin CC, Bueso-Ramos CE, Luthra R, Medeiros LJ, Zuo Z. Higher body mass index is associated with better survival in patients with myelodysplastic syndromes. Leukemia Res 71(10):63-66, 2018. e-Pub 2018. PMID: 30015105.
Ahmadi Moghaddam P, Singh R, Mahmoodi M, Mehrotra M, Benaim G, Luthra R, Paniz-Mondolfi A. Poorly differentiated osteoclast-like giant cell variant of cutaneous squamous cell carcinoma: Uncovering its mutational landscape through massive parallel sequencing. Pathol Res Pract 18(10), 2018. e-Pub 2018. PMID: 30146254.
Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II, Davies MA. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. J Neuropathol Exp Neurol 77(7):628-635, 2018. e-Pub 2018. PMID: 29873738.
Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing tumors beyond diagnosis for targeted therapy. Mol Cancer Ther 17(7):1575-1584, 2018. e-Pub 2018. PMID: 29695638.
Roy-Chowdhuri S, Mehrotra M, Bolivar AM, Kanagal-Shamanna R, Barkoh BA, Hannigan B, Zalles S, Ye W, Duose D, Broaddus R, Staerkel G, Wistuba I, Medeiros LJ, Luthra R. Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling. Mod Pathol 31(7):1036-1045, 2018. e-Pub 2018. PMID: 29463880.
Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma 59(7):1-5, 2018. e-Pub 2018. PMID: 29119847.
Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol 107(6):689-695, 2018. e-Pub 2018. PMID: 29464484.
Kurt H, Bueso-Ramos CE, Khoury JD, Routbort MJ, Kanagal-Shamanna R, Patel UV, Jorgensen JL, Wang SA, Ravandi F, DiNardo C, Luthra R, Medeiros LJ, Patel KP. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol 42(5):569-577, 2018. e-Pub 2018. PMID: 29635257.
Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CY. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget 9(9):8441-8449, 2018. e-Pub 2018. PMID: 29492206.
Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra R. Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget 9(12):10259-10271, 2018. e-Pub 2018. PMID: 29535804.
Fang L, Chen H, Tang Z, Kalhor N, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R, Singh RR, Routbort MJ, Hong D, Medeiros LJ, Lu X. MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget 9(16), 2018. e-Pub 2018. PMID: 29560123.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2018. PMID: 29134664.
Jour G, Andeen NK, Al-Rohil R, Aung PP, Mehrotra M, Duose D, Hoch B, Argenyi Z, Luthra R, Wistuba II, Prieto VG. Novel enriched pathways in superficial malignant peripheral nerve sheath tumors (MPNST) and spindle/desmoplastic melanomas (SDM). J Pathol 244(1):97-106, 2018. e-Pub 2018. PMID: 28991373.
Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 180(1):33-40, 2018. e-Pub 2018. PMID: 29164608.
Badshah SL, Sun J, Mula S, Gorka M, Baker P, Luthra R, Lin S, van der Est A, Golbeck JH, Redding KE. Mutations in algal and cyanobacterial Photosystem I that independently affect the yield of initial charge separation in the two electron transfer cofactor branches. Biochim Biophys Acta 1859(1):42-55, 2018. e-Pub 2018. PMID: 29066393.
Fujii T, Matsuda N, Kono M, Harano K, Chen H, Luthra R, Roy-Chowdhuri S, Sahin AA, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT. Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. Eur J Cancer 89:64-71, 2018. e-Pub 2018. PMID: 29232568.
Sabir SH, Krishnamurthy S, Gupta S, Mills GB, Wei W, Cortes AC, Mills Shaw KR, Luthra R, Wallace MJ. Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing. ProQuest 12(12):e0189651, 2017. e-Pub 2017.
Loree JM, Pereira AA, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani SM, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris J, Luthra R, Meric-Bernstam F, Overman MJ, Maru DM, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res, 2017. e-Pub 2017. PMID: 29180604.
Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood 130(19):2084-2091, 2017. e-Pub 2017. PMID: 28835440.
Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123(19):3717-3724, 2017. e-Pub 2017. PMID: 28608976.
Kanagal-Shamanna R, Loghavi S, DiNardo CD, Medeiros LJ, Garcia-Manero G, Jabbour E, Routbort MJ, Luthra R, Bueso-Ramos CE, Khoury JD. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102(10):1661-1670, 2017. e-Pub 2017. PMID: 28659335.
Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102(9):3591-3599, 2017. e-Pub 2017. PMID: 28911154.
Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer. Clin Cancer Res 23(18):5648-5656, 2017. e-Pub 2017. PMID: 28536309.
Mehrotra M, Duose DY, Singh RR, Barkoh BA, Manekia J, Harmon MA, Patel KP, Routbort MJ, Medeiros LJ, Wistuba II, Luthra R. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One 12(8):e0181968, 2017. e-Pub 2017. PMID: 28767674.
Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130(9):1125-1131, 2017. e-Pub 2017. PMID: 28674026.
Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G, Meeting Group MC. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer 125(8):615-626, 2017. e-Pub 2017. PMID: 28475299.
Kanagal-Shamanna R, Hidalgo Lopez JE, Milton DR, Kim HR, Zhao C, Zuo Z, Janania Martinez M, Stingo F, Lee J, Luthra R, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. Am J Hematol 92(8):E168-E171, 2017. e-Pub 2017. PMID: 28456995.
Patel U, Luthra R, Medeiros LJ, Patel KP. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms. Clin Lymphoma Myeloma Leukemia 17S(2152-2650):S62-S74, 2017. e-Pub 2017. PMID: 28760304.
Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, Simien CM, Hernandez M, Behrens C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Wistuba II, Kopetz S, Luthra R. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn 19(4):514-524, 2017. e-Pub 2017. PMID: 28506684.
Salem A, Loghavi S, Tang G, Huh YO, Jabbour EJ, Kantarjian H, Wang W, Hu S, Luthra R, Medeiros LJ, Khoury JD. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Am J Hematol 92(6):520-528, 2017. e-Pub 2017. PMID: 28253536.
Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res 23(18):5648-5656, 2017. e-Pub 2017. PMID: 28536309.
Roy-Chowdhuri S, Chen H, Singh RR, Krishnamurthy S, Patel KP, Routbort MJ, Manekia J, Barkoh BA, Yao H, Sabir S, Broaddus RR, Medeiros LJ, Staerkel G, Stewart J, Luthra R. Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol 30(4):499-508, 2017. e-Pub 2017. PMID: 28084342.
Mehrotra M, Luthra R, Abraham R, Mishra BM, Virani S, Chen H, Routbort MJ, Patel KP, Medeiros LJ, Singh RR. Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples. Cancer Genet 212-213:24-31, 2017. e-Pub 2017. PMID: 28449808.
Luthra R, Patel KP, Routbort MJ, Broaddus RR, Yau J, Simien C, Chen W, Hatfield DZ, Medeiros LJ, Singh RR. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. J Mol Diagn 19(2):255-264, 2017. e-Pub 2017. PMID: 28017569.
Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol 28(3):642-650, 2017. e-Pub 2017. PMID: 27993791.
Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn 19(2):313-327, 2017. e-Pub 2017. PMID: 28188106.
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2017. PMID: 28003274.
Ballester LY, Fuller GN, Powell SZ, Sulman EP, Patel KP, Luthra R, Routbort MJ. Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. J Neuropathol Exp Neurol 76(3):179-188, 2017. e-Pub 2017. PMID: 28395087.
Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget 8(7):10845-10857, 2017. e-Pub 2017. PMID: 28125801.
Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid 27(1):81-87, 2017. e-Pub 2017. PMID: 27785980.
Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CR, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. e-Pub 2017. PMID: 28096270.
Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol 91(11):E478-E479, 2016. e-Pub 2016. PMID: 27468087.
Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 174(5):760-6, 2016. e-Pub 2016. PMID: 27301277.
Singh RR, Mehrotra M, Chen H, Almohammedsalim AA, Sahin A, Bosamra A, Patel KP, Routbort MJ, Lu X, Ronald A, Mishra BM, Virani S, Medeiros LJ, Luthra R. Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. J Mol Diagn 18(5):676-87, 2016. e-Pub 2016. PMID: 27392636.
Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, Davies MA, Prieto VG, Broaddus RR, Ram P, Luthra R, Esmaeli B. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol 240(1):84-95, 2016. e-Pub 2016. PMID: 27287813.
Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504-7, 2016. e-Pub 2016. PMID: 27235138.
Ballester LY, Loghavi S, Kanagal-Shamanna R, Barkoh BA, Lin P, Medeiros LJ, Luthra R, Patel KP. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk 16(7):395-403.e1, 2016. e-Pub 2016. PMID: 27268124.
Alayed K, Medeiros LJ, Patel KP, Zuo Z, Li S, Verma S, Galbincea J, Cason RC, Luthra R, Yin CC. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Hum Pathol 52:61-67, 2016. e-Pub 2016. PMID: 26980021.
Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther 15(6):1397-404, 2016. e-Pub 2016. PMID: 27207774.
Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol 40(5):676-88, 2016. e-Pub 2016. PMID: 26872013.
Yabe M, Medeiros LJ, Tang G, Wang SA, P Patel K, Routbort M, Bhagat G, Bueso-Ramos CE, Jorgensen JL, Luthra R, Chen W, Muzzafar T, Kanagal-Shamanna R, Khoury JD, Daneshbod Y, Davanlou M, Li S, Young KH, Miranda RN. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Hum Pathol 50:109-17, 2016. e-Pub 2016. PMID: 26997444.
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Shamanna RK, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127(10):1269-75, 2016. e-Pub 2016. PMID: 26729897.
Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber DM, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros LJ, Young KH. Crystal-Storing Histiocytosis: A Clinicopathologic Study of 13 Cases. Histopathology 68(4):482-91, 2016. e-Pub 2016. PMID: 26118455.
Jain P, Ok CY, Konoplev S, Patel KP, Jorgensen J, Estrov Z, Luthra R, Kantarjian H, Ravandi F. Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?. J Clin Oncol 34(7):e57-60, 2016. e-Pub 2016. PMID: 24982452.
Maher OM, Khatua S, Mukherjee D, Olar A, Lazar A, Luthra R, Liu D, Wu J, Ketonen L, Zaky W. Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature. J Neurooncol 127(1):155-63, 2016. e-Pub 2016. PMID: 26718692.
Lou Y, Pecot CV, Tran HT, DeVito VJ, Tang XM, Heymach JV, Luthra R, Wistuba II, Zuo Z, Tsao AS. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clin Lung Cancer 17(2):e5-11, 2016. e-Pub 2016. PMID: 26700910.
Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7(12):14251-8, 2016. e-Pub 2016. PMID: 26883102.
Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Young Ok C, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R, Patel KP. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol 145(3):418-27, 2016. e-Pub 2016. PMID: 27124925.
Goswami RS, Luthra R, Singh RR, Patel KP, Routbort MJ, Aldape KD, Yao H, Dang HD, Barkoh BA, Manekia J, Medeiros LJ, Roy-Chowdhuri S, Stewart J, Broaddus RR, Chen H. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. Am J Clin Pathol 145(2):222-37, 2016. e-Pub 2016. PMID: 27124905.
Okoye EI, Bruegl AS, Fellman B, Luthra R, Broaddus RR. Defective DNA Mismatch Repair Influences Expression of Endometrial Carcinoma Biomarkers. Int J Gynecol Pathol 35(1):8-15, 2016. e-Pub 2016. PMID: 25851713.
Peng J, Zuo Z, Fu B, Oki Y, Tang G, Goswami M, Priyanka P, Muzzafar T, Medeiros LJ, Luthra R, Wang SA. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. Eur J Haematol 96(1):65-71, 2016. e-Pub 2016. PMID: 25809997.
Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 39(12):1367-74, 2015. e-Pub 2015. PMID: 26547258.
Mehrotra M, Luthra R, Singh RR, Barkoh BA, Galbincea J, Mehta P, Goswami RS, Jabbar KJ, Loghavi S, Medeiros LJ, Verstovsek S, Patel KP. Clinical Validation of a Multipurpose Assay for Detection and Genotyping of CALR Mutations in Myeloproliferative Neoplasms. Am J Clin Pathol 144(5):746-55, 2015. e-Pub 2015. PMID: 26486739.
Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. Am J Clin Pathol 144(5):713-21, 2015. e-Pub 2015. PMID: 26486734.
Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol 90(11):1065-70, 2015. e-Pub 2015. PMID: 26299958.
Roy-Chowdhuri S, Goswami RS, Chen H, Patel KP, Routbort MJ, Singh RR, Broaddus RR, Barkoh BA, Manekia J, Yao H, Medeiros LJ, Staerkel G, Luthra R, Stewart J. Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol 123(11):659-68, 2015. e-Pub 2015. PMID: 26230354.
Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget 6(29):26886-94, 2015. e-Pub 2015. PMID: 26330075.
Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(27):24581, 2015. e-Pub 2015. PMID: 26405159.
Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol 28(9):1225-35, 2015. e-Pub 2015. PMID: 26111976.
Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully intergrated molecular diagnostic system. Oncotarget 6(29):26886-94, 2015. e-Pub 2015. PMID: 26330075.
Mehrotra M, Patel KP, Chen T, Miranda RN, Wang Y, Zuo Z, Muddasani R, Mishra BM, Abraham R, Luthra R, Lu G. Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion. Clin Lymphoma Myeloma Leuk 15(8):496-505.e2, 2015. e-Pub 2015. PMID: 26027540.
Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126(6):790-7, 2015. e-Pub 2015. PMID: 26124496.
Loghavi S, Al-Ibraheemi A, Zuo Z, Garcia-Manero G, Yabe M, Wang SA, Kantarjian HM, Yin CC, Miranda RN, Luthra R, Medeiros LJ, Bueso-Ramos CE, Khoury JD. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. e-Pub 2015. PMID: 26123119.
Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res 21(11):2644-51, 2015. e-Pub 2015. PMID: 25695693.
Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125(21):3360-3, 2015. e-Pub 2015. PMID: 25999449.
Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. e-Pub 2015. PMID: 26014291.
Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(14):12809-21, 2015. e-Pub 2015. PMID: 25980577.
Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. e-Pub 2015. PMID: 26015395.
Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, Davies MA, Wargo JA, Routbort MA, Broaddus RR, Prieto VG, Lazar AJ, Tetzlaff MT. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol 42(5):308-17, 2015. e-Pub 2015. PMID: 25754356.
Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami R, Aldape KD, Medeiros LJ, Routbort MJ. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry. Am J Surg Pathol 39(4):454-61, 2015. e-Pub 2015. PMID: 25634750.
Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SA. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res 39(3):348-54, 2015. e-Pub 2015. PMID: 25573287.
Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clin Chem 61(3):544-53, 2015. e-Pub 2015. PMID: 25626406.
Paniz-Mondolfi A, Singh R, Jour G, Mahmoodi M, Diwan AH, Barkoh BA, Cason R, Huttenbach Y, Benaim G, Galbincea J, Luthra R. Cutaneous carcinosarcoma and the EMT: to transition, or not to transition? That is the question. Virchows Arch. e-Pub 2015. PMID: 25619916.
Gu J, Patel KP, Bai B, Liu CH, Tang G, Kantarjian HM, Tang Z, Abraham R, Luthra R, Medeiros LJ, Lin P, Lu X. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Mol Cytogenet 8:68, 2015. e-Pub 2015. PMID: 26300976.
Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 8:45, 2015. e-Pub 2015. PMID: 25952993.
Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res 20(24):6336-45, 2014. e-Pub 2014. PMID: 25326232.
Singh RR, Patel K P, Routbort M J, Aldape K, Lu X, Manekia J, Abraham R, Reddy N G, Barkoh B A, Veliyathu J, Medeiros L J, and Luthra R. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer, 2014. e-Pub 2014. PMID: 25314059.
Mehrotra M, Medeiros LJ, Luthra R, Sargent RL, Yao H, Barkoh BA, Singh R, Patel KP. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. Hum Pathol 45(10):1995-2005, 2014. e-Pub 2014. PMID: 25128227.
Vilar E, Mork ME, Cuddy A, Borras E, Bannon SA, Taggart MW, Ying J, Broaddus RR, Luthra R, Rodriguez-Bigas MA, Lynch PM, You YQ. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet 207(10-12):495-502, 2014. e-Pub 2014. PMID: 25432668.
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 89(10):964-8, 2014. e-Pub 2014. PMID: 24990142.
Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, Luthra R, Popat U, Verstovsek S. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia 28(10):2090-2, 2014. e-Pub 2014. PMID: 24854988.
Paniz-Mondolfi A, Singh R, Jour G, Mahmoodi M, Diwan AH, Barkoh BA, Cason R, Huttenbach Y, Benaim G, Galbincea J, Luthra R. Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing. Virchows Arch 465(3):339-50, 2014. e-Pub 2014. PMID: 25031014.
Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. J Invest Dermatol. e-Pub 2014. PMID: 25148578.
Batte BA, Bruegl AS, Daniels MS, Ring KL, Dempsey KM, Djordjevic B, Luthra R, Fellman BM, Lu KH, Broaddus RR. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome. Gynecol Oncol 134(2):319-25, 2014. e-Pub 2014. PMID: 24933100.
Bruegl AS, Djordjevic B, Batte B, Daniels M, Fellman B, Urbauer D, Luthra R, Sun C, Lu KH, Broaddus RR. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila) 7(7):686-97, 2014. e-Pub 2014. PMID: 24771847.
Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer 120(14):2142-9, 2014. e-Pub 2014. PMID: 24737502.
Dumbre Patil S, Dumbre Patil V, Abane S, Luthra R, Ranaware A. Acute Compartment Syndrome of the Foot due to Infection after Local Hydrocortisone Injection: A Case Report. J Foot Ankle Surg. e-Pub 2014. PMID: 24838218.
Zhang L, Singh RR, Patel KP, Stingo F, Routbort M, You MJ, Miranda RN, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Luthra R, Khoury JD. BRAF Kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with Wild-Type RAS. Am J Hematol 89(5):499-504, 2014. e-Pub 2014. PMID: 24446311.
Portier BP, Kanagal-Shamanna R, Luthra R, Singh R, Routbort MJ, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, Aldape K, Patel KP. Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol 141(4):559-72, 2014. e-Pub 2014. PMID: 24619758.
Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123(17):2645-51, 2014. e-Pub 2014. PMID: 24627528.
Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 89(3):282-7, 2014. e-Pub 2014. PMID: 24779033.
Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Singh RR. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica 99(3):465-73, 2014. e-Pub 2014. PMID: 24142997.
Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120(3):373-80, 2014. e-Pub 2014. PMID: 24151050.
Leventaki V, Manning JT, Luthra R, Mehta P, Oki Y, Romaguera JE, Medeiros LJ, Vega F. Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum Pathol 45(2):421-6, 2014. e-Pub 2014. PMID: 24439229.
Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. e-Pub 2014. PMID: 24487412.
Dinardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. e-Pub 2014. PMID: 24138309.
Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Rep 6(2):377-387, 2014. e-Pub 2014. PMID: 24440717.
Mehrotra M, Luthra R, Ravandi F, Sargent RL, Barkoh BA, Abraham R, Mishra BM, Medeiros LJ, Patel KP. Identification of Clinically Important Chromosomal Aberrations in Acute Myeloid Leukemia by Array-Based Comparative Genomic Hybridization. Leuk Lymphoma. e-Pub 2014. PMID: 24446873.
Bruegl AS, Djordjevic B, Urbauer DL, Westin SN, Soliman PT, Lu KH, Luthra R, Broaddus RR. Utility of MLH1 Methylation Analysis in the Clinical Evaluation of Lynch Syndrome in Women with Endometrial Cancer. Curr Pharm Des 20(11):1655-63, 2014. e-Pub 2014. PMID: 23888949.
Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. Clin Lymphoma Myeloma Leuk. e-Pub 2013. PMID: 24332214.
Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther 12(12):2857-63, 2013. e-Pub 2013. PMID: 24092809.
Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88(12):1055-61, 2013. e-Pub 2013. PMID: 23940084.
Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood 122(23):3784-6, 2013. e-Pub 2013. PMID: 24068492.
Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 98(11):1686-8, 2013. e-Pub 2013. PMID: 23812943.
Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 122(16):2807-11; quiz 2920, 2013. e-Pub 2013. PMID: 23896412.
Djordjevic B, Barkoh BA, Luthra R, Broaddus RR. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol 26(10):1401-12, 2013. e-Pub 2013. PMID: 23599155.
Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD, Luthra R. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 15(5):607-22, 2013. e-Pub 2013. PMID: 23810757.
Jaso JM, Yin CC, Lu VW, Zhao M, Abruzzo LV, You MJ, Yang Y, Luthra R, Medeiros LJ, Lu G. B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease. Mod Pathol. e-Pub 2013. PMID: 24030742.
Paniz Mondolfi AE, Jour G, Johnson M, Reidy J, Cason RC, Barkoh BA, Benaim G, Singh R, Luthra R. Primary cutaneous carcinosarcoma: insights into its clonal origin and mutational pattern expression analysis through next-generation sequencing. Hum Pathol. e-Pub 2013. PMID: 24071013.
Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated Nucleophosmin-1 (NPM1) in patients with Acute Myeloid Leukemia (AML) in remission and relapse. Leuk Lymphoma. e-Pub 2013. PMID: 24004182.
Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. e-Pub 2013. PMID: 23913852.
Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122(7):1214-21, 2013. e-Pub 2013. PMID: 23836561.
Lee N, Luthra R, Lopez-Terrada D, Wang WL, Lazar AJ. Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature. J Cutan Pathol 40(8):730-3, 2013. e-Pub 2013. PMID: 23672746.
Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM, Paladugu AV, Manekia JH, Kalhor N, Chowdhuri SR, Staerkel GA, Medeiros LJ, Luthra R, Patel KP. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. e-Pub 2013. PMID: 23907151.
Sandoval MR, Balakrishnan K, Luthra R, Keating M, Gandhi V. DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells. Leuk Lymphoma. e-Pub 2013. PMID: 23772636.
Greaves WO, Verma S, Bisrat T, Strati P, Rahimi H, Paladugu AV, Luthra R, Patel KP, Medeiros LJ, Yao H, Pierce S, Bueso-Ramos CE, Verstovsek S. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma 54(7):1552, 2013. e-Pub 2013. PMID: 23121011.
Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. e-Pub 2013. PMID: 23774633.
Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol 161(5):659-66, 2013. e-Pub 2013. PMID: 23530930.
Collier P, Patel K, Waeltz P, Rupar M, Luthra R, Liu PC, Hollis G, Huber R, Verstovsek S, Burn TC. Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples. Genet Test Mol Biomarkers 17(5):429-37, 2013. e-Pub 2013. PMID: 23537216.
Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 15(2):220-6, 2013. e-Pub 2013. PMID: 23273605.
Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73(1):276-84, 2013. e-Pub 2013. PMID: 23066039.
Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma 54(1):138-44, 2013. e-Pub 2013. PMID: 22691121.
Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 2013. e-Pub 2013. PMID: 23115106.
Yin CC, Luthra R. Molecular detection of t(11;14)(q13;q32) in mantle cell lymphoma. Methods Mol Biol 999:211-6, 2013. e-Pub 2013. PMID: 23666700.
Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 3(12):1566-75, 2012. e-Pub 2012. PMID: 23248156.
Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer 118(23):5819-22, 2012. e-Pub 2012. PMID: 22605576.
Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 18(22):6373-83, 2012. e-Pub 2012. PMID: 22966018.
Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 118(22):5550-9, 2012. e-Pub 2012. PMID: 22569880.
Warren M, Luthra R, Yin CC, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Zuo Z. Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol 25(10):1405-12, 2012. e-Pub 2012. PMID: 22684224.
Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica 97(8):1242-5, 2012. e-Pub 2012. PMID: 22532519.
Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, Bisrat T, Ravandi-Kashani F, Cortes JE, Kantarjian HM, Medeiros LJ, Luthra R. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn 14(4):336-45, 2012. e-Pub 2012. PMID: 22642896.
Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O'Brien S, Thomas DA, Kantarjian H, Medeiros LJ, Luthra R, Patel KP. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol 138(1):153-6, 2012. e-Pub 2012. PMID: 22706871.
Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer 118(10):2665-73, 2012. e-Pub 2012. PMID: 22020636.
Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, Broaddus RR. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 25(5):699-708, 2012. e-Pub 2012. PMID: 22301702.
Deqin M, Chen Z, Nero C, Patel KP, Daoud EM, Cheng H, Djordjevic B, Broaddus RR, Medeiros LJ, Rashid A, Luthra R. Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas. Arch Pathol Lab Med 136(5):510-6, 2012. e-Pub 2012. PMID: 22540299.
Al-Zaid T, Ditelberg JS, Prieto VG, Lev D, Luthra R, Davies MA, Diwan AH, Wang WL, Lazar AJ. Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. J Cutan Pathol 39(5):493-9, 2012. e-Pub 2012. PMID: 22486434.
Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. Biol Blood Marrow Transplant 18(4):584-92, 2012. e-Pub 2012. PMID: 21867666.
Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-82, 2012. e-Pub 2012. PMID: 22271473.
Bains A, Lu G, Yao H, Luthra R, Medeiros LJ, Sargent RL. Molecular and clinicopathologic characterization of AML with isolated trisomy 4. Am J Clin Pathol 137(3):387-94, 2012. e-Pub 2012. PMID: 22338050.
Bartley AN, Luthra R, Saraiya DS, Urbauer DL, Broaddus RR. Identification of Cancer Patients with Lynch Syndrome: Clinically Significant Discordances and Problems in Tissue Based Mismatch Repair Testing. Cancer Prev Res (Phila) 5(2):320-7, 2012. e-Pub 2012. PMID: 22086678.
Ellezam B, Theeler BJ, Luthra R, Adesina AM, Aldape KD, Gilbert MR. Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor. Acta Neuropathol 123(2):285-7, 2012. e-Pub 2012. PMID: 21997360.
Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One 7(5):e38033, 2012. e-Pub 2012. PMID: 22675430.
Zuo Z, Medeiros LJ, Chen Z, Liu D, Bueso-Ramos CE, Luthra R, Wang SA. Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML. PLoS One 7(7):e41485, 2012. e-Pub 2012. PMID: 22844482.
Bartley AN, Yao H, Barkoh BA, Ivan C, Mishra BM, Rashid A, Calin GA, Luthra R, Hamilton SR. Complex Patterns of Altered MicroRNA Expression during the Adenoma-Adenocarcinoma Sequence for Microsatellite-stable Colorectal Cancer. Clin Cancer Res 17(23):7283-93, 2011. e-Pub 2011. PMID: 21948089.
Patel KP, Barkoh BA, Chen Z, Ma D, Reddy N, Medeiros LJ, Luthra R. Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia An Algorithmic Approach Using High-Resolution Melting Curve Analysis. J Mol Diagn. e-Pub 2011. PMID: 21889610.
Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. e-Pub 2011. PMID: 21821712.
Barakat FH, Luthra R, Yin CC, Barkoh BA, Hai S, Jamil W, Bhakta YI, Chen S, Medeiros LJ, Zuo Z. Detection of nucleophosmin 1 mutations by quantitative real-time polymerase chain reaction versus capillary electrophoresis: a comparative study. Arch Pathol Lab Med 135(8):994-1000, 2011. e-Pub 2011. PMID: 21809990.
Ma D, Chen Z, Patel KP, Mishra BM, Yao H, Abruzzo LV, Medeiros LJ, Wierda W, Keating M, Sargent R, Luthra R. Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S17-24, 2011. e-Pub 2011. PMID: 22035742.
Schweighofer CD, Huh YO, Luthra R, Sargent RL, Ketterling RP, Knudson RA, Barron LL, Medeiros LJ, Keating MJ, Abruzzo LV. The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. Int J Cancer 128(11):2759-64, 2011. e-Pub 2011. PMID: 20715110.
Huh YO, Schweighofer CD, Ketterling RP, Knudson RA, Vega F, Kim JE, Luthra R, Keating MJ, Medeiros LJ, Abruzzo LV. Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. Am J Clin Pathol 135(5):686-96, 2011. e-Pub 2011. PMID: 21502423.
Gurevich I, Luthra R, Konoplev SN, Yin CC, Medeiros LJ, Lin P. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings. Am J Clin Pathol 135(3):398-403, 2011. e-Pub 2011. PMID: 21350094.
Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10(3):558-65, 2011. e-Pub 2011. PMID: 21216929.
Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitor. Mol Cancer Ther 10(3):558-65, 2011. e-Pub 2011. PMID: 21216929.
Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 135(1):35-45, 2011. e-Pub 2011. PMID: 21173122.
Bains A, Luthra R, Medeiros LJ, Zuo Z. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 135(1):62-9, 2011. e-Pub 2011. PMID: 21173125.
Schweighofer CD, Coombes KR, Barron LL, Diao L, Newman RJ, Ferrajoli A, O'Brien S, Wierda WG, Luthra R, Medeiros LJ, Keating MJ, Abruzzo LV. A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia. PLoS One 6(12):e28277, 2011. e-Pub 2011. PMID: 22194822.
Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6(7):e22769, 2011. e-Pub 2011. PMID: 21829508.
Al-Kali A, Verstovsek S, Kantarjian H, Luthra R, Cortes J. Competing cell clones in myeloproliferative neoplasm. Blood 116(23):5074-5, 2010. e-Pub 2010. PMID: 21127188.
Zuo Z, Jones D, Yao H, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Abruzzo LV, Medeiros LJ, Chen SS, Luthra R. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod Pathol 23(11):1524-34, 2010. e-Pub 2010. PMID: 20729815.
Admirand JH, Knoblock RJ, Coombes KR, Tam C, Schlette EJ, Wierda WG, Ferrajoli A, O'Brien S, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol 23(11):1518-23, 2010. e-Pub 2010. PMID: 20657554.
Yin CC, Cortes J, Galbincea J, Reddy N, Breeden M, Jabbour E, Luthra R, Jones D. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci 101(9):2005-2010, 2010. e-Pub 2010. PMID: 20557306.
Earle JS, Luthra R, Romans A, Abraham R, Ensor J, Yao H, Hamilton SR. Association of MicroRNA Expression with Microsatellite Instability Status in Colorectal Adenocarcinoma. J Mol Diagn 12(4):433-40, 2010. e-Pub 2010. PMID: 20413677.
Chen Z, Li Y, Zhang H, Huang P, Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 29(30):4362-8, 2010. e-Pub 2010. PMID: 20498629.
Lin P, Luthra R, Nussenzveig RH, Medeiros LJ. JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome. Hum Pathol 41(5):758-62, 2010. e-Pub 2010. PMID: 20153505.
Chandra P, Luthra R, Zuo Z, Yao H, Ravandi F, Reddy N, Garcia-Manero G, Kantarjian H, Jones D. Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. Am J Clin Pathol 133(5):686-93, 2010. e-Pub 2010. PMID: 20395514.
Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. J Clin Oncol 28(11):1856-62, 2010. e-Pub 2010. PMID: 20212254.
Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, Abruzzo LV, Kantarjian HM, Medeiros LJ, Wang SA. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood 115(10):1985-92, 2010. e-Pub 2010. PMID: 20040759.
Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27(32):5418-24, 2009. e-Pub 2009. PMID: 19826111.
Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33(11):1481-1484, 2009. e-Pub 2009. PMID: 19193436.
Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 114(11):2232-5, 2009. e-Pub 2009. PMID: 19531657.
Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, Barkoh BA, Koeppen H, Medeiros LJ, Luthra R. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 22(8):1023-31, 2009. e-Pub 2009. PMID: 19430420.
Jain N, Cortes J, Quintás-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFR alpha mutation status. Leuk Res 33(6):837-9, 2009. e-Pub 2009. PMID: 19013640.
Yin CC, Lin KI, Ketterling RP, Knudson RA, Medeiros LJ, Barron LL, Huh YO, Luthra R, Keating MJ, Abruzzo LV. Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes. Am J Clin Pathol 131(5):663-70, 2009. e-Pub 2009. PMID: 19369625.
Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra R. MicroRNA-196a is a Potential Marker of Progression during Barrett's Metaplasia-Dysplasia-Invasive Adenocarcinoma Sequence in Esophagus. Am J Pathol 174(5):1940-8, 2009. e-Pub 2009. PMID: 19342367.
Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra R, Medeiros LJ, Wang SA. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol 131(5):647-55, 2009. e-Pub 2009. PMID: 19369623.
Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer 115(7):1576-85, 2009. e-Pub 2009. PMID: 19156915.
Singh RR, Cho-Vega JH, Davuluri Y, Ma S, Kasbidi F, Milito C, Lennon PA, Drakos E, Medeiros LJ, Luthra R, Vega F. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res 69(6):2550-8, 2009. e-Pub 2009. PMID: 19244133.
Johnson MR, Verstovsek S, Jorgensen JL, Manshouri T, Luthra R, Jones DM, Bueso-Ramos CE, Medeiros LJ, Huh YO. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol 22(1):50-7, 2009. e-Pub 2009. PMID: 19116630.
Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A, Quintás-Cardama A, Ravandi F, Ault P, Bueso-Ramos C, Cortes JE. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 15(1):368-73, 2009. e-Pub 2009. PMID: 19118067.
Sargent R, Jones D, Abruzzo LV, Yao H, Bonderover J, Cisneros M, Wierda WG, Keating MJ, Luthra R. Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn 11(1):25-34, 2009. e-Pub 2009. PMID: 19074592.
Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR. Carcinoma of the lower uterine segment: a newly described association with Lynch Syndrome. J Clin Oncol 26(36):5965-71, 2008. e-Pub 2008. PMID: 19001318.
Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, Hai S, Ravandi F, de Lima M, Kantarjian H, Jorgensen JL. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood 112(13):5190-2, 2008. e-Pub 2008. PMID: 18809762.
Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, Broaddus RR, Rashid A, Albarracin CT. MicroRNA-196a targets Annexin A1: A microRNA-mediated mechanism of Annexin A1 downregulation in cancers. Oncogene 27(52):6667-78, 2008. e-Pub 2008. PMID: 18663355.
Lin P, Chen L, Luthra R, Konoplev SN, Wang X, Medeiros LJ. Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Mod Pathol 21(8):1029-36, 2008. e-Pub 2008. PMID: 18536654.
Huh YO, Lin KI, Vega F, Schlette E, Yin CC, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 142(1):36-44, 2008. e-Pub 2008. PMID: 18477041.
Vega F, Cho-Vega JH, Lennon PA, Luthra MG, Bailey J, Breeden M, Jones D, Medeiros LJ, Luthra R. Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (POT1) and sonic hedgehog (SHH) genes. Br J Haematol 142(2):216-226, 2008. e-Pub 2008. PMID: 18492102.
Guo M, Gong Y, Deavers M, Silva EG, Jan YJ, Cogdell DE, Luthra R, Lin E, Lai HC, Zhang W, Sneige N. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol 46(1):274-80, 2008. e-Pub 2008. PMID: 17977987.
Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25(33):5158-64, 2007. e-Pub 2007. PMID: 17925543.
Abruzzo LV, Barron LL, Anderson K, Newman RJ, Wierda WG, O'brien S, Ferrajoli A, Luthra M, Talwalkar S, Luthra R, Jones D, Keating MJ, Coombes KR. Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. J Mol Diagn 9(4):546-55, 2007. e-Pub 2007. PMID: 17690214.
Izzo JG, Luthra R, Sims-Mourtada J, Chao KS, Lee JH, Wu TT, Correa AM, Luthra M, Aggarwal B, Hung MC, Ajani JA. Emerging molecular targets in esophageal cancers. Gastrointest Cancer Res 1(4 Suppl 2):S3-6, 2007. e-Pub 2007. PMID: 19360144.
Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC, Ajani JA. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev 16(6):1200-5, 2007. e-Pub 2007. PMID: 17548685.
Izzo JG, Luthra R, Wu TT, Correa AM, Luthra M, Anandasabapathy S, Chao KS, Hung MC, Aggarwal B, Hittelman WN, Ajani JA. Molecular mechanisms in Barrett's metaplasia and its progression. Semin Oncol 34(2 Suppl 1):S2-6, 2007. e-Pub 2007. PMID: 17449347.
Guo M, Sneige N, Silva EG, Jan YJ, Cogdell DE, Lin E, Luthra R, Zhang W. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Mod Pathol 20(2):256-266, 2007. e-Pub 2007. PMID: 17192787.
Luthra MG, Ajani JA, Izzo J, Ensor J, Wu TT, Rashid A, Zhang L, Phan A, Fukami N, Luthra R. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 13(3):912-9, 2007. e-Pub 2007. PMID: 17289885.
Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, Ajani JA. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol 25(6):698-707, 2007. e-Pub 2007. PMID: 17308274.
Yin CC, Medeiros LJ, Cromwell CC, Mehta AP, Lin P, Luthra R, Abruzzo LV. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma. Mod Pathol 20(1):1-7, 2007. e-Pub 2007. PMID: 17057651.
Luthra R, Luthra MG, Izzo J, Wu TT, Lopez-Alvarez E, Malhotra U, Choi IS, Zhang L, Ajani JA. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol 33(6 Suppl 11):2-5, 2006. e-Pub 2006. PMID: 17178277.
Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 5(11):2844-50, 2006. e-Pub 2006. PMID: 17121931.
Rosen DG, Cai KQ, Luthra R, Liu J. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol 19(11):1414-20, 2006. e-Pub 2006. PMID: 16941012.
Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, Chao KS. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 12(21):6565-72, 2006. e-Pub 2006. PMID: 17085672.
Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767-73, 2006. e-Pub 2006. PMID: 16855631.
Lin P, Jones D, Medeiros LJ, Chen W, Vega-Vazquez F, Luthra R. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol 126(4):530-3, 2006. e-Pub 2006. PMID: 16938665.
Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24(5):748-54, 2006. e-Pub 2006. PMID: 16401681.
Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 24(2):259-67, 2006. e-Pub 2006. PMID: 16344314.
Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, White KG, Luthra R, Lu KH. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 106(1):87-94, 2006. e-Pub 2006. PMID: 16323174.
Chang KH, Albarracin C, Luthra R, Wang L, Zheng W, Malpica A, Deavers MT, Silva EG, Liu J. Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis. Int J Gynecol Cancer 16(1):178-82, 2006. e-Pub 2006. PMID: 16445630.
Soliman PT, Broaddus RR, Schmeler KM, Daniels MS, Gonzalez D, Slomovitz BM, Gershenson DM, Lu KH. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?. J Clin Oncol 23(36):9344-50, 2005. e-Pub 2005. PMID: 16361634.
Chen W, Jones D, Medeiros LJ, Luthra R, Lin P. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol 130(5):726-8, 2005. e-Pub 2005. PMID: 16115128.
Yin CC, Glassman AB, Lin P, Valbuena JR, Jones D, Luthra R, Medeiros LJ. Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia. Am J Clin Pathol 123(6):840-8, 2005. e-Pub 2005. PMID: 15899774.
Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11(9):3425-32, 2005. e-Pub 2005. PMID: 15867244.
Albarracin CT, Silva EG, Malpica A, Luthra R, Liu J. The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype. Oncol Rep 12(6):1217-9, 2004. e-Pub 2004. PMID: 15547740.
Bowman A, Jones D, Medeiros LJ, Luthra R. Quantitative PCR detection of t(14;18) bcl-2/JH fusion sequences in follicular lymphoma patients: comparison of peripheral blood and bone marrow aspirate samples. J Mol Diagn 6(4):396-400, 2004. e-Pub 2004. PMID: 15507680.
Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104(7):1979-88, 2004. e-Pub 2004. PMID: 15198956.
Oyarzo MP, Lin P, Glassman A, Bueso-Ramos CE, Luthra R, Medeiros LJ. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 122(3):348-58, 2004. e-Pub 2004. PMID: 15362364.
Broaddus RR, Lynch PM, Lu KH, Luthra R, Michelson SJ. Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol 17(8):981-9, 2004. e-Pub 2004. PMID: 15143336.
Luthra R, Medeiros LJ. Isothermal multiple displacement amplification: a highly reliable approach for generating unlimited high molecular weight genomic DNA from clinical specimens. J Mol Diagn 6(3):236-42, 2004. e-Pub 2004. PMID: 15269301.
Jones D, Ibrahim S, Patel K, Luthra R, Duvic M, Medeiros LJ. Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. Clin Cancer Res 10(16):5587-94, 2004. e-Pub 2004. PMID: 15328201.
Beran M, Luthra R, Kantarjian H, Estey E. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res 28(6):547-50, 2004. e-Pub 2004. PMID: 15120929.
Mundhada S, Luthra R, Cano P. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11). BMC Cancer 4:25, 2004. e-Pub 2004. PMID: 15202948.
McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol 28(6):712-8, 2004. e-Pub 2004. PMID: 15166663.
Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, Broaddus R, Liu J. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol 35(5):552-9, 2004. e-Pub 2004. PMID: 15138928.
Luthra R, Sanchez-Vega B, Jeffrey Medeiros L. TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol 17(1):96-103, 2004. e-Pub 2004. PMID: 14657955.
Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, Gershenson DM, Broaddus R, Luthra R. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol 17(1):75-80, 2004. e-Pub 2004. PMID: 14631366.
Chung L, Broaddus R, Crozier M, Luthra R, Levenback C, Lu K. Unexpected endometrial cancer at prophylactic hysterectomy in a woman with hereditary nonpolyposis colon cancer. Obstet Gynecol 102(5 Pt 2):1152-5, 2003. e-Pub 2003. PMID: 14607039.
Cao SN, Chang KH, Luthra R, Liu J. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma. Mod Pathol 16(10):1048-52, 2003. e-Pub 2003. PMID: 14559989.
Vega F, Luthra R, Medeiros LJ, Dunmire V, Lee SJ, Duvic M, Jones D. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood 100(9):3369-73, 2002. e-Pub 2002. PMID: 12384439.
Han XY, Pham AS, Tarrand JJ, Sood PK, Luthra R. Rapid and accurate identification of mycobacteria by sequencing hypervariable regions of the 16S ribosomal RNA gene. Am J Clin Pathol 118(5):796-801, 2002. e-Pub 2002. PMID: 12428802.
Sanchez-Vega B, Vega F, Medeiros LJ, Lee MS, Luthra R. Quantification of bcl-2/JH fusion sequences and a control gene by multiplex real-time PCR coupled with automated amplicon sizing by capillary electrophoresis. J Mol Diagn 4(4):223-9, 2002. e-Pub 2002. PMID: 12411590.
Thomazy VA, Luthra R, Uthman MO, Davies PJ, Medeiros LJ. Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas. J Mol Diagn 4(4):201-8, 2002. e-Pub 2002. PMID: 12411587.
Kabbani W, Houlihan PS, Luthra R, Hamilton SR, Rashid A. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol 15(6):599-605, 2002. e-Pub 2002. PMID: 12065772.
Medeiros LJ, Hai S, Thomazy VA, Estalilla OC, Romaguera J, Luthra R. Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas. Mod Pathol 15(5):556-64, 2002. e-Pub 2002. PMID: 12011261.
Abruzzo LV, Rosales CM, Medeiros LJ, Vega F, Luthra R, Manning JT, Keating MJ, Jones D. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 26(5):630-6, 2002. e-Pub 2002. PMID: 11979093.
Sanchez-Vega B, Vega F, Hai S, Medeiros LJ, Luthra R. Real-Time t(14;18)(q32;q21) PCR assay combined with high-resolution capillary electrophoresis: a novel and rapid approach that allows accurate quantitation and size determination of bcl-2/JH fusion sequences. Mod Pathol 15(4):448-53, 2002. e-Pub 2002. PMID: 11950920.
Vega F, Medeiros LJ, Bueso-Ramos C, Jones D, Lai R, Luthra R, Abruzzo LV. Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol 116(3):410-9, 2001. e-Pub 2001. PMID: 11554170.
Vega F, Medeiros LJ, Jones D, Abruzzo LV, Lai R, Manning J, Dunmire V, Luthra R. A novel four-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions. Am J Clin Pathol 116(1):17-24, 2001. e-Pub 2001. PMID: 11447747.
Bruckner JV, Kyle GM, Luthra R, Acosta D, Mehta SM, Sethuraman S, Muralidhara S. Acute, short-term, and subchronic oral toxicity of 1,1,1-trichloroethane in rats. Toxicol Sci 60(2):363-72, 2001. e-Pub 2001. PMID: 11248149.
Lu D, Duvic M, Medeiros LJ, Luthra R, Dorfman DM, Jones D. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol 115(3):413-21, 2001. e-Pub 2001. PMID: 11242798.
Frazier ML, O'Donnell FT, Kong S, Gu X, Campos I, Luthra R, Lynch PM, Amos CI. Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res 61(4):1269-71, 2001. e-Pub 2001. PMID: 11245417.
Katz RL, Caraway NP, Gu J, Jiang F, Pasco-Miller LA, Glassman AB, Luthra R, Hayes KJ, Romaguera JE, Cabanillas FF, Medeiros LJ. Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma. Am J Clin Pathol 114(2):248-57, 2000. e-Pub 2000. PMID: 10941340.
Estalilla OC, Medeiros LJ, Manning JT, Jr, Luthra R. 5'-->3' exonuclease-based real-time PCR assays for detecting the t(14;18)(q32;21): a survey of 162 malignant lymphomas and reactive specimens. Mod Pathol 13(6):661-6, 2000. e-Pub 2000. PMID: 10874671.
Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 6(3):1190-7, 2000. e-Pub 2000. PMID: 10741751.
Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 60(2):249-52, 2000. e-Pub 2000. PMID: 10667569.
Luthra R, Sarris AH, Hai S, Paladugu AV, Romaguera JE, Cabanillas FF, Medeiros LJ. Real-time 5'-->3' exonuclease-based PCR assay for detection of the t(11;14)(q13;q32). Am J Clin Pathol 112(4):524-30, 1999. e-Pub 1999. PMID: 10510675.
Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 131(2):88-95, 1999. e-Pub 1999. PMID: 10419446.
Frazier ML, Sinicrope FA, Amos CI, Cleary KR, Lynch PM, Levin B, Luthra R. Loci for efficient detection of microsatellite instability in hereditary non-polyposis colorectal cancer. Oncol Rep 6(3):497-505, 1999. e-Pub 1999. PMID: 10203581.
Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18(5):1185-96, 1999. e-Pub 1999. PMID: 10022124.
Luthra R, McBride JA, Cabanillas F, Sarris A. Novel 5' exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma. Am J Pathol 153(1):63-8, 1998. e-Pub 1998. PMID: 9665466.
Sarris AH, Luthra R, Cabanillas F, Morris SW, Pugh WC. Genomic DNA amplification and the detection of t(2;5)(p23;q35) in lymphoid neoplasms. Leuk Lymphoma 29(5-6):507-14, 1998. e-Pub 1998. PMID: 9643564.
Luthra R, Pugh WC, Waasdorp M, Morris W, Cabanillas F, Chan PK, Sarris AH. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products. Hematopathol Mol Hematol 11(3-4):173-83, 1998. e-Pub 1998. PMID: 9844824.
Luthra R, McBride JA, Hai S, Cabanillas F, Pugh WC. The application of fluorescence-based PCR and PCR-SSCP to monitor the clonal relationship of cells bearing the t(14;18)(q32;q21) in sequential biopsy specimens from patients with follicle center cell lymphoma. Diagn Mol Pathol 6(2):71-7, 1997. e-Pub 1997. PMID: 9098644.
Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Ann Oncol 8 Suppl 2:59-63, 1997. e-Pub 1997. PMID: 9209643.
Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood 88(5):1771-9, 1996. e-Pub 1996. PMID: 8781434.
McBride, Rodriguez J, Luthra R, Ordoñez N, Cabanillas F, Pugh W. T cell rich B large cell lymphoma simulating mixed cellularity Hodgkin's disease. Am J Surg Path 20(2):193-201, 1996. e-Pub 1996.
Luthra R, Hai S, Pugh WC. Polymerase chain reaction detection of the t(11;14) translocation involving the bcl-1 major translocation cluster in mantle cell lymphoma. Diagn Mol Pathol 4(1):4-7, 1995. e-Pub 1995. PMID: 7735555.
Rodriguez J, Pugh WC, Romaguera JE, Luthra R, Hagemeister FB, McLaughlin P, Rodriguez MA, Swan F, Cabanillas F. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol 5(9):847-9, 1994. e-Pub 1994. PMID: 7848887.
Pugh WC, Luthra R. Molecular strategies in the diagnosis of malignant lymphoma and lymphoproliferative disorders. Cancer Bulletin 45:29-36, 1993. e-Pub 1993.
Romaguera JE, Pugh W, Luthra R, Goodacre A, Cabanillas F. The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma. Ann Oncol 4(1):51-4, 1993. e-Pub 1993. PMID: 8435363.
Heindel JJ, Berkowitz AS, Kyle G, Luthra R, Bruckner JV. Assessment in rats of the gonadotoxic and hepatorenal toxic potential of dibromochloropropane (DBCP) in drinking water. Fundam Appl Toxicol 13(4):804-15, 1989. e-Pub 1989. PMID: 2620797.
Bruckner JV, MacKenzie WF, Muralidhara S, Luthra R, Kyle GM, Acosta D. Oral toxicity of carbon tetrachloride: acute, subacute, and subchronic studies in rats. Fundam Appl Toxicol 6(1):16-34, 1986. e-Pub 1986. PMID: 3710021.
Luthra R, Kyle GM, Mehta PS, Bruckner JV. Effects of carbon tetrachloride and 1,1-dichloroethylene on rat hepatic microsomal calcium- and/or magnesium-stimulated ATPase. Biochem Pharmacol 33(20):3295-8, 1984. e-Pub 1984. PMID: 6148949.
Bruckner JV, Luthra R, Kyle GM, Maralidhara S, Ramanathan, Acosta D. Influence of time of exposure to carbon tetrachloride on toxic liver injury. Ann Rev Chronopharmacol, 1984. e-Pub 1984.
Kyle GM, Luthra R, Bruckner JV, MacKenzie WF, Acosta D. Assessment of functional, morphological, and enzymatic tests for acute nephrotoxicity induced by mercuric chloride. J Toxicol Environ Health 12(1):99-117, 1983. e-Pub 1983. PMID: 6226807.
Luthra R, Olson MS. The interaction of chlorotetracycline with calcium transport of rat liver mitochondria. Arch Biochem Biophys 194:494-502, 1978. e-Pub 1978.
Luthra R, Olson MS. The inhibition of calcium uptake and release by rat liver mitochondria by ruthenium red. FEBS Lett 81(1):142-6, 1977. e-Pub 1977. PMID: 902768.
Luthra R, Olson MD. Studies of mitochondrial calcium movements using chlorotetracycline. Biochim Biophys Acta 440(3):744-58, 1976. e-Pub 1976. PMID: 822874.

Invited Articles

Luthra R, Chen H, Roy-Chowdhuri S, Singh RR. Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges. Cancers (Basel) 7(4):2023-36, 2015. e-Pub 2015. PMID: 26473927.
Chen H, Luthra R, Goswami RS, Singh RR, Roy-Chowdhuri S. Analysis of Pre-Analytic Factors Affectings the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies. Cancers (Basel) 7(3):1699-715, 2015. e-Pub 2015. PMID: 26343728.
Vega F, Medeiros LJ, Luthra R. TaqMan PCR in the detection and quantification of chromosal translocations in follicular lymphoma, mantle cell lymphoma and chronic myeloid leukemia. J Pathol, 2002. e-Pub 2002.
Luthra R, Medeiros LJ. Real-time fluorogenic 5'-3' exonuclease-based polymerase chain reaction. J Clin Ligand Assay 23:6-10, 2000. e-Pub 2000.

Review Articles

DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer 124(13):2704-2713, 2018. e-Pub 2018. PMID: 29682723.
Loghavi S, Routbort MJ, Patel KP, Luthra R, Wang WL, Broaddus RR, Davies MA, Lazar AJ. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. J Natl Compr Canc Netw 14(6):787-92, 2016. e-Pub 2016. PMID: 27283170.
Luthra R, Medeiros LJ. TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Methods Mol Biol 335:135-45, 2006. e-Pub 2006. PMID: 16785625.

Editorials

Luthra R, Zuo Z. COLD-PCR Finds Hot Application in Mutation Analysis. Clin Chem 55(12):2077-8, 2009. PMID: 19833831.

Abstracts

Shuai W, Chen W, Floyd K, Routbort M, San Lucas F, Kanagal-Shamanna R, Zuo Z, Loghavi S, Ok CY, Yin CC, Luthra R, Medeiros LJ, Patel K. Ultra-Rapid Reporting of TP53 Mutation in Myeloid Neoplasms by Using Next Generation Sequencing. LABORATORY INVESTIGATION 34(Supplement 2):891-892, 2021. e-Pub 2021.
Wang J, Albarracin C, Huo L, Ding QQ, Wu Y, Roy-Chowdhuri S, Patel K, Routbort M, Luthra R, Chen H. PTEN Alteration in ER plus Breast Cancer: Correlative Study of Immunohistochemistry and Next Generation Sequencing. LABORATORY INVESTIGATION 34(Supplement 2):161, 2021. e-Pub 2021.
Nezami B, Toruner G, San Lucas F, Yang R, Seyedjafari R, Chen H, Rashid A, Loghavi S, Roy-Chowduri S, Kanagal-Shamanna R, Yin CC, Zuo Z, Ok CY, Tang ZY, Medeiros LJ, Luthra R, Patel K. Clinical Utility of NGS-Based Gene Fusion Testing in Solid Tumors. LABORATORY INVESTIGATION 101(Supplement 1):513-514, 2021. e-Pub 2021.
Shuai W, Chen W, Floyd K, Routbort M, San Lucas F, Kanagal-Shamanna R, Zuo Z, Loghavi S, Ok CY, Yin CC, Luthra R, Medeiros LJ, Patel K. Ultra-Rapid Reporting of TP53 Mutation in Myeloid Neoplasms by Using Next Generation Sequencing. LABORATORY INVESTIGATION 101(Supplement 1):891-892, 2021. e-Pub 2021.
Nezami B, Toruner G, San Lucas F, Yang R, Seyedjafari R, Chen H, Rashid A, Loghavi S, Roy-Chowduri S, Kanagal-Shamanna R, Yin CC, Zuo Z, Ok CY, Tang ZY, Medeiros LJ, Luthra R, Patel K. Clinical Utility of NGS-Based Gene Fusion Testing in Solid Tumors. LABORATORY INVESTIGATION 34(Supplement 2):513-514, 2021. e-Pub 2021.
Wang J, Albarracin C, Huo L, Ding QQ, Wu Y, Roy-Chowdhuri S, Patel K, Routbort M, Luthra R, Chen H. PTEN Alteration in ER plus Breast Cancer: Correlative Study of Immunohistochemistry and Next Generation Sequencing. LABORATORY INVESTIGATION 101(Supplement 1):161-161, 2021. e-Pub 2021.
Morris VK, Raghav KPS, Dasari A, Overman MJ, Kee BK, Johnson B, Parseghian CM, JPYC S, Huey R, Raymond VM, Duose DY, Luthra R, Hong DS, Janku F, Kopetz S. Utility of Circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY 39(Issue 3/ Supplement S), 2021. e-Pub 2021.
Tashakori, ] M, Khoury, ] JD, [ ] LR. Exploring the Molecular Grey Zone of Myeloid Neoplasms: Concurrent SRSF2 and Classic MPN Driver Mutations. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 20:S340-S340. e-Pub 2020.
Sarshekeh, AM, Lam, M, Luthra R. Consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer: A phase II trial of bintrafusp alfa in CMS4 metastatic CRC. Journal of Clinical Oncology 38(15). e-Pub 2020.
Ramani, ] N, Routbort, ] M. Factors Affecting the Success of Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing 100(SUPPL 1):1891-1892, 2020. e-Pub 2020.
Ramani, ] N, Routbort, ] M, [ ] LR. Utilization of Cytology Smears for NGS-Based RNA Fusion Testing Improves Adequacy Rates. LABORATORY INVESTIGATION 100(SUPPL 1):408-409, 2020. e-Pub 2020.
Sukswai, ] N, Khoury, ] J, [ ] LR. Characterization of Bone Marrow Morphologic and Genetic Features of Myeloid Neoplasms with Germline DDX41 Mutation in 10 Distinct Pedigrees. LABORATORY INVESTIGATION 100(SUPPL 1):1394-1394, 2020. e-Pub 2020.
Yang, ] R, Abdulrazzaq, ] M, [ ] LR. Utility of NGS Assessment of Somatic Mutations in Mismatch Repair Genes in Solid Tumors: Improved Overall Survival in Stage III or IV Patients Treated with Immune Checkpoint Blockade. LABORATORY INVESTIGATION 100(SUPPL 1):1720-1721, 2020. e-Pub 2020.
Yang, ] R, Ronaghy, ] A, [ ] LR. Determination of Eligibility for Pembrolizumab Treatment: Comparison of Mismatch Repair Deficiency (dMMR) by IHC, Microsatellite Instability-High (MSI-H) Status by PCR, and MMR Gene Mutations (MMRmut) by NGS. LABORATORY INVESTIGATION 100(SUPPL 2):838-839, 2020. e-Pub 2020.
Ruiz-Cordero, R, Ma, J, Luthra R. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer 20(1), 2020. e-Pub 2020.
Chen, Za, b, Wang, SAa, Ra L. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leukemia Research 86(106227), 2019. e-Pub 2019.
Fang L, Lu X, Hu S, Tang Z, Luthra R, Routbort, Patel KP, Wang R, Broaddus R, Chen H. MET Amplification Predicts Primary Resistance to EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Patients with Sensitive EGFR Mutation. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):1032-1032, 2017. e-Pub 2017.
Mallampati S, Duose DY, Zalles S, Harmon MA, Kanagal-Shamanna R, Mehrotra M, Chen W, Lan C, Windham JP, Wistuba II, Singh RR, Kopetz S, Luthra R. Linear Amplification Coupled Exponential (LACE) PCR: A Novel Approach to Improve the Performance of Molecular Barcoded Next-Generation Sequencing Technology. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):1064-1064, 2017. e-Pub 2017.
Duose D, Lan CY, Luthra R, WistubaII, Jain N, Konopleva M, Patel KP. Validation of a Next Generation Sequencing-Based Assay to Detect Recurrent Translocations in Ph-Like Acute Lymphoblastic Leukemia. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):959-959, 2017. e-Pub 2017.
Kanagal-Shamanna R, Luthra R, Routbort MJ, Singh R, Flyod K, Abraham R, Hai S, Zuo Z, Ok CY, Loghavi S, Medeiros L, Patel KP. Multi-Platform-Based Comprehensive Molecular Analysis of Hematological Malignancies for Somatic Mutations, Copy Number Changes and Translocations for Routine Clinical Testing. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):964-964, 2017. e-Pub 2017.
Luthra R, Patel KP, Routhbort MJ, Medeiros L, Quesada AE, Kanagal-Shamanna R. Sequential NGS-Based Multi-Gene Mutational Analysis in de novo Acute Myeloid Leukemia with RUNX1 Mutation. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):969-969, 2017. e-Pub 2017.
Mallampati S, Duose D, Mehrotra M, Lan C, Windham JP, Wistuba II, Verstovsek S, Luthra R, Patel KP. A Balanced Formulation of Dimethyl Sulfoxide and Bovine Serum Albumin Provides Highly Uniform Coverage of CEBPA in a Droplet PCR-Based NGS Panel. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):970-970, 2017. e-Pub 2017.
Ruiz-Cordero R, Chen, W, Flyod KC, Rodriquez S. Breaking the Turnaround Time Barrier in Next Generation Sequencing Based Clinical Mutation Profiling Using an Integrated Workflow and Informatics Approach. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):997-998, 2017. e-Pub 2017.
Mehortra M, Duose D, Singh RR, Lan C, Barkoh BA, Routhort MJ, Patel KP, Medieros LJ, Kopetz S, Wistuab II, Luthra R. Ultra-Sensitive Tag Sequencing for Detection of Low Level Somatic Alterations in Plasma Cell Free DNA of Metastatic Colorectal Tumors on Ion S5XL Platform. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):1014-1014, 2017. e-Pub 2017.
Yemelyanova A, Routbort MJ, Chen H, Rashid A, Chowdhuri SR, Lazar AJ, Manekia J, Mohammad M, Mantha G, Singh R, Luthra R, Medeiros JL, Patel KP. Tumor in Normal or Normal in Tumor: What to Do When Somatic Mutations Are Detected in "Normal" Germline Control Used for NGS-Based Targeted Somatic Mutation Testing. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):1027-1027, 2017. e-Pub 2017.
Barkoh BA, Mehrotra M, Singh RR, Yubitza L, Vidal D, Zalles S, Hannigan B, Bolivar A, Dzifa D, Harmon MA, Patel KP, Routbourt. Validation of a Single-Gene Next-Generation Sequencing Assay for TP53 Mutation Detection in Solid Tumor FFPE Samples in CLIA Laboratory Using Illumina MiSeq. JOURNAL OF MOLECULAR DIAGNOSTICS 19(6):1027, 2017. e-Pub 2017.
Shi X, Duose DY, Mehrotra, M, u P, Wistuba II, Kopetz S, Luthra R. Performance of Traditional Ampliseq Based NGS Panel for Genotyping of Circulating Cell Free DNA from plasma of Metastatic Colorectal Cancer Patients. JOURNAL OF MOLECULAR DIAGNOSTICS 16(9):1040-1040, 2017. e-Pub 2017.
Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W, Tang G, Loghavi S, Luthra R, Yang W, Kantarjian HM, Hu S. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer 10(1038):e583, 2017. e-Pub 2017. PMID: 28708130.
Janku F, De Groot JF, Javle MM, Penas-Prado M, Shroff RT, Luthra R, k B, Lanman RB, Conley AP, Broaddus, r, Davies MA, Kopetz S, Yung WKA, Heymach J, Fu SQ, Shaw KR, Meric-Bernstam F. Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations. JOURNAL OF CLINICAL ONCOLOGY 35(15), 2017. e-Pub 2017.
Ding QQ, Chen H, Lim B, Damodaran S, Chen WW, Tripathy D, Piha-Paul SA, Luthra R, Broaddus RR, Meric-Bernstam F, Sahin AA. HER2 Somatic Mutation Analysis in Breast Cancer: Correlation with Clinicopathologic Features. Laboratory Investigation 97(1):39A-39A, 2017. e-Pub 2017.
Mehrotra M, Singh RR, Chen W, Barkoh B, Behren C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Kopetz S, Wistuba II, Luthra R. Detection of Clonal Evolution in Solid Tumors by Ultra-Deep Sequencing of Plasma Cell-Free Nucleic Acid Using Miseq. Modern Pathology 30(1), 2017. e-Pub 2017.
Ding QQ, Chen H, Lim B, Damodaran S, Chen WW, Tripathy D, Piha-Paul SA, Luthra R, Broaddus RR, Meric-Bernstam F, Sahin AA. HER2 Somatic Mutation Analysis in Breast Cancer: Correlation with Clinicopathologic Features. Modern Pathology 30:39A-39A, 2017. e-Pub 2017.
Fang LH, Chen H, Medeiros LJ, Hu SM, Pei L, Luthra R, Singh RR, Routbort MJ, Hong D, Lu ZY. Optimization of METFISH Reporting Criteria in Non-Small Cell Lung Cancer: MD Anderson Experience. Modern Pathology 30, 2017. e-Pub 2017.
Fang LH, Chen H, Medeiros LJ, Hu SM, Pei L, Luthra R, Singh RR, Routbort MJ, Hong D, Lu ZY. Correlation Between MET Gene Copy Number and Molecular Profiling in Non-Small Cell Lung Cancer. Modern Pathology 30:478A-478A, 2017. e-Pub 2017.
LI Y, Luthra R, Hu JH, Shen L, Broaddus RR, Resetova E, Wu Y, Albarracin CT. mir-182*, mir-183, and mir-143 Are Deregulated in Endometrial Endometroid Cancers. Modern Pathology 30:459A-459A, 2017. e-Pub 2017.
Ballester L, Fuuler GN, Powell SZ, Sulman EP, Patel KP, Luthra R, Routort MJ. Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. Modern Pathology 30:429A-429A, 2017. e-Pub 2017.
Wang W, Routbort MJ, Cy O, Patel KP, Luthra R, Medeiros LJ, Wang S. TP53 Mutations with a Normal Karyotype in Myelodysplastic Syndromes and Cytopenia(s) of Unknown Significance. Modern Pathology 30:384A-384A, 2017. e-Pub 2017.
Quesada AE, Huang RSP, Luthra R, Patel KP, Hodges K, OK CY, Routbort MJ, Bues-Ramos CE, Medeiros LJ, Kanagal_Shamanna R. Genetic Landscape of Non-R882 DNMT3A Mutations Is Distinct from DNMT3A R882 Mutations. Modern Pathology 30, 2017. e-Pub 2017.
Siroy AE, Sui D, Ning J, Luthra R, Patel KP, Routbort MJ, Broaddus RR, Nagarajan P, Aujng PP, Ivan D, Curry JL, Torres-Cabala CA, Priet VG, Davies MA, Lazar AJ, Tetzlaff MT. An Assessment of Copy Number Variations and Somatic Mutations in Advanced Melanomas by Clinical Next-Generation Sequencing. Modern Pathology 30:136A-136A, 2017. e-Pub 2017.
Chen H, Routbort MJ, Rashid A, Roy-Chowdhuri S, Patel KP, Lazar A, Broaddus R, Manekia J, Singh R, Luthra R, Yemelyanova A. Challenges in Next-Generation sequencing analysis of somatic mutations in transplant patients. Journal of Molecular Diagnostics 18(6):1022, 2016. e-Pub 2016.
Mehrotra M, Luthra R, Wistuba II, Chen W, Barkoh BA, Montes-Moreno S, Burns C, Dailey D, Bolivar A, Routbort MJ, Medeiros L, Patel KP, Singh RR, Kanagal-Shamanna R. "Single-Gene" next-generation sequencing-based assay for detection of low-level TP53 mutations. Journal of Molecular Diagnostics 18(6):1047-1048, 2016. e-Pub 2016.
Mehrotra M, Singh RR, Barkoh BA, Duose DY, Patel KP, Kopetz S, Medeiros LJ, Wistuba II, Luthra R. Comparison of Ultrasensitive Droplet Digital PCR and MassARRAY Platforms for Plasma Cell-Free DNA Genotyping. Journal of Molecular Diagnostics 18(6):1046-1047, 2016. e-Pub 2016.
Singh RR, Hatfield DZ, Reddy NG, Shamanna RK, Routbort M, Galbincea JM, Stewart J, Wierda WG, Medeiros L, Luthra R, Patel KP. Development of a targeted Next-Generation Sequencing (NGS) panel for prognostication and detection of treatment resistance in patients with Chronic Lymphocytic Leukemia (CLL). Journal of Molecular Diagnostics 18(6):951, 2016. e-Pub 2016.
Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin C, Kanagal-Shamana R, Wang SA, Jorgensen JL, Medeiros L, Ok CY. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by Next-Generation sequencing. Journal of Molecular Diagnostics 18(6):961, 2016. e-Pub 2016.
Lee S, Broaddus RR, Pattanaprichaku P, Singh RR, Routbort M, Patel KP, Luthra R, Rashid A, Chen H. Molecular characterization of appendiceal mucinous neoplasms: Stratification of KRAS, GNAS, and TP53 mutations by tumor grade. Journal of Molecular Diagnostics 18(6):1001, 2016. e-Pub 2016.
Olar A, Broaddus R, Routbort M, Roy-Chowdhuri S, Hodges KB, Singh RR, Lazar AJ, Rashid A, Chen H, Yemelyanova A, Medeiros JL, Hamilton SR, Luthra R, Patel KP. Value of paired tumor-normal analysis in solid tumor genotyping by Next-Generation sequencing. Journal of Molecular Diagnostics 18(6):1005, 2016. e-Pub 2016.
Mehrotra M, Singh RR, Loghavi S, Barkoh BA, Simien C, Hernandez M, Manekia J, Behrens C, Routbort MJ, Patel KP, Kopetz S, Medeiros LJ, Wistuba II, Luthra R. Ultradeep sequencing using semiconductor-based high-throughput Next- Generation sequencing platforms for cell-free DNA genotyping in patients with solid tumors. Journal of Molecular Diagnostics 18(6):1022, 2016. e-Pub 2016.
Patel KP, Barkoh BA, Lewing C, Mantha GS, Broaddus R, Routbort MJ, Middleton LP, Phipps RA, Hamilton SR, Medeiros L, Luthra R. Transforming a clinical molecular diagnostics laboratory into a high reliability organization. Journal of Molecular Diagnostics 18(6):1045, 2016. e-Pub 2016.
Loghavi S, Routbort MJ, Kanagal-Shamanna R, Wang SA, Khoury JD, Ok C, Yin CC, Singh RR, Zuo Z, Bueso-Ramos CE, Medeiros L, Luthra R, Patel KP. Myeloid neoplasms with recurrent GNAS mutations. Journal of Molecular Diagnostics 18(6):960, 2016. e-Pub 2016.
Roy-Chowdhuri S, Routbort MJ, Singh R, Broaddus R, Lazar AJ, Rashid A, Chen H, Yemelyanova A, Manekia J, Chen W, Medeiros LJ, Hamilton SR, Luthra R, Patel KP. SNP Signature-Based Sample Identification as a Patient Safety Tool in NGS-Based Targeted Oncologic Testing. Journal of Molecular Diagnostics 18(6):1049, 2016. e-Pub 2016.
Luthra R, Singh RR, Lazar AJ, Wang W, Meis JM, Patel KP, Routbort MJ, Panditi DD, Yau J, Hatfield DZ, Medeiros J. A Nanofluidics-Based High Throughput Real-Time PCR Analysis for Gene Fusions in Sarcomas. Journal of Molecular Diagnostics 18(6):1003-1004, 2016. e-Pub 2016.
Tetzlaff MT, Singh R, Seviour EG, Curry JL, Bell D, Broaddus R, Ram P, Prieto V, Luthra R, Esmaeli B. Whole Exome Sequencing of 409 Cancer Associated Genes Demonstrates Frequent Clinically Actionable Mutations in Sebaceous Carcinoma. MODERN PATHOLOGY 29(137A-137A), 2016. e-Pub 2016.
Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 50 Cases of Newly Diagnosed Acute Myeloid Leukemia Arising from Myelodysplastic Syndrome by Next Generation Sequencing: A Clinico-Pathologic Correlation. MODERN PATHOLOGY 29:350A-351A, 2016. e-Pub 2016.
Ghosh K, Hodjat P, Priyanka P, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 117 Cases Newly Diagnosed Myelodysplastic Syndrome: IPSS-R High and Very High Risk by Next Generation Sequencing: A Clinico-Pathologic Correlation. MODERN PATHOLOGY 29(346A-347A), 2016. e-Pub 2016.
Sarshekeh AM, Overman MJ, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Sanchez EV, Manuel S, Shureiqui I, Wolff RA, Patel K, Luthra R, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz, S. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. Journal of Clinical Oncology 34(4), 2016. e-Pub 2016.
Lee SM, Broaddus R, Singh R, Luthra R, Chen H. Mutation Profile of Colorectal Neuroendocrine Neoplasm. MODERN PATHOLOGY 29(182A-182A), 2016. e-Pub 2016.
Chowdhuri SR, Singh R, Manekia J, Barkoh BA, Yao H, Krishnamurthy S, Medeiros LJ, Staekel G, Stewart JM, Luthra R. Comparing Next-Generation Sequencing in Concurrently Acquired Cytology Fine Needle Aspirations and Surgical Core Needle Biopsies of Solid Organ Malignancies. Modern Pathology 29:114A-114A, 2016. e-Pub 2016.
Mehrotra M, Duose DY, Singh R, BArkoh BA, Manekia J, Yau J, Harmon MA, Routbort M, Medeiros LJ, Wistuba II, Luthra R. Scalable Next Generation Sequencing Workflow for Mutation Screening of Solid Tumors Using Ion S5XL Sequencer. Modern Pathology 29:518A-518A, 2016. e-Pub 2016.
Salim AA, Luthra R, Singh R, Patel KP, Routbort M, Barkoh BA, Manekia J, Chowdhuri SR, Broaddus R, Chen H. Pre-Analytical Factors Involved in the Clinical Analysis of a Comprehensive Next-Generation Sequencing Panel. Modern Pathology 29:504A-504A, 2016. e-Pub 2016.
Chen H, Broaddus R, Barkoh B, Abraham R, Singh R, Luthra R, Chowduri SR. Evaluating Pathologist Accuracy in Estimation of Percentage of Malignant Cells. MODERN PATHOLOGY 29(492A-492A), 2016. e-Pub 2016.
Holmes MP, Bell D, Singh R, Luthra R, Broaddus R, Tetzlaff MT, Esmaeli B. Conjunctival Melanomas Harbor BRAF Mutations: Confirmatory Exome Sequencing Analysis of 409 Cancer-Related Genes. Modern Pathology 29:431A-431A, 2016. e-Pub 2016.
Quesada A, Luthra R, Patel KP, Singh R, Routbort M, Loghavi S, Khoury JD, Medeiros J, Bueso-Ramos CE, Kanagal-Shamanna R. De Novo Acute Myeloid Leukemia (AML) with RUNX1 Mutations Shows Characteristic Clinicopathologic Features. MODERN PATHOLOGY 29:371A-371A, 2016. e-Pub 2016.
Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 45 Cases of Newly Diagnosed Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities by Next Generation Sequencing: A Clinico-Pathologic Correlation. MODERN PATHOLOGY 29:352A-352A, 2016. e-Pub 2016.
Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 8 Cases of Newly Diagnosed Acute Myeloid Leukemia Arising from Myeloproliferative Neoplasms by Next Generation Sequencing: A Clinico-Pathologic Correlation. MODERN PATHOLOGY 29:351A-351A, 2016. e-Pub 2016.
Hodjat P, Priyanka P, Ghosh K, Thakral B, Patel KP, Routbort M, Kanagal-Shamana R, Yin CC, Zuo Z, Luthra R, Muzzafar T. Mutation Analysis in 122 Cases of Newly Diagnosed Normal Karyotype Acute Myeloid Leukemia by Next Generation Sequencing: A Clinico-Pathologic Correlation. Modern Pathology - 105th Annual Meeting of USCAP 29(Supplement 2):351A-351A, 2016. e-Pub 2016.
Mehrotra M, Abraham R, Mishra B, Virani S, Patel KP, Luthra R, Singh RR. Validation of Quantitative PCR Based Assays for Detection of Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumor Samples. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):838-838, 2015. e-Pub 2015.
Chen H, Lu X, Singh R Huo L, Bousamra A, Abraham R, Virani S, Mehrotra M, Mishra B, Roy-Chowdhuri S, Routbort MJ, Kenneth A, Broaddus R, Yao H, Sahin A, Patel KP, Luthra R. Quantitative Assessment of ESR, PGR and Genome-Wide Copy Number Aberrations in Advanced Breast Cancer by SNP Microarray. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):840-840, 2015. e-Pub 2015.
Singh RR, Paladugu AV, Jeter KE, Manekia JH, Routbort MJ, Barkoh BA, Patel KP, Luthra R. Comparison of Ion PGM and Proton Platforms for Targeted Hotspot Mutation Analysis. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):822-823, 2015. e-Pub 2015.
Liu C, Chen H, Hu PC, Abraham R, Robinson MK, Yea H, Singh RR, Luthra R. Characterization of METAmplification in Lung Adenocarcinomas Using OncoScan SNP Microarray. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):822-822, 2015. e-Pub 2015.
Routbort MJ, Villareal J, Mantha G, Reddy N, Harmon A, Lui W, Riggins D, Patel KP, Luthra R. High Throughput, High Fidelity Sample Management Using Robotic Tube Labeling and Scanning with a Generalizable Software Toolkit. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):811-811, 2015. e-Pub 2015.
Bole MD, Pepper RC, Raju S, Roth M, Veliyathu JJ, Bhakta YI, Lewing C, Mantha GS, Luthra R, Barkoh NA, Patel KP. Implementation of a Patient Safety Committee in a Clinical Laboratory. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):811-812, 2015. e-Pub 2015.
OK CY, Loghavi S, Salim AA, Chen H, Kanagal-Shamanna R, Chowduri SR, Broaddus RR, Lazar AJ, Rashid A, Manekia JH, Barkoh BA, Medeiros JL, Singh RR, Routbort MJ, Luthra R, Patel KP. To Confirm or Not to Confirm, That is the Question for Equivocal NGS Findings. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):810-810, 2015. e-Pub 2015.
Chen WV, Reddy N, Jiao O, Suh E, Galbincea J, Singh RR, Patel KP, Luthra R, Routbort M. A Custom HiSeq Bioinformatics Pipeline for TruSeq Based Next-Generation Sequencing Analysis. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):803-804, 2015. e-Pub 2015.
OK C, Yang H, Villarreal JC, Barkoh BA, Routbort MJ, Singh RR, Mantha GS, Lu H, Medeiros JL, Luthra R, Patel KP. Development of a Decision Support System for Specimen Accessioning and Uniform Triaging of Oncologic Molecular Testing. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):809-809, 2015. e-Pub 2015.
Almohammedsalim AA, Luthra R, Ok CY, Loghavi S, Mehrotra M, Abraham R, Harmon M, Lu X, Medeiros LJ, Patel KP, Kanagal-Shamanna R. Single Nucleotide Polymorphism-Array-Based Comparative Genomic Hybridization Analysis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Study of 168 Cases with Comparison to Traditional Genetic Testing Methods. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):773-773, 2015. e-Pub 2015.
Ballester LY, Loghavi S, Kanagal-Shamanna R, Barkoh BA, Lin P, Medeiros L, Luthra R, Patel KP. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. JOURNAL OF MOLECULAR DIAGNOSTICS 17(6):766-767, 2015. e-Pub 2015.
Bousamra A, Chen H, Luthra R, Lu XY, Aldape K, Singh R, Lu G, Abraham R, Virani S, Mishra B, Sahin A. Assessing Tumor Percentage: A Possible Solution in Evaluating HER2 Copy Number (HER2CN) Data Generated by Molecular Inversion Probe (MIP) Technology on Formalin-Fixed Paraffin-Embedded (FFPE) Sections of Breast Cancer (BC) With Low Tumor Cellularity. American Journal of Clinical Pathology 144:A239-A239, 2015. e-Pub 2015.
Janku F, Vibat CRT, Falchook GS, Huang HJ, Hong DS, Piha-Paul SA, Subbiah V, Ramzanali NM, Hancock S, Naing A, Karp DD, Nittti G, Cabrilo G, Luthra R, Patel SP, Overman MJ, Kopetz S, Erlander MG, Melnikova V, Meric-Bernstam F. Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers. Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
BAsho RK, Gagliato DD, Ueno NT, Alvarez RH, Wathoo C, Chen HQ, Wei CM, Sahin AA, Roy-Chowdhuri S, Moulder SL, Chavez-Mac Gregor M, Litton JK, Valero V, Luthra R, Shae KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Berstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
Badar T, Cortes JE, Jabbour E, Borthakur G, Konopleva M, KAdia TM, Bohannan Z, Pierce S, Ravandi F, PAtel K, Luthra R, Kantarjian HM, Garcia-Manero G. RAS mutation acquisition at transformation from myelodysplastic syndrome to acute myeloid leukemia to predict poor outcome. Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
Badar T, Luthra R, Kantarjian HM, Jabbour E, Borthakur G, Daver NG, Huang XL, Singh R, Alvarez B, Morrison T, Cortes JE. New tool for monitoring molecular response in chronic myeloid leukemia. Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
Loghavi S, Broaddus R, Daniels M, Meric-Bernstam F, Kopetz S, Chen K, Strong L, Almoammedsalim A, OK CY, Brusco L, Kopetz S, Lu K, Lee J, Medeiros LJ, Singh R, Patel K, Luthra R, Routbort M. Dealing With the Incidental: Experiences Implementing the ACMG Guidelines for Reporting Germline Findings in a Comprehensive Somatic Mutation Assay. LABORATORY INVESTIGATION 95:460A-460A, 2015. e-Pub 2015.
Bousamra A, Chen H, Luthra R, Lu XY, Aldape K, Singh R, Lu G, Abraham R, Virani S, Mishra B, Sahin A. Molecular Inversion Probe (MIP) Technology Generates High-Quality HER2 Copy Number Data in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer. LABORATORY INVESTIGATION 95:511A-512A, 2015. e-Pub 2015.
Chowdhuri SR, Goswami R, Chen H, Barkoh B, Manekia J, Patel K, Routbort M, Singh R, BRoaddus R, Medeiros LJ, Staerkel G, Luthra R, Stewart J. Factors Affecting the Success of Next-Generation Sequencing in Cytology Specimens. LABORATORY INVESTIGATION 95:105A-105A, 2015. e-Pub 2015.
Singh R, Tamboli P, Czerniak BA, Medeiros LJ, Luthra R, Sircar K. Intratumoral Morphologic and Molecular Heterogeneity of Rhabdoid Renal Cell Carcinoma Pose a Challenge for Personalized Cancer Therapy. LABORATORY INVESTIGATION 95:259A-260A, 2015. e-Pub 2015.
Chen H, Singh R, Huo L, Lu, XY, Bousamra A, Abraham R, Mehrotra M, Mishra BM, Virani S, Chowdhuri SR, Routbort M, Aldape K, Broaddus R, Sahin A, Patel K, Luthra R. FGFR1 and EGFR Amplification in Breast Cancer. LABORATORY INVESTIGATION 95:38A-38A, 2015. e-Pub 2015.
Goswami R, Chen H, Patel, K, Routbort M, Yao H, Dang H, Barkoh B, Aldape K, Chowdhuri SR, Stewart J, Medeiros LJ, Broaddus R, Singh R, Luthra R. Improving Next-Generation Sequencing (NGS) Success in Solid Tumors. LABORATORY INVESTIGATION 95:499A-499A, 2015. e-Pub 2015.
Chen H, Luthra R, Routbort M, Patel K, Singh R, Dung H, Barkoh B, Cabanillas M, Aldape K, Broaddus R, Williams M. Mutation Profile of Advanced Thyroid Carcinomas By Next-Generation Sequencing: The MDACC Experience. LABORATORY INVESTIGATION 95:322A-322A, 2015. e-Pub 2015.
Kanagal-Shamanna R, Bueso-Ramos C, Singh R, Routbort M, Miranda R, Lu G, Ravandi F, Dinardo C, Kantarjian H, Medeiros LJ, Patel K, Luthra R. Next-Generation Sequencing of Sporadic Acute Myeloid Leukemia Demonstrates GATA2 Mutation To Be a Secondary Event Frequently Associated With Other Driver Mutations. LABORATORY INVESTIGATION 95:354A-354A, 2015. e-Pub 2015.
Loghavi S, Kanagal-Shamanna R, OK CY, Almohammedsalim A, Bueso-Ramos C, Routbort M, Mehrotra M, Verstovek S, Kantajian H, Medeiros LJ, Luthra R, Patel K. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Megakaryocytic Features and Increased Vasculr Proliferation. LABORATORY INVESTIGATION 95:361A-361A, 2015. e-Pub 2015.
OK CY, Salim A, Loghavi S, Luthra R, Routbort M, Singh R, Zuo Z, Pierce S, Garcia-Manero G, Kantarjian H, Cortes J, Ravandi F, Andreef M, Medeiros LJ, Patel K. DNMT3A Mutation as a Molecular Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia. LABORATORY INVESTIGATION 95:370A-370A, 2015. e-Pub 2015.
Broaddus R, Litzenburger B, Shaw K, Lee JJ, Kinyua W, Sajan B, Routbort M, Patel K, Luthra R, Singh R, Kopetz S. Two-Staged Approach in Identifying Therapeutic Targets for Patients With Advanced Cancers. LABORATORY INVESTIGATION 95:454A-454A, 2015. e-Pub 2015.
Fernandes H, Luthra R, Patel K, Singh R, Routbort M, Zhang P, Rennert H, Peterson J, de Abreu F, Barokh B, Tsongalis G. Multicenter Specimen Exchange Shows a High Concordance for Next-Generation Sequencing-Based Multi-Gene Mutation Profiling of Solid Tumors. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):746-746, 2014. e-Pub 2014.
Roy-Chpwdhuri S, Goswami RS, Chen H, Routbort M, Patel KP, Aldape K, Lazar AJ, Broaddus R, Singh RR, Luthra R, Kanagal-Shamanna R. Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2) Mutations in Solid Organ Malignancies by Next-Generation Sequencing. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):767-767, 2014. e-Pub 2014.
Roy-Chowdhuri S, Patel KP, Chen W, Lazar AJ, Broaddus R, Aldape K, Singh RR, Luthra R, Routbort M. BRAF p.V600E Mutation Detection Is Independent of Estimated Sample Tumor Percentage in a Large Cohort of Melanoma Samples Evaluated by Next-Generation Sequencing. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):768-768, 2014. e-Pub 2014.
Chen H, Singh R, Routbort M, Patel KP, Goswami R, Abraham R, Dang HD, Aldape K, Broaddus R. CSF1R Amplification in Poorly Differentiated Colorectal Adenocarcinoma with Neuroendocrine Differentiation. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):770-771, 2014. e-Pub 2014.
Singh R, Abraham R, Mehrotra M, Patel K, Chowdguri SR, Chen H, Broaddus R, Routbort MJ, Wang X, Mishra B, Aldape K, Luthra R. Validation of Molecular Inversion Probe-based Array for Detection of Copy Number Variations in Solid Organ Cancers using Formalin-Fixed, Paraffin Embedded Tissue. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):770-770, 2014. e-Pub 2014.
Goswami RS, Luthra R, Patel KP, Routbort MJ, Singh RR, Dang HD, Barkoh BA, Yao H, Aldape KD, Broaddus RR< Chen H. Factors Affecting the Success of Next-Generation Sequencing Analysis in Solid Tumors. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):778-778, 2014. e-Pub 2014.
Patel KP, Routbort M, Aldape K, Broaddus R, Lazar A, Chowdhuri SR, Rashid A, Singh R, Zuo Z, Chen H, Shamanna RK, Goswami R, Jabbar K, Barkoh B, ManekiaJ, Medeiros L, Luthra R. Development of a Quality Assurance Framework for Clinical Reporting of. Next-Generation Sequencing-Based Molecular Oncology Testing. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):778-778, 2014. e-Pub 2014.
Shamanna R, Luthra R, Singh R, Abraham R, Harmon MA, Mishra B, Hai S, Ho MN, Medeiros L, Patel KP. Clinical Validation of Single Nucleotide Polymorphism Array-Based Comparative Genomic Hybridization in Acute Myeloid Leukemia. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):724-724, 2014. e-Pub 2014.
Routbort MJ, Patel, KP, Harmon MA, Singh RR, Luthra R Chen WV. Managing Software Change in the Next-Generation Sequencing Lab: Tools and Approaches to in Silico Validation. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):780-781, 2014. e-Pub 2014.
Mehtotra M, Luthra R, Barkoh B, Galbincea J, Mehta P, Singh R, Goswami R, Jabbar K, Patel K. Clinical Validation of a Multi-Purpose Assay for Detection, Genotyping and Monitoring of CALR Mutations in Myeloproliferative Neoplasms. JOURNAL OF MOLECULAR DIAGNOSTICS 16(6):722-723, 2014. e-Pub 2014.
Meric-Bersram F, Brusco L, Kopetz S, Davies M, Routbort M, Piha-Paul SA, Alvarez R, Khose S, DeGroot J, Ravi V, Janku F, Hong D, Li Y, Luthra R, Patel KP, Broaddus R, Shaw K, Mendelsohn J, Mills GB. Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials. EUROPEAN JOURNAL OF CANCER 50:3-3, 2014. e-Pub 2014.
Alatyed K, Patel KP, Konoplev SN, Singh R, Routbort MJ, Reddy N, Pemmaraju N, Zhang LP, Alshaikh A, Aladily T, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 Mutations, Myelodysplastic Features, and a Distinct lmmunoprofile Characterize Blastic Plasmacytoid Dendritic Cell Neoplasm in the Bone Marrow. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 14:S128-S128, 2014. e-Pub 2014.
Jabbar KJ, Luthra R, Patel K, Singh R, Goswami R, Medeiros LJ, Aldape K, Routbort MJ. Comparison of Next Generation Sequencing Mutation Profiling with BRAF and IDH1 Mutation Specific Immunohistochemistry. LABORATORY INVESTIGATION 94:462A-462A, 2014. e-Pub 2014.
Goswami RS, Patel KP, Aldape KD, Singh RR, Jabbar KJ, Kopetz S, Alvarez RH, Davies MA, Subbiah V, Shaw K, Meric-Bernstam F, Luthra R, Routbort MJ. Clonal Evolution of Cancer Examined Via Next-Generation Sequencing of 266 Paired Primary and Metastatic Tumors. LABORATORY INVESTIGATION 94:461A-461A, 2014. e-Pub 2014.
Chowdhuri SR, Routbort M, Patel KP, Singh R, Broaddus R, Lazar A, Sahin A, Mills G, Mendelsohn J, Meric-Bernstam F, Aldape K, Luthra R. Multi-Gene Mutational Profiling of Breast Carcinoma Using Next Generation Sequencing (NGS). LABORATORY INVESTIGATION 94:530A-530A, 2014. e-Pub 2014.
Goswami RS, Ok CY, Patel KP, Wang SA, Routbort MJ, Manekia JH, Jabbar KJ, Barkoh BA, Medeiros LJ, Singh RR, Luthra R. Novel Mutations inTherapy-Related and De Novo Myelodysplasia: Results from a Next-Generation Sequencing Pilot Study. LABORATORY INVESTIGATION 94:461A-461A, 2014. e-Pub 2014.
Wang SA, Hasserjian RP, Jesse J, Weinzierl E, Geyer JJ, Chabot- Richards D, Rogers HJ, Hatem J, Patel KP, Kanagal-Shamanna R, Bagg A, Hsi ED, Arber DD, Foucar K, Luthra R, Orazi A. A Multicenter Study of Atypical Chronic Myeloid Leukemia (aCML) and Myelodysplastic/Myeloproliferative Neoplasm-Unclassifiable (MDS/MPN-U). LABORATORY INVESTIGATION 94:383A-384A, 2014. e-Pub 2014.
OK CY, Patel KP, Wang SA, Routbort MJ, Fu B, Singh R, Kanagal-Shamanna R, Medeiros LJ, Luthra R. Multigene Mutational Analysis Using Next Generation Sequencing (NGS) of 484 Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). LABORATORY INVESTIGATION 94:367A-368A, 2014. e-Pub 2014.
Loghavi S, Zuo Z, Zhang L, Stingo F, PAtel KP, Singh RR, Luthra R, Routbort MJ, Medeiros J, Cortes JE, Ravandani-Kashani F, Kantarjian HM, Khoury JD. De Novo Acute Myeloid Leukemia with DNMT3A, FLT3, and NPM1 Mutations. LABORATORY INVESTIGATION 94:359A-359A, 2014. e-Pub 2014.
Salim AA, Wang WL, Aldape K, Luthra R, Routbort M, Lazar A. Clinical Next Generation Sequencing of Sarcomas: Initial Experience of 133 Cases. LABORATORY INVESTIGATION 94:27A-27A, 2014. e-Pub 2014.
Kanagal-Shamanna R, Singh RR, Routbort MJ, Ravandi F, Kantarjian H, Medeiros LJ, Luthra R, Patel KP. Acute Myeloid Leukemia (AML) with Type A NPM1 Mutation Is More Frequently Associated with FLT3 Mutations Compared with AML with Non-Type A NPM1 Mutations. LABORATORY INVESTIGATION 94:354A-354A, 2014. e-Pub 2014.
Chowdhuri SR, Routbort MJ, Singh RR, Aldape KA, Broaddus R, Lazar AJ, Barkoh BA, Reddy NG, Medeiroa LJ, Luthra R, Patel KP. The Art and Science of Next Generation Sequencing Data Interpretation: Value of Pattern Recognition and Statistical Analysis in Distinguishing True Mutations from Artifacts. LABORATORY INVESTIGATION 94:530A-530A, 2014. e-Pub 2014.
Bousamra A, Luthra R, Lu X, Aldape KD, Sahin AA, Singh RR, Lu G, Abraham R. Quantitative Assessment of Her2 Using Molecular Inversion Probe Arrays in Patients with High Grade Tumors Expressing Her2 Amplification by FISH. LABORATORY INVESTIGATION 94:519A-519A, 2014. e-Pub 2014.
Siroy AE, Prieto VG, Gershenwald JE, Woodman SE, Roszil J, Aldape KD, Luthra R, Patel KP, Routbort MJ, Davies MA, Lazar AJ. Clinical Next-Generation Sequencing Reveals Divergent Mutational Patterns in BRAFV600,BRAF Non-V600, and NRAS Mutations in Advanced Melanoma. LABORATORY INVESTIGATION 94:143A-143A, 2014. e-Pub 2014.
Kanagal-Shamanna R, Singh R, Barkoh BA, Reddy N, Patel KP, Routbort M, Aldape K, Medeiros L, Luthra R. Multi-Gene Mutational Profiling of Acute Myeloid Leukemia Specimens on the Ion Personal Genome Machine in a Clinical Diagnostics Laboratory. Journal of Molecular Diagnostics 15(6):867-867, 2013. e-Pub 2013.
Reddy NG, Haghshenas V, Patel KP, Routbort M, Luthra R, Singh RR. Comparison of Analysis Pipelines for Next-Generation Sequencing Output from MiSeq. Journal of Molecular Diagnostics 15(6):944-945, 2013. e-Pub 2013.
Patel KP, Barkoh BA, Reddy N, Singh R, Aldape K, Routbort M, Luthra R. Quality Control Measures for Next-Generation Sequencing-Based Targeted Gene Panels in a Clinical Diagnostics Laboratory. Journal of Molecular Diagnostics 15(6):941-941, 2013. e-Pub 2013.
Routbort M, Portier B, Patel K, Medeiros L, Singh R, Hamilton S, Aldape KJ Luthra R. HER2/neu Amplification Assessed by an Amplicon Based Benchtop Next-Generation Sequencing Assay for Mutation Profiling. Journal of Molecular Diagnostics 15(6):926, 2013. e-Pub 2013.
Singh R, Manekia J, Harmon M, Yao H, Kanagal-Shamanna R, Patel KP, Routbort MJ, Aldape K, Luthra R. Clinical Validation of Mutation Screening Assay Interrogating 409 Cancer-Related Genes Using Ion Proton, a High Capacity Next Generation Sequencer. Journal of Molecular Diagnostics 15(6):925-925, 2013. e-Pub 2013.
Chowduri SR, Routbort M, Patel KP, Kanagal-Shamanna R, Singh R, Simon G, Broaddus R, Aldape K, Luthra R. Multi-Gene Mutational Profiling of Lung Carcinoma Using Next-Generation Sequencing (NGS). Journal of Molecular Diagnostics 15(6):922-922, 2013. e-Pub 2013.
Alayed K, Patel K, Zuo Z, Verma S, Cason R, Galbincea J, Luthra R, Medeiros L, Yin C. BRAF Mutation Occurs More Frequently in Pulmonary Langerhans Cell Histiocytosis and in Younger Patients. Journal of Molecular Diagnostics 15(6):858-859, 2013. e-Pub 2013.
Portier BP, Patel KP, Singh R, Routort M, Handal B, Barkoh BA, Reddy N, Lazar A, Davies M, Medeiros L, Aldape K, Luthra R. Next Generation Sequencing of a Large Cohort of Solid Tumors Reveals IDH1 Mutations Present in Melanoma at a Higher Frequency Than Expected. Laboratory Investigation 93:119A, 2013. e-Pub 2013.
Bruegl A, Djordjevic B, Urbauer D, Luthra R, Broaddus R. Utility of MLH1 Methylation Analysis in the Clinical Evaluation of Lynch Syndrome in Women with Endometrial Cancer. Laboratory Investigate 93:491A-491A, 2013. e-Pub 2013.
Portier BP, Luthra R, Singh R, Routbort M, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, Aldape K, Patel KP. Quantitative Assessment of Mutant Allele Burden in Solid Tumors by Semiconductor Based Multi-Gene Next Generation Sequencing. Laboratory Investigative 93:499A-500A, 2013. e-Pub 2013.
Zhang L, Aladily TN, Chakhachiro Z, Yao H, Su X, Routbort M, Wang SA, Luthra R, Miranda R, Medeiros LJ, Bueso-Ramos C, Khoury JD. RAS Mutation Is a Poor Prognostic Factor in Patients with Chronic Myelomonocytic Leukemia. Laboratory Investigation 93:369A-369A, 2013. e-Pub 2013.
Mehrotra M, Luthra R, Singh R, Sargent R, Medeiros L, Patel KP. Assessment of Tissue and Subcellular Distribution of miRNA Expressed Differentially between ALK plus and ALK- Anaplastic Large Cell Lymphoma. Laboratory Investigation 93:364A-347A, 2013. e-Pub 2013.
Lu G, Yin CC, Abruzzo LV, Luthra R, Abraham R, Kanagal-Shamanna R, Medeiros L. Acquired Silent Cytogenetic Clones Arising in Patients Treated Successfully for Lymphoma. Laboratory Investigation 93:343A-343A, 2013. e-Pub 2013.
Ramineni M, Malpica A, Luthra R, Deavers MT, Euscher ED. V600E BRAF Mutation in Vulvovaginal Melanoma Is Rare: A Study of Anti-Human BRAF V600E Monoclonal Antibody in 24 Cases. Laboratory Investigation 93:293A-293A, 2013. e-Pub 2013.
Okoye E, Bruegl A, Fellman B, Luthra R, Broaddus R. Microsatellite Instability Influences Expression of Endometrial Carcinoma Biomarkers. Laboratory Investigation 93:290A-290A, 2013. e-Pub 2013.
Bruegl A, Djordjevic B, Fellman B, Urbauer D, Luthra R, Broaddus R. Screening by Young Age and Family History of Colon Cancer Misses the Majority of Endometrial Cancer Patients with Lynch Syndrome. Laboratory Investigation 93:267A-267A, 2013. e-Pub 2013.
Sun H, Hatzis C, Fu C, Avritscher R, Ahrar K, Tam A, Curley S, Yao H, Vauthey JN, Valero V, Booser D, Mara D, Hamilton S, Luthra R, Lau R, Gould RE, Puszatai L, Wallace M, Symmans WF. The Proportion of Contaminating Host Organ RNA within Clinical Biopsies of Metastatic Breast Cancer Is Minimal. Laboratory Investigation 93:438A-438A, 2013. e-Pub 2013.
Yi CYA, Cortes J, Faderl S, Garcia-Manero G, Konopleva M, Estrov Z, O'Brien S, Borthakur G, Levis MJ, Thomas DA, Pierce SA, Brandt M, Pratz KW, Luthra R, Andreeff M, Kantarjian HM, Ravandi F. Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. Blood 120(21), 2012. e-Pub 2012.
Reddy NG, Singh RR, Patel KP, Grant F, Rahimi H, Harmon M, Handal B, Barkoh BA, Routbort M, Aldape KD, Medeiros JL Luthra R. Does Formalin-Fixation and Paraffin-Embedding Affect Genotyping by Next Generation Sequencing?. Journal of Molecular Diagnostics 14(6):747, 2012. e-Pub 2012.
Singh RR, Reddy NG, Barkoh BA, Handal B, Patel KP, Routbort M, Aldape KD, Medeiros JL, Luthra R. Clinical Validation of a 46 Cancer Gene Mutation Panel using Semi-Conductor Based Next-Generation Sequencing Technology. Journal of Molecular Diagnostics 14(6):725, 2012. e-Pub 2012.
Kanagal-Shamanna R, Singh RR, Routbort M, Aldape KD, Handal B, Rahimi H, Reddy. Application of Next-Generation Sequencing in Using Fine Needle Aspiration Smears and Cell Blocks from Solid Tumors. Journal of Molecular Diagnostics 14(6):705, 2012. e-Pub 2012.
Patel KP, Luthra MG, Schlette EJ Wierda W, Keating MJ, Medeiros LJ, Abruzzo LV, Mishra, BM Luthra R, Sargent RL. Charaterization of 6q Deletions in Chronic Lymphocytic Leukemia (CLL) Using Array-Based Comparative Genomic Hybridization. Journal of Molecular Diagnostics 14(6):666-667, 2012. e-Pub 2012.
Patel KP, Singh R, Reddy N, Routbort M, Aldape K, Medeiros L, Sargent R, Chen SS, Yin CC, Zuo J, Barkoh BA, Handal B, Paladugu A, Patel R, Rahimi H, Grant F Luhtra R. Comparison of Next Generation Sequencing Platforms for Multi-Gene Mutational Profiling of Hematologic Malignancies in a Clinical Diagnostics Laboratory. Journal of Molecular Diagnostics 14(6):660, 2012. e-Pub 2012.
Lu G, Patel KP, Miranda RN, Medeiros L, Chen T, Mishra BM, Abraham R, Muddasani R, Luthra R. Genomic Analysis by Array Comparative Genomic Hybridization of Primary Myelofibrosis with Isolated del(13q). Journal of Molecular Diagnostics 14(6):658, 2012. e-Pub 2012.
Romo CG, Kantarjian HM, Luthra R, Quintas-Cardama A, Jabbour EJ, Borthakur G, Khadia TM, Ravandi F, Pemmaraju N, Pierce SA, O'Brien S, Cortes JE. Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts. Blood 120(21), 2012. e-Pub 2012.
Ravandi F, Patel KP, Luthra R, Pierce SA, Borthakur G, Jabbour EJ, Kadia TM, Pemmaraju N, Daver N, Konopleva M, Faderl S, Garcia-Manero G, Cortes JE, Kantarjian HM. Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (+/- Histone Deacetylase Inhibitors). Blood 120(21), 2012. e-Pub 2012.
Nazha A, Kantarjian HM, Jain P, Jabbour EJ, Quintas-Cardama A, Luthra R, Abruzzo LV, Borthakur G, Ravandi F, Pierce SA, O'Brien S, Cortes JE. Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood 120(21), 2012. e-Pub 2012.
Jain P, Kantarjian HM, Faderl S, Patel KP, Manero GG, Benjamini O, Borthakur G, Pemmaraju N, Kadia TM, Daver NG, Nazha A, Luthra R, Pierce SA, Cortes JE, Ravandi F. Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia. Blood 120(21), 2012. e-Pub 2012.
Ghanem H, Kantarjian HM, Faderl S, Jabbour EJ, Daver N, Pierce SA, Brandt M, Quintas-Cardama A, Luthra R, Garcia-Manero G, Cortes JE, Ravandi F. Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO). Blood 120(21), 2012. e-Pub 2012.
Falchi L, Kantarjian HM, Quintas-Cardama A, O'Brien S, Jabbour EJ, Ravandi F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia. Blood 120(21), 2012. e-Pub 2012.
Konoplev S, Yin C, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. NPM1 Mutation Occurs in a Subset of Ph+ AML Suggesting that this Entity Is Distinct from CML in Myeloid Blast Phase. Journal of Molecular Diagnostics 13(6):731, 2011. e-Pub 2011.
Zuo Z, Greaves WO, Luthra R, Sargent R, Chen SS, Galbincea J, Medeiros L, Yin C. KIT Mutation Is Rare in Acute Myeloid Leukemias, Almost Always Involves Exon 17, and Occurs Predominantly in AML with t(8;21)(q22;q22). Journal of Molecular Diagnostics 13(6):729, 2011. e-Pub 2011.
Barkoh BA, Do D, Hai S, Yin C, Chen S, Sargent R, Mederios L, Luthra R, Patel K. High Resolution Melting Analysis as an Upfront Cost Effective Screening Method for Detection of KIT Exon 17 Mutations in Acute Myeloid Leukemia in the Clinical Laboratory. Journal of Molecular Diagnostics 13(6), 2011. e-Pub 2011.
Kanagal-Shamanna R, Paladugu A, Barkoh B, Rahimi H, Chen SS, Sargent RL, Medeiros L, Luthra R, Patel KP. Validation of High Resolution Melting Curve Analysis (HRMA) Using Light Cycler 480 for Screening of TP53 Mutations in Human Malignancies. Journal of Molecular Diagnostics 13(6):783-784, 2011. e-Pub 2011.
Barkoh BA, Patel R, Manekia J, Bartley AN, Zuo Z, Patel KP Luthra R. Comparison of SNaPshot® Fluorescent Capillary Electrophoresis and Sequenom® MassARRAY Based Platforms for Multiplex Solid Tumor Mutation Screening. Journal of Molecular Diagnostics 13(6):775, 2011. e-Pub 2011.
Greaves WO, Patel KP, Reddy N, Rodriguez S, Hai S, Mishra B, Barkaoh BA, Chen SS, Medeiros LJ, Luthra R. A Novel Nanofluidics-Based Approach for Simultaneous and Quantitative Detection of Multiple Recurrent Translocations in Hematologic Malignancies. Journal of Molecular Diagnostics 13(6):734-735, 2011. e-Pub 2011.
Bartley AN, Luthra R, Yao H, Zuo Z, Medeiros J, Patel KP. Distinct Molecular Characteristics of FLT3 Mutations Involving Multiple. Journal of Molecular Diagnostics 13(6):726, 2011. e-Pub 2011.
Ma D, Chen Z, Nero C, Patel KP, Daoud EM, Cheng H, Djordjevic B, Broaddus RR, Medeiros LJ, Rashid A, Luthra R. Somatic Deletions of the PolyA Tract in the 3��-UTR of EGFR are Common in Microsatellite Instability-High Endometrial and Colorectal Carcinomas. Journal of Molecular Diagnostics 13(6):766-767, 2011. e-Pub 2011.
Rahimi H, Singh R, Bartley AN, Patel KP, Barkoh BA, Manekia J, Luthra R. Identification of Rare Mutations in Cancers While Screening for High Frequency Mutations Using Sequenom® MassARRAY System. Journal of Molecular Diagnostics 13(6):766, 2011. e-Pub 2011.
Reddy NG, Singh R, Paladugu AV, Rahimi H, Patel KP, Luthra R. High Resolution Melt Analysis (HRMA), a Sensitive Screening Method to Detect Exonic Mutations in Phosphatase and Tensin Homologue (PTEN) Gene in Cancers. Journal of Molecular Diagnostics 13(6):766, 2011. e-Pub 2011.
Ravandi F, Thomas D, O'Brien S, Faderl S, Jorgensen J, Luthra R, Kebriaei P, Garris R, Cortes J, Kantarjian H. Minimal Residual Disease Monitoring in Patients with Philadelphia-Chromosome Positive (PH1) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of HyperCVAD and a Tyrosine Kinase Inhibitor. Annals of Oncology 22(4):223-224, 2011. e-Pub 2011.
Bartley AN, Luthra R, Saraiya D, Broaddus RR. Discordance between Molecular and Immunohistochemical Analyses for Lynch Syndrome Assessment. Modern Pathology 24(1):144A-144A, 2011. e-Pub 2011.
Bains A, Lu G, Yao H, Luthra R, Medeiros LJ, Sargent RL. Molecular and Clinicopathologic Characterization of De Novo AML with Isolated Trisomy 4. Modern Pathology 24(1):286A-286A, 2011. e-Pub 2011.
Chen SS, Zuo Z, Luthra R, Lu G, Borthakur G, Wang SA, Medeiros LJ, Yin CC. Double Mutations of NRAS and KRAS in Acute Myeloid Leukemia and Myelodysplastic Syndrome Are Associated with Monocytic Differentiation, Multilineage Dysplasia, Increased Myeloblasts and Prior Chemotherapy. Modern Pathology 24(1):290A-290A, 2011. e-Pub 2011.
Greaves WO, Patel KP, Barkoh BA, Mishra BM, Li S, Hui Y, Medeiros LJ, Luthra R. microRNA Profiling in Blastoid Mantle Cell Lymphoma. Modern Pathology 24(1):299A-299A, 2011. e-Pub 2011.
Ma D, Luthra R, Chen SS, Yin CC, Sargent RL, Patel KP, Medeiros J, Zuo Z. RAS Mutational Analysis in 9334 Solid and Hematopoietic Malignancies. Modern Pathology 24(1):394A-394A, 2011. e-Pub 2011.
Bartley AN, Luthra R, Saraiya D, Broaddus R. Quality Control in Microsatellite Instability Testing. Modern Pathology 24(1):431A-431A, 2011. e-Pub 2011.
Ma D, Chen Z, Cheng H, Djordjevic B, Patel KP, Luthra MG, Barkoh BA, Xie SS, Ma S, Chen G, Medeiros J, Broaddus R, Luthra R. Increased Expression of MicroRNA-210 in Microsatellite Instability High Endometrial Carcinoma and Its Potential Role in DNA Damage Repair. Modern Pathology 24(1):444A-444A, 2011. e-Pub 2011.
Patel KP, Barkoh BA, Chen Z, Ma D, Medeiros LJ, Luthra R. Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia: An Analgorithmic Approach Using High Resolution Melting Curve Analysis. Modern Pathology 24(1):453A-453A, 2011. e-Pub 2011.
Patel KP, Luthra R, Abraham R, Chen SS. Incorporation of Laser Capture Microdissection into Clinical Molecular Testing Workflow. Journal of Molecular Diagnostics 12(6):919, 2010. e-Pub 2010.
Janku F, Tsimberidou AM, Garrido-Laguna I, Hong DS, Naing AM, Falchook GS, Fu S, Luthra R, Wang X, Kurzrock R. Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors. EJC Supplements 8(7):83-83, 2010. e-Pub 2010.
Ravandi F, Thomas DA, O'Brien S, Faderl S, Jorgensen J, Luthra R, Jones D, Garris R, Cortes JE, Kantarjian H. Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia. Blood 116(21):879-879, 2010. e-Pub 2010.
Borthakur G, Beitinjaneh A, Lin E, Cortes JE, Luthra R, Ravandi F, Pierce SA, Patel AH, Rondon G, Giralt S, Champlin R, Kantarjian H, de Lima M. Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant. Blood 116(21):721-721, 2010. e-Pub 2010.
Al-Kali A, Luthra R, Bueso-Ramos CE, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of RAS Mutations In Myelodysplastic Syndrome (MDS). Blood 116(21):1205-1205, 2010. e-Pub 2010.
Ravandi F, Patel KP, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau SM, Garcia-Manero G, Cortes JE, Kantarjian H. Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction. Blood 116(21):1115-1116, 2010. e-Pub 2010.
Manekia JH, Patel KP, Barkoh BA, Ma D, Luthra R. Validation of a Leukemia Tumor Mutation Panel by Sequenom MassArray System. Journal of Molecular Diagnostics 12(6):866, 2010. e-Pub 2010.
Ma D, Djordjevic B, Patel KP, Ao X, Barkoh B, Chen Z, Broaddus R, Luthra R. Assessment of High Resolution Melting Analysis and Immunohistochemical Staining for the Detection of PTEN Mutations. Journal of Molecular Diagnostics 12(6):905, 2010. e-Pub 2010.
Barkoh BA, Ma D, Patel KP, Manekia JH, Luthra R. Design and Evaluation of a Solid Tumor Mutation Panel by Sequenom MassARRAY System. Journal of Molecular Diagnostics 12(6):906, 2010. e-Pub 2010.
Padula A, Patel KP, Abraham R, Luthra R, Chen SS. PicoPure DNA Extraction A Simple and Efficient Method of DNA Extraction from Formalin Fixed Paraffin Embedded Tissue for Clinical Diagnostic Applications. Journal of Molecular Diagnostics 12(6):913-914, 2010. e-Pub 2010.
Chen SS, Zuo Z, Galbincea JM, Medeiros L, Luthra R. False Positive vs True-Positive Results of EGFR Mutation Analysis Using Formalin Fixed Paraffin Embedded Tissue. Journal of Molecular Diagnostics 12(6):920-921, 2010. e-Pub 2010.
Patel KP, Ma D, Barkoh BA, Yao H, Sargent R, Drakos E, Medeiros LJ, Luthra R. MicroRNA Profiling of Anaplastic Large Cell Lymphoma. Modern Pathology 23(1410 Suppl. 1):315A-316A, 2010. e-Pub 2010.
Bains A, Luthra R, Medeiros LJ, Zuo Z. Different Roles of NPM1 and FLT3 Mutations in Myelodysplastic Syndromes. Modern Pathology 23(1284 Suppl. 1):286A-286A, 2010. e-Pub 2010.
Bartley AN, Patel KA, Barkoh BA, Mishra B, Yao H, Rashid A, Luthra R, Hamilton SR. MicroRNA Expression during the Colorectal Adenoma-Adenocarcinoma Sequence. Modern Pathology 23(602 Suppl. 1):136A-136A, 2010. e-Pub 2010.
Agarwal A, Sethi S, Lin E, Luthra R, Rashid A, Hamilton SR, Eng C, Maru DM. Histologic Subtypes of Microsatellite Instability-High (MSI-H) Colorectal Adenocarcinomas (CRCs) and Their Association with Clinicopathologic Features and Prognosis. Modern Pathology 23(591 Suppl. 1):134A-134A, 2010. e-Pub 2010.
Powers MP, Rushton JR, Yao H, Barkoh BA, Jones D, Luthra R. MicroRNA Expression and Response to Sorafenib, Cytarabine, and Idarubicin in Patients with Acute Myeloid Leukemia. Modern Pathology 23(1904 Suppl. 1):427A-427A, 2010. e-Pub 2010.
Barakat FH, Luthra R, Medieros LJ, Barkoh BA, Li J, Hai S, Jamil W, Bhakta YI, Herrmann S, Chen SS, Zuo Z. NPM1 Mutation Detection: A Comparative Study of Quantitative Real-Time PCR and Capillary Electrophoresis in 157 Clinical Samples. Modern Pathology 23(1920 Suppl. 1):431A-431A, 2010. e-Pub 2010.
Chen SS, Luthra R, Medeiros LJ, Zuo Z. Molecular Profiles of EGFR and KRAS Mutations in Non-Small-Cell Lung Carcinoma: A Survey of 344 Cases. Modern Pathology 23(1782 Suppl. 1):399A-399A, 2010. e-Pub 2010.
Patel KP, Ravandi F, Ma D, Barkoh BA, Paladugu A, Mishra BM, Kantarjian H, Medeiros LJ, Luthra R. The Study of Novel IDH1(R132) Mutations in Acute Myeloid Leukemias. Modern Pathology 23(1409 Suppl. 1):315A-315A, 2010. e-Pub 2010.
Patel K, Ravandi F, Ma D, Yao H, Abraham R, Barkoh B, Pierce S, Kantarjian H, Luthra R. Detection of Cytogenetic Abnormalities Associated with Outcome Differences in Acute Myeloid Leukemia Using Array-Based Comparative Genomic Hybridization (aCGR) Analysis. Blood 114(22):653-653, 2009. e-Pub 2009.
Zuo Z, Jones DM, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Medeiros LJ, Luthra R, Chen SS. A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph plus ALL). Journal of Clinical Oncology 27(15 Suppl. S):7014, 2009. e-Pub 2009.
Zuo Z, Soape M, Doan S, Chandra P, Galbincea J, Barkoh B, Luthra R. Application of COLD-PCR for Improved Detection of KRAS Mutations in Clinical Samples. Modern Pathology 22(1773 Suppl. 1):391A-391A, 2009. e-Pub 2009.
Gullett AE, Duan X, Fuller GN, Brown R, Li Y, Luthra R, Wiseman W, Resetkova E, Yao H, Puduvalli V, Wu Y, Bruner JM, Albarracin CT. Expression of Annexin A1 and Constitutive Activation of the Akt/mTOR Pathway in High-Grade Diffuse Gliomas: A Potential Connection with S Phase Kinase-Associated Protein (Skp2) in Glioma Progression. Modern Pathology 22(1492 Suppl. 1):329A-329A, 2009. e-Pub 2009.
Sargent RL, Abruzzo LV, Keating MJ, Wierda WG, Medeiros LJ, Luthra R, Jones D. Structural Alterations of the 14q32/IGH Locus in CLL Revealed by Fluorescence In Situ Hybridization and Array-Based Comparative Genomic Hybridization. Modern Pathology 22(1289 Suppl. 1):285A-285A, 2009. e-Pub 2009.
Kim JE, Singh RR, Milito C, Cho-Vega JH, Karanikou M, Kasbidi F, Medeiros LJ, Luthra R, Vega F. Sonic Hedgehog Signaling Pathway as a Therapeutic Target in Diffuse Large B-Cell Lymphoma. Modern Pathology 22(1230 Suppl. 1):271A-271A, 2009. e-Pub 2009.
Chandra P, Luthra R, Garcia-Manero G, Jones D. Genetic Instability and RAS Mutations Characterize Leukemic Progression in t(9;11)-Bearing Acute Myeloid Leukemia. Modern Pathology 22(1171 Suppl. 1):257A-257A, 2009. e-Pub 2009.
Maru DM, Singh RR, Hannah C, Albarracin CT, Romans A, Li YX, Abrahams R, Yao H, Luthra MG, Swisher SG, Hofstetter WL, Rashid AR, Luthra R. microRNA-196A: A Potential Marker of Progression in Barrett's Esophagus-Dysplasia-Adenocarcinoma Sequence. Modern Pathology 22(626 Suppl. 1):139A-139A, 2009. e-Pub 2009.
Gurevich I, Luthra R, Medeiros LJ, Lin P. Clinicopathologic Analysis of 18 Cases with Refractory Anemia with Ringed Sideroblasts and Thrombocytosis. Modern Pathology 22(1203 Suppl. 1):265A-265A, 2009. e-Pub 2009.
Milito C, Khokhar FA, Newton K, Singh RR, Kasbidi F, Schlette E, Yao H, Biasoli I, Medeiros LJ, Jones D, Luthra R, Vega F. Extra Copies of GLI1 Gene at 12q13.12 Are Detected in a Subset of Cases of Trisomy 12 Negative Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomas. Modern Pathology 22(1259 Suppl. 1):277A-277A, 2009. e-Pub 2009.
Ravandi F, Cortes J, Faderl S, Garcia-Manero G, O'Brien S, Borthakur G, Pierce S, Brandt M, Lang M, Zhang WG, Luthra R, Jones D, Levis MJ, Konopleva M, Andreeff M, Kantarjian HM. Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years. Blood 112(11):285-285, 2008. e-Pub 2008.
Earle JS, Romans A, Abraham R, Ensor J, Sieger K, Hamilton S, Luthra R. miRNA Expression in Colorectal Carcinoma by RT-qPCR: Consideration of Multiple Normalization Strategies and Correlation with Microsatellite Instability. Journal of Molecular Diagnostics 10(6):602-602, 2008. e-Pub 2008.
Maru DM, Luthra R, White-Cross J, Singh R, Rashid A. Frequent loss of heterozygosity (LOH) of chromosome 1q in esophageal adenocarcinoma. Modern Pathology 21(585 Suppl. 1):129A-129A, 2008. e-Pub 2008.
Sargent R, Luthra R, Bailey J, Tsang P, Sheffer-Wong A, Vacha S, Keating M, Abruzzo L, Jones D. Genomic profiling using array-based comparative genomic hybridization (aCGH) in chronic lymphocytic leukemia (CLL). Modern Pathology 21(1248 Suppl. 1):273A-273A, 2008. e-Pub 2008.
Johnson MR, Verstovsek S, Jorgensen J, Manshouri T, Luthra R, Jones D, Medeiros LJ, Huh YO. Utility of the world health organization (WHO) criteria for diagnosis of systemic mastocytosis (SM) in bone marrow (BM). Modern Pathology 21(1186 Suppl. 1):259A-259A, 2008. e-Pub 2008.
Cho-Vega JH, Singh RR, Luthra R, Ma S, Davuluri Y, Drakos E, Rassidakis GZ, Mederios LJ, Vega F. Sonic hedgehog signaling is activated by NPM/ALK in ALK-positive anaplastic large cell lymphomas. Modern Pathology 21(1142 Suppl. 1):249A-249A, 2008. e-Pub 2008.
Earle JSL, Romans A, Abraham R, Rashid A, Hamilton S, Luthra R. miRNA expression in colorectal carcinoma: Correlation with microsatellite instability. Modern Pathology 21(532 Suppl. 1):117A-117A, 2008. e-Pub 2008.
Hannah C, Abruzzo L, Jorgensen JL, Reeves N, Luthra R, Jones D. Somatic hypermutation status in CLL correlates with patterns of genotypic aberrations: Results of a large single institution data set. Modern Pathology 20(1113 Suppl. 2):243A-243A, 2007. e-Pub 2007.
Guo M, Sneige N, Zhang W, Silva E, Cogdell D, Jan YJ, Lin E, Luthra R. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Modern Pathology 20(908 Suppl. 2):199A-199A, 2007. e-Pub 2007.
Guo M, Sneige N, Gong Y, Deavers M, Silva E, Jan YJ, Zhang W, Cogdell D, Lin E, Luthra R. Comparison of INFORM HPV in situ hybridization with PCR assay for detection of human papillomavirus (HPV) in cervical carcinoma and cervical intraepithelial neoplasia. Modern Pathology 20(909 Suppl. 2):199A-199A, 2007. e-Pub 2007.
Vega F, Lennon P, Luthra M, Jones D, Breeden M, Cho J, Medeiros L, Luthra R. Array-based comparative genomic hybridization (aCGH) of splenic and nodal marginal zone lymphomas (MZLs). Modern Pathology 20(1201 Suppl. 2):262A-262A, 2007. e-Pub 2007.
Aoki E, Kantarjian H, O'Brien S, Talpaz M, Giles F, Verstovsek S, Wierda W, Salavado A, Letvak L, Garcia-Manero G, Jones D, Luthra R, Shan JQ, Cortes J. High-dose (HD) imatinib provides better responses in patients with untreated early chronic phase (CP) CML. Blood 108(11):608A-608A 2143 Part 1, 2006. e-Pub 2006.
Jones D, Luthra R, Kantarjian HM, Breeden M, O'Brien S, Faderl S, Cortes J, Thomas D. Kinase domain point mutations in Ph plus acute lymphoblastic leukemia (ALL) and lymphoid blast crisis of chronic myeloid leukemia (CML) and their emergence following therapy with Bcr-Abl kinase inhibitors. Blood 108(11):519A-519A 1831 Part 1, 2006. e-Pub 2006.
Zhao W, Khitamy AA, Barkoh BA, Bueso-Ramos CE, Verstovsek S, Luthra R, Jones DM. Quantitative detection of the Kit D816V mutation using pyrosequencing helps to differentiate mastocytosis from mixed mast cell myeloproliferative disorders. Journal of Molecular Diagnostics 8(5):634-634, 2006. e-Pub 2006.
Chen SS, Habeebu SS, Galbincea JM, Jones D, Luthra R. GST11 genotype predicts for failure to achieve molecular remission in adult Philadelphia chromosome positive acute lymphoblastic leukemia. Journal of Molecular Diagnostics 8(5):638-638, 2006. e-Pub 2006.
Izzo JG, Wu T, Malhotra U, Ensor J, Luthra R, Chao CK, Swisher SG, Liao Z, Aggarwal BB, Hittelman WN, Ajani JA. Transcription factor NF kappa B a potential molecular marker for predicting and improving treatment efficacy in esophageal cancer. Journal of Clinical Oncology 24(18):556S-556S 10065 Part 1 Suppl. S, 2006. e-Pub 2006.
Quintas-Cardama A, Kantarjian H, Jones D, Talpaz M, Jabbour E, O'Brien S, Luthra R, Wierda W, Nicaise C, Cortes J. Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. Journal of Clinical Oncology 24(18):343S-343S Part 1 Suppl. S, 2006. e-Pub 2006.
Aoki E, Kantarjian H, O'Brien S, Talpaz M, Giles F, Garcia-Manero G, Wierda W, Verstovsek S, Jones D, Luthra R, Cortes J. High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up. Journal of Clinical Oncology 24(18):345S-345S Part 1 Suppl. S, 2006. e-Pub 2006.
Jorgensen JL, Jones D, Luthra R, Cooper DG, Brahmandam A. Novel Anti-ZAP-70 antibody for flow bytometry in chronic lymphocytic leukemia: comparison with ZAP-70 immunohistochemistry and IgVh mutation status. Modern Pathology 19 Suppl 1:231A, 2006. e-Pub 2006.
Hannah C, Luthra R, Jorgensen JL, Jones D. Chronic lymphocytic leukemia with intermediate rates of VH mutation encompass both pre-germinal and post-germinal subjects. Modern Pathology 19(1532 Suppl. 1):328A-329A, 2006. e-Pub 2006.
Konoplev S, Luthra R, Rassidakis G, Medeiros LJ, Lin P. Activates STAT3 but not MAP kinase p38 is expressed in acute promyelocytic leukemia (APL). Modern Pathology 19(1087 Suppl. 1):234A-234A, 2006. e-Pub 2006.
Yin CC, Medeiros LJ, Lin P, Cromwell C, Jones D, Luthra R, Abruzzo L. Sequence analysis proves clonal identity in five patients withtypical and blastoid mantle cell lymphoma. Modern Pathology 19(1173 Suppl. 1):253A-253A, 2006. e-Pub 2006.
Chen L, Guo J, Jones D, Luthra R, Lin P. Clinical implications of quantitative and qualitative post-treatment detection of AML1-ETO in AML. Modern Pathology 19(1014 Suppl. 1):218A-218A, 2006. e-Pub 2006.
Luthra R, Ajani JA, Bailey JA, Lopez-Alvarez E, Wu T, Zhang L, Luthra MG. Global Gene Expression and Ingenuity Pathway Analysis in Esophageal Cancers: Identification of Potential Functional Pathways Associated with Chemoradiation Resistance. Journal of Molecular Diagnostics 7(5):681-681, 2005. e-Pub 2005.
Jorgensen JL, Jones D, Luthra R, Cooper DG. Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: addition of a novel second monoclonal antibody improves correlation with IgVh mutation status. Blood 106(11):916A-916A 3277 Part 1, 2005. e-Pub 2005.
Vega C, Luthra R, Yin C, Verstovsek S, Kantarjian H, Jones D. Quantitative Detection of the V617F Mutation in JAK 2 and its Role in the Diagnosis of Chronic Myeloproliferative Disorders. Journal of Molecular Diagnostics 7(5):666-666, 2005. e-Pub 2005.
Luthra R, Mehta P, Galbincea JM, Hai S, Jones, D. A Multiplex Bead Array-Based Assay for Rapid Identification of the Common Leukemia Associated Translocations. Journal of Molecular Diagnostics 7(5):663-663, 2005. e-Pub 2005.
Izzo JG, Wu TT, Luthra R, Luthra MG, Swisher S, Aggarwal BB, Bresalier RS, Milas L, Liao Z, Hittelman WN, Ajani J. Association of activated transcription factor NF-kappaB with chemoradiotherapy resistance and poor outcome in esophageal adenocarcinoma. Journal of Clinical Oncology 23(16):315S-315S Part 1 Suppl. S, 2005. e-Pub 2005.
Lu KH, Schorge JO, Rodabaugh KJ, Sun CC, Daniels MS, White KG, Soliman PT, Luthra R, Broaddus RR. Defining criteria for Lynch Syndrome/HNPCC in women under 50 with endometrial cancer: Final results of a prospective, multi-center study. Journal of Clinical Oncology 23(16):848S-848S Part 1 Suppl. S, 2005. e-Pub 2005.
Yin CC, Lin P, Valbuena JR, Jones D, Luthra R, Medeiros LJ, Glassman AB. Morphologic, cytogenetic and molecular abnormalities in therapy-related acute promyelocytic leukemia. Modern Pathology 18(1195 Suppl. 1):258A-258A, 2005. e-Pub 2005.
Barkoh B, Jones D, Jaju M, Vadlamudi K, Lopez-Alvarez E, Estey E, Kantarjian H, Luthra R. Mutational Analysis of CEBPA in Acute Myeloid Leukemia: An Integrated Approach using Denaturing and Non-denaturing Capillary Electrophoresis and Direct Sequencing. Modern Pathology 18(1511 Suppl. 1):325A-325A, 2005. e-Pub 2005.
Galbincea J, Jones D, Pham V, Hamilton S, Medeiros LJ, Luthra R. Pyrosequencing as an Alternative Method for Detection of ras Mutations in Clinical Tumor Samples. Modern Pathology 18(1069 Suppl. 1):230A-230A, 2005. e-Pub 2005.
Valbuutena JR, Rassidakis GZ, Estey E, Luthra R, Yin C, Medeiros LJ, Jones D. RAS mutations are associated with monocytic differentiation in myeloid leukemias and are an adverse prognostic factor in chronic myelonnonocytic leukemia (CMML). Modern Pathology 18(1180 Suppl. 1):255A-255A, 2005. e-Pub 2005.
Yin CC, Luthra R, Galbincea J, Cortes J, Jones D. A pyrosequencing method for quantitation of mutated BCR-ABL transcripts in chronic myelogenous leukemia patients with imatinib resistance. Modern Pathology 18(1196 Suppl. 1):258A-259A 1196 Suppl. 1, 2005. e-Pub 2005.
Galbincea J, Quebodeaux A, Hai S, Jones D, Medeiros LJ, Luthra R. GeneScan Assessment of Clonal IgH Rearrangements Amplified by Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) Improves Specificity of Monitoring for Minimal Residual Disease in B-cell Leukemia/Lymphoma Patients. Jornal of Molecular Diagnostics 6(4):416-417 H12, 2004. e-Pub 2004.
Jabbour E, Kantarjian H, Jones D, O'Brien S, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Long-term incidence and outcome of BCR-ABL mutations in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate - P-loop mutations are not associated with worse outcome. Blood 104(11):288A-288A 1007 Part 1, 2004. e-Pub 2004.
Jones D, Abruzzo LV, Medeiros LJ, Reeves NA, Guo JQ, Admirand J, Keating M, Luthra R. Routine somatic hypermutation analysis of the IgH variable region in clinical samples: Methodology and correlation with other candidate prognostic markers in CLL. Journal of Molecular Diagnostics 6(4):417-417 H19, 2004. e-Pub 2004.
Yin C, Luthra R, Cortes J, Reeves N, Hayes K, Glassman A, Kantarjian H, Jones D. Imatinib resistance in chronic myelogenous leukemia is frequently associated with either ABL kinase mutations or with secondary rearrangements of the BCR-ABL. Journal of Molecular Diagnostics 6(4):416-416 H8, 2004. e-Pub 2004.
Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Garcia-Manero G, Giles F, Shan J, Verstovsek S, Rios MB, Kantarjian H. Clinical significance of molecular monitoring in chronic myeloid leukemia (CML) in chronic phase (CP) with imatinib therapy. Blood 104(11):81A-81A 272 Part 1, 2004. e-Pub 2004.
Phan AT, Rashid A, Luthra R, Lopez-Alvarez E, Swisher S, Komaki R, Bresalier R, Ajani JA. Molecular predictors of patients with localized upper gastrointestinal cancers after chemoradiation. Journal of Clinical Oncology 22(14):317S-317S 4015 Suppl. S, 2004. e-Pub 2004.
Jabbour E, Kantarjian H, Verstovsek S, Jones D, O'Brien S, Luthra R, Ravandi-Kashani F, Wierda W, Giles F, Rios MB, Cortes J. Imatinib mesylate for patients (pts) with hypereosinophilic syndrome (HES) and systemic mastocytosis (SM): A phase II trial. Journal of Clinical Oncology 22(14):317S-317S 4015 Suppl. S, 2004. e-Pub 2004.
Cortes J, O'Brien S, Talpaz M, Luthra R, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Ferrajoli A, Wierda W, Thomas D, Faderl S, Kantarjian H. Clinical significance of molecular response in chronic myeloid leukemia (CML) after imatinib mesylate (Gleevec) therapy: Low levels of residual disease predict for response duration. Blood 102(11):416A-416A 1513 Part 1, 2003. e-Pub 2003.
Lu K, Schorge J, Rodabaugh K, Daniels M, Tran N, Chung L, Intengan M, Luthra R, Broaddus R. Prevalence of MLH1 or MSH2 germline mutations in young women with endometrial cancer. Cancer Epidemiology Biomarkers and Prevention 12(11):1352S-1353S Part 2 Suppl. S, 2003. e-Pub 2003.
Barkan GA, Luthra R, Katz RL, Caraway NP. The use of molecular studies to aid in the diagnosis of lymphoproliferative disorders by fine needle aspiration. Modern Pathology 16(1):256, 2003. e-Pub 2003.
Sanchez-Vega B, Amaya DN, Medeiros LJ, Luthra R. Quantitative t(9;22) PCR in CML patients for BCR-ABL transcripts and normalizer by single tube multiplex Taqman PCR coupled with capillary electrophoresis and genescan analysis. Modern Pathology 16(1):1144, 2003. e-Pub 2003.
Vega F, Cano P, Sanchez-Vega B, Lopez-Alvarez E, Hayes K, Glassman A, Kantarjian H, Medeiros LJ, Luthra R. Comprehensive correlation of conventional cytogenetics (CC), FISH and quantitative real-time reverse transcriptase PCR (qRT-PCR) results for detecting t(9;22) in chronic myeloid leukemia (CML) patients. Modern Pathology 16(1):1171, 2003. e-Pub 2003.
Albarracin CT, Luthra R, Thompson J, Kao S, Huang S, Liu J. RIZ, a novel tumor suppressor, is not a target of frameshift mutations in ovarian endometrioid carcinomas with microsatellite instability. Mod Path 15(1):796, 2002. e-Pub 2002.
Albarracin CT, Silva E, Malpica A, Luthra R, Ku S, Yee G, Liu J. Microsatellite Instability in ovarian endometrioid carcinoma: Identification of frameshift mutations in DNA mismatch repair genes, hMSH3 and hMSH6. Modern Pathology 15(1):795, 2002. e-Pub 2002.
Cao SN, Luthra R, Liu J. Frameshift mutations of BAX gene are not involved in endometrioid ovarian carcinoma with a microsatellite-instability phenotype. Mod Path 15(1):807, 2002. e-Pub 2002.
Liu J, Chang KH, Thompson JA, Zheng W, Gershenson DM, Broaddus R, Luthra R. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer: Clinical significance. Mod Path 15(1):846, 2002. e-Pub 2002.
Wang L, Chang KH, Thompson JA, Luthra R, Zheng W, Deavers MT, Silva EG, Liu J. Genetic evidence for the multifocal origin of endometrioid carcinomas in the ovary and the uterus. Mod Path 15(1):894, 2002. e-Pub 2002.
Abruzzo LV, Highsmith WE, Krogmann TA, Barron LL, Luthra R, Medeiros LJ, Huh YO, Keating MJ, Coombes KR. Gene expresion profiling of untreated B-cell chronic lymphocytic leukemia using cDNA microarrays. Mod Path 15(1):952, 2002. e-Pub 2002.
Sanchez-Vega B, Vega F, Hai S, Medeiros LF, Luthra R. TaqMan Real-time PCR combined with Capillary Electrophoresis: A novel and rapid approach that allows quantification and accurate size determination of bcl-2/JH fusion sequences. Mod Path 15(1):1437, 2002. e-Pub 2002.
Vega F, Lai R, Luthra R, Duvic M, Ibrahim S, Lang W, Medeiros LJ, Jones D. Differentiating benign dermatopathic changes from tumor infiltrates in lymph nodes of cutaneous T-cell lymphoma. Mod Path 14(1):1066, 2001. e-Pub 2001.
Vega F, Medeiros J, Dunmire V, Jones D, Abruzzo L, Luthra R. Characterization of TCRγ-gene rearrangements patterns in T-cell lymphomas: a four color multiplex PCR and GeneScan (GS) Analysis. Modern Pathology 14(1):1395, 2001. e-Pub 2001.
Jones D, Vega F, Dunmire V, Medeiros LJ, Luthra R. A molecular approach to monitoring disease progression in mycosis fungoides (MF). Modern Pathology 14(1):390, 2001. e-Pub 2001.
Thomazy V, Luthra R, Uthman M, Davies P, Medeiros LJ. B-celll specific overexpression of cyclin D1 in mantle cell lymphomas determined by real-time quantitative PCR (qRT-PCR) analysis of microdissected paraffin sections. Mod Path 14(1):88, 2001. e-Pub 2001.
Kabbani W, Houlihan PS, Luthra R, Hamilton SR, Rashid A. Genetic alterations in appendiceal adenocarcinomas: Frequent K-ras mutations and lack of microsatellite instability. Mod Path 14(1):87a, 2001. e-Pub 2001.
Fang WJ, Sahain A, Luthra R. Detection of metastasis in axillary sentinel lymph nodes from breast cancer patients with real-time reverse transcription polymerase chain reaction. American Journal of Clinical Pathology 112(4):24, 1999. e-Pub 1999.
Luthra R, Estalilla O, Romaguera J, Cabanillas F, Sarris AH, Medeiros LJ. Real-time fluorogenic (RTF) PCR detection of t(11;14)(q13;q32) in mantle cell lymphoma (MCL). Labortory Investigation 79(1):1131, 1999. e-Pub 1999.
Estalilla O, Medeiros LJ, Sarris AH, Cabanillas F, Luthra R. Real-time fluorogenic (RTF) PCR assay for the detection of t(14;18)(q32;q21) in non-Hodgkin's lymphoma (NHL). Laboratory Investigation 79(1):793, 1999. e-Pub 1999.
Luthra R, McBride JA, Cabanillas F, Sarris AH. A 5 ' exonuclease-based real-time PCR (ERTPCR) assay for detection of t(14;18) (q32;q21) in follicular lymphoma. British Journal of Hematology 102(1):144-145 Suppl. S, 1998. e-Pub 1998.
Luthra R, Medeiros LJ, McBride A, McLaughlin P, Cabanillas F, Sarris AH. Detection of t(14;18)(q32;q21) in lymphoma with a 5 ' exonuclease-based real-time PCR (ERTPCR) assay. Blood 92(10):972 Part 1 Suppl. 1, 1998. e-Pub 1998.
Luthra R, Medeiros LJ, Romaguera J, Cabanillas F, Sarris AH. 5 '-exonuclease real-time PCR (ERTPCR) detection of t(11;14)(q13;q32) in non-Hodgkin's lymphoma (NHL). Blood 92(10):973 Part 1 Suppl. 1, 1998. e-Pub 1998.
Ford RJ, Luthra R, Bryant J, Tamayo A, Curiel T. In vitro and in vivo models for mantle cell lymphoma. Blood 92(10):1288 Part 1 Suppl. 1, 1998. e-Pub 1998.
Herling M, Luthra R, Pugh W, Romaguera J, Morris SW, Falini B, Cabanillas F, Sarris AH. The t(2;5) and failure-free survival (FFS) of adults with anaplastic large cell lymphoma (ALCL). Blood 92(10):3963 Part 2 Suppl. 1, 1998. e-Pub 1998.
Sarris AH, Luthra R, Kliche KO, McBride A, Andreeff M, Cabanillas F. The t(2;5)(p23;q35) is not detectable in normal donor peripheral blood mononuclear cells by polymerase chain reaction amplification (PCR) of genomic DNA. Blood 90(10):1496-1496 Part 1 Suppl. 1, 1997. e-Pub 1997.
Sarris AH, Romaguera J, Kliche KO, Luthra R, Santiago M, Pugh W, McBride A, Andreeff M, Cabanillas F. Anaplastic large cell lymphoma (ALCL): Presentation, failure-free survival (FFS) and prognostic factors with doxorubicin-based regimens. Blood 90(10):1497-1497 Part 1 Suppl. 1, 1997. e-Pub 1997.
Luthra R, McBride JA, Hai S, Cabanillas F, Pugh WC. Fluorescence PCR (FPCR) and PCR-SSCP analysis of JH-bcl2 amplicons in sequential samples from patients (PTS) with follicular lymphoma(FL): Correlation with DNA sequence analysis. Laboratory Investigation 74(1):1017-1017, 1996. e-Pub 1996.
Goodacre AM, Luthra R, Clodi K, Grace C, Younes A, Cabanillas F, Pugh W, Andreeff M. Partial trisomy of 3q21qter is a consistent abnormally in mantle cell lymphoma identified by comparative genomic hybridization (CGH). Blood 88(10):1519-1519 Part 1 Suppl. 1, 1996. e-Pub 1996.
Sarris AH, Luthra R, Waasdorp M, McBride JA, Cabanillas F, Duvic M, Chen PK, Morris SW, Pugh WC. Genomic DNA PCR defines unique t(2;5) breakpoints in anaplastic large cell lymphoma (ALCL). Blood 88(10):3300-3300 Part 2 Suppl. 1, 1996. e-Pub 1996.
Czerniak B, Ooi A, Luthra R, Pugh W, Logothetis C, Wertz F, Koss LG, Batsakis JG. Urinary-Bladder Carcinogenesis and Its Molecular-Genetic Basis - A Multigene Study. Laboratory Investigation 72(1):A74-A74, 1995. e-Pub 1995.
Sarris AH, Luthra R, Papadimitracopoulou V, Dimopoulos MA, McBride JA, Cabanillas F, Morris SW, Deisseroth AB, Pugh WC. A genomic DNA PCR technique demonstrates the presence of the t(2;5) rearrangement in anaplastic large cell lymphoma but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood 86(10):715-715 Suppl. 1, 1995. e-Pub 1995.
Sendelbach KM, Pugh WC, Rodriguez J, Luthra R, Osborne BM, Manning JT, Butler JJ. Splenic Marginal Zone Lymphoma (MGZL) - Clinical and Pathological Characteristics of 11 Cases. Laboratory Investigation 70(1):A120-A120, 1994. e-Pub 1994.
Osborne BM, Butler JJ, Pugh WC, Luthra R, Ordonez NG. Follicular Lymphoma Variant Mimicking Progressive Transformation of Germinal-Centers (PTGC) - Immunophenotypic, Genotypic, and Clinical Findings in 7 Patients. Laboratory Investigation 70(1):A118-A118, 1994. e-Pub 1994.
Shahab I, Majlis A, Luthra R, Ordonez N, Cabanillas F, Pugh WC. Evidence of the T(1418) Involving Conventional Breakpoint Regions is Detected Infrequently in Cutaneous Follicular Lymphoma (CFL). Laboratory Investigation 70(1):A121-A121, 1994. e-Pub 1994.
Sarris AH, Luthra R, McBride JA, Dimopoulos M, Younes A, Deisseroth A, Cabanillas F, Morris S, Pugh W. The NPM Gene is Rearranged only in a Fraction of Adult Patients with Anaplastic Large-Cell Lymphomas. Blood 84(10):A648-A648 Suppl. 1, 1994. e-Pub 1994.
Buesoramos C, Yang Y, Luthra R, Pugh WC, Albitar M. Oncoprotein MDM-2 is Deregulated in Hematologic Neoplasms. Blood 82(10):A115-A115 Suppl. 1, 1993. e-Pub 1993.
Sioutos N, Bagg A, Michaud G, Pugh WC, Luthra R, Locker J, Cossman J. PCR vs Southern Blot (SB) Hybridization - Detection of Immunoglobulin Heavy-Chain (IGH) Gene Rearrangements. Blood 82(10):A45-A45 Suppl. 1, 1993. e-Pub 1993.
Luthra R, Olson MS. Studies of Endogenous Divalent Metal-Cations of Isolated Liver-Mitochondria. Federation Proceedings 35(7):1760-1760, 1976. e-Pub 1976.

Book Chapters

Roy-Chowdhuri, Sa, Rb L, Wistuba, IIc. Diagnostic molecular pathology. In: Oncological Surgical Pathology. Springer International Publishing, 2145-2159, 2020.
Yin CC, Luthra R. Molecular detection of t(14:18)(q32:q21) in follicular lymphoma. In: Methods Mol Biol, 203-9, 2013.
Yin CC, Luthra R. Detection of t(2;5)(p23; q35) in anaplastic large-cell lymphoma by long-range nested polymerase chain reaction assay. In: Methods Mol Biol, 217-22, 2013.
Yin CC, Luthra R. Molecular detectionog t(11;14)(q13:q32) in mantle cell lymphoma. In: Molecular Methods, 2013.
Verma S, Barkoh B, Luthra R. Pyrosequencing in Cancer. In: Modern Clinical Molecular Techniques, 2012.
Chen S, Hai S, Gulley ML, Luthra R. Epstein-Barr virus and cytomegalovitus viral load monitoring by quantitative real-time polymerase reaction. In: Modern Clinical Molecular Techniques, 2012.
Patel K, Galbincea J, Luthra R. Mutation Analysis in Cancer. In: Modern Clinical Molecular Techniques, 2012.
Greaves WO, Luthra R. Minimal Residual Disease. In: Modern Clinical Molecular Techniques, 2012.
Luthra R, Medeiros LJ. TaqMan RT-PCR coupled with capillary electrophoresis for quantification and identification of bcr-abl Transcript Type. In: Molecular Methods, 2006.
Luthra R, Medeiros LJ. Isothermal multiple displacement amplification: A highly reliable approach for generating unlimited high molecular weight genomic DNA from clinical specimens. In: Pathology Yearbook of 2005, 2005.

Books (edited and written)

Luthra R, Sing RR, Patel K. Clinical Applications of PCR, Methods in Molecular Biology, Springer Protocols. Humana Press, 2016.

Letters to the Editor

Kanagal-Shamanna R, Lopez JEH, MIlton DR, KIm HR, Zhao C, Zuo Z, Artinez MJ, Stingo F, Lee J, Luthra R. Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. American Journal of Hematology 92: E168-E171, 2017.
Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W, Tang G, Loghavi S, Luthra R, Yang W, Hm K, Hu S. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer Journal 7: E553, 2017.
Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology 91: E478-E480, 2016.
Loghavi S, Penmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, LIn P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125: 3360-3363, 2015.
Paniz-Mondolfi A, Singh RR, Jpr G, Mahmoodi MM, Diwan AH, Barkoh BA, Cason R, Huttenbach Y, Benaim G, Galbincea J Luthra R. Cutaneous carcinosarcoma and the EMT: to transition, or not to transition? That is the question. Virchow Archiv 466: 359-360, 2015.

Patents

. Patent Number: MDA07-074.
. Patent Number: MDA07-064.
. Patent Number: MDA06-024.

Less

CV information above last modified March 24, 2026

Rajyalakshmi Luthra, Ph.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patents

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Rajyalakshmi Luthra, Ph.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patents

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson